

Το Σύγχρονο Νοσοκομείο

Βασίλης Σπυρόπουλος



Ελληνικά Ακαδημαϊκά Ηλεκτρονικά
Συγγράμματα και Βοηθήματα
www.kallipos.gr

HEALLINK
Σύνδεσμος Ελληνικών Ακαδημαϊκών Βιβλιοθηκών



ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΠΡΟΓΡΑΜΜΑ
ΕΚΠΑΙΔΕΥΣΗ ΚΑΙ ΔΙΑ ΒΙΟΥ ΜΑΘΗΣΗ
ανάπτυξη στην κοινωνία της γνώσης
ΥΠΟΥΡΓΕΙΟ ΠΑΙΔΕΙΑΣ ΚΑΙ ΘΡΗΣΚΕΥΜΑΤΩΝ
ΕΙΔΙΚΗ ΥΠΗΡΕΣΙΑ ΔΙΑΧΕΙΡΙΣΗΣ
Με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης



ΕΣΠΑ
2007-2013
Ευρωπαϊκό Ταμείο Περιφερειακής Ανάπτυξης

μ μ , μ

μ



μ



Ελληνικά Ακαδημαϊκά Ηλεκτρονικά
Συγγράμματα και Βοηθήματα
www.kallipos.gr

μ

:

:

@ Copyright © ΣΕΑΒ, 2015



Creative Commons

μ

-

μ

- μ

μ 3.0.

<https://creativecommons.org/licenses/by-nc-sa/3.0/gr/>

9, 15780

www.kallipos.gr

ISBN: 978-960-603-137-3

μ

	μ	3
	μ - μ	15
	μ	18
		22
	1: E	μ μ	23
1.1.	μ	23
1.2.	E	27
1.3.	μ μ	μ	33
1.3.1.		38
1.4.		40
	/	42
		44
	1	44
	/	44
	2	44
	/	45
	3	45
	/	45
	2: in vivo	46
2.1.	μ	μ	46
2.2.		μ	49
2.3.		52
2.4.	,	55
2.5.	μ	58
	/	74
		76
	1	76
	/	76
	2	76
	/	76
	3	76
	/	76
	3: in vitro	μ	77
3.1.	in vitro	in vitro	77

3.1.1.		μ	77								
3.1.2.	μ		μ	79							
3.1.3.	20	:		μ	80						
3.2.			μμ		μ	81					
3.2.1.			μμ	83							
3.3.		μ		μ		μ	in vitro	85			
3.3.1.			in vitro	85							
3.3.2.		/		(/)			in vitro	89			
3.3.3.		μ		in vitro	91						
3.4.			:			μ	100				
3.4.1.			μ	100							
3.4.2.		98/79/	103								
3.5.		21	:		μ	,	104				
3.5.1.		in vitro		μ	104						
3.5.2.		Lab-on-a-chip (LOC)	106								
3.6.		μ		in vitro	109						
3.7.		μ	111								
3.7.1.		μ		μ		μ		μ	111		
3.7.2.				μ	116						
3.7.3.				μ		μ	118				
3.7.4.		μ		μ	on-line		μ	μ		μ	119
		μ		RFID	119						
3.7.5.		μ		μ		μ	122				
		/	124								
			128								
		1.	128								
		/	128								
		2.	129								
		/	129								
		3.	129								
		/	129								
		4:	130								
4.1.		:		Röntgen	130						
4.2.		132									
4.3.		μ		(CT)	136						
4.4.		μ		μ	140						
4.5.		142									
4.6				μ	145						
4.7				μ	(MRI)	147					
4.8.		μ	152								

	/	153
		155
	1.	155
	/	155
	2.	155
	/	155
	3.	155
	/	155
5:		μ	156
5.1.	μ	156
5.2.	μ	162
5.3.	« μ »	172
5.4.		173
5.5.		177
	/	181
		183
	1.	183
	/	183
	2.	183
	/	183
	3.	183
	/	183
6:		184
6.1.		184
6.2.	H	188
6.3.		: Betatron μ '80.....	190
6.4.	μ μ T	, (⁶⁰ C, ¹³⁷ Cs) μ '90	192
6.5.	μ	195
6.6.	μμ	197
6.7.	μ	205
6.8.	μ (Treatment planning)	(Simulators) μ μ	209
6.9.	μ	μ μ μ	212
6.10.		215
	/	218
		221
	1.	221
	/	221
	2.	221

/	221
	3.....	221
/	221
7:	222
7.1.	μ	222
7.2.	μ μ μ	223
7.3.	227
7.4.	μ	229
7.5.	μ μ	234
7.6.	μ	235
7.7.	237
7.8.	μ	238
7.9.	μ	239
/	242
	243
	1.....	243
/	243
	2.....	244
/	244
	3.....	244
/	244
8:	245
8.1.	μ	245
8.2.	249
8.3.	253
/	256
	257
	1.....	257
/	257
	2.....	257
/	257
	3.....	257
/	258
9:	259
9.1.	- : μ μ	259
9.2.	264
/	268

	269
1.	269
/	269
2.	269
/	269
3.	269
/	269
10:	270
10.1.	270
10.2.	271
10.3. in vivo	273
10.4. in vitro	279
10.5.	281
10.6.	283
10.7.	285
10.8.	286
10.9.	291
/	291
	294
1.	294
/	294
2.	294
/	294
3.	294
/	294
11:	295
11.1.	295
11.2.	296
11.4.	301
11.5.	301
11.6.	302
11.7.	302
/	307
	308
1.	308
/	308
2.	309
/	309
3.	309

	/	309
12:		μ	310
12.1.		310
12.2.		μ μ μ	311
12.3.		313
12.4.		μ	314
12.5.		μ μ	317
	/	318
		319
	1.	319
	/	319
	2.	319
	/	319
	3.	319
	/	319
13:		μ (HIS, LIS, PACS-RIS, S .)	320
13.1.		μ	320
13.2.		μ	324
13.3.		μ μ μ μ	327
	/	333
		334
	1.	334
	/	334
	2.	334
	/	334
	3.	334
	/	334
14:		335
14.1.		335
14.2.		336
14.3.		336
14.4.		μ	336
14.4.1.		μ (ISO)	336
14.4.2.		(CEN)	337
14.5.		μ μ	337
14.5.1.		Health Level Seven (HL7)	337
14.5.2.		DICOM (Digital Imaging and Communications in Medicine)	338
14.5.3.		ASTM E2369 Standard Specification for Continuity of Care Record	338
14.6.		μ	340

14.6.1.	- International Classification of Diseases ICD	340
14.6.2.	Current Procedural Terminology (CPT)	341
14.6.3.	Systematized Nomenclature of Human & Veterinary Medicine SNOMED	341
14.6.4.	International Classification in Primary Care - ICPC-2	342
14.6.5.	Read Codes	342
14.6.6.	Diagnosis Related Group (DRG)	342
14.6.7.	LOINC	344
14.6.8.	ATC (Anatomical Therapeutic Chemical).....	345
14.6.9.	Clinical Care Classification (CCC) System	346
	/	347
	348
	1.....	348
/	348
	2.....	348
/	349
	3.....	349
/	349
15:	350
15.1.	μ	350
15.2.	μ μ	351
15.3.	μ	354
	/	358
	359
	1.....	359
/	359
	2.....	359
/	359
	3.....	359
/	359
16:	- DRGs.....	360
16.1.	360
16.2.	μ μ DRGs	362
16.3.	μ μ	364
16.4.	μ	370
16.5.	μ μ μ μ	383
	/	386
	388
	1.....	388
/	388

	2.....	388
/	388
	3.....	388
/	388
	17: μ , , μ μ	389
17.1.	μ	389
17.2.	μ	390
17.2.1.	in vivo	390
17.2.2.	in vitro	391
17.2.3.	391
17.2.4.	392
17.3.	μ μ	393
17.4.	μ μ	394
17.5.	μ μ μ μ μ	395
17.6.	μ (CT, MRI ..)	398
17.7.	μ μ μ μ	400
/	401
	402
	1.....	402
/	402
	2.....	402
/	402
	3.....	402
/	402
	18:	404
18.1.	μ , ISO 9001:2008.....	404
18.2.	404
18.3.	μ μ	411
18.4.	μ μ IVD-POCT μ μ ISO-15189 ISO-22870	413
18.5.	μ n-line - μ ISO 9001:2000 μ	417
/	421
	422
	1.....	422
/	422
	2.....	423
/	423
	3.....	423
/	423

19:	424
19.1.	μ 424
19.2.	μ	μ 425
19.3.	μ	I μ 425
19.4.	 426
19.5.	 427
19.6.	μ 429
19.7.	μ	μ 430
19.8.	Geiger-Mueller 431	
19.9.	μ 432
19.10.	μ	μ 432
19.11.	μ	μ 433
19.12.	μ	μ μ ¹³¹ I 433
19.13.	 434
19.13.1.	μ 434
19.13.2.		μ 435
19.13.3.		μ 437
19.13.4.		μ μ 438
19.13.5.	μ	μ μ 441
19.13.6.	 447
19.13.7.	μ 448
19.14.	μ 448
19.14.1.	μ 448
19.14.2.	μ 449
19.14.3.	μ 452
19.14.5	 456
/	458
	458
1	458
/	458
2	459
/	459
3	459
/	460
20:	μ 461
20.1.	 461
20.2.		μ μ 463
20.3.	CO 464	
20.4.	C _n H _m 465	
20.5.	SO ₂ 465	
20.6.	O _x 466	


20.7.	3.....	467
20.8.	Cl.....	468
20.9.	468
20.10.	μ μ	469
20.11.	μ	470
	/	470
	470
	1.....	471
/	471
	2.....	471
/	471
	3.....	471
/	471
	21:	472
21.1.	472
21.2.	-	472
21.3.	-	473
21.4	μ	474
21.5.	μ μ	475
21.6.	477
21.7.	μ	478
21.8.	μ	479
	/	481
	482
	1.....	482
/	482
	2.....	482
/	482
	3.....	483
/	483
	22:	484
22.1.	484
22.2.	μ	486
22.3.	μ	486
22.4.	μ μ	489
22.5.	μμ μ	491
22.6.	μ μ	494
	/	494
	495

		1.....	495	
/		495	
		2.....	495	
/		495	
		3.....	495	
/		495	
	23:	496	
23.1.	μ (/M) μ	496	
23.2.		496	
23.3.		497	
23.4.	μ μ	498	
23.5.		502	
23.6.	μ	504	
23.7.	μ μ /	/	505
23.8.	μ - - μ	508	
23.9.	μ	509	
23.10.	μ μ	509	
23.11.		512	
/		514	
		515	
		1.....	515	
/		515	
		2.....	515	
/		515	
		3.....	515	
/		515	
	24:	- μ -	516
24.1.	μ	516	
24.2.	μ	517	
24.3.		μ	518
24.4.		520	
24.5.	μ	522	
24.6.		HIV, HBV, HCV	524
24.7.	μ	525	
/		528	
		529	
		1.....	529	
/		529	
		2.....	529	

/	529
	3.....	529
/	529
25:	μ μμ	530
25.1.	μ μ μ	530
25.2.	530
25.3.	μ	540
25.4.	μ μ μμ	541
25.5.	μ & μμ μ μ	543
25.6.	μ μ	545
25.7.	μ μ & μμ	548
/	552
	553
	1.....	553
/	553
	2.....	553
/	553
	3.....	553
/	553

μ - μ

	μ
	μ
	μ μ
	μ
. .	μ
	μ
	E
. . .	μ μ
. .	
	μ μ
	μ μ
	μ μ
	μ μ
	μ
/	
/	/
, , ERG	μ
, EGG	μ
, EDG	μ μ
, G	μ
, CG, EKG	
, EAG	μ
, G	μ μ
, ENyG	μ μ
, EOFG	μ
, EHG	μ
. . . .	μ μ
. . .	& μ
	μ
	μ μ

	μ
	μ
	μ
	μ
	μ
	() μ
MR	μ
	/ μ
. .	μ
	μ
. . .	μ
	μ
	μ
	μ
. .	μ
. . .	
ADP	
ATC	Anatomic Therapeutical Classification System
CAD/CAM	Computer-Aided Design / Computer-Aided Manufacturing
CBCT	Cone Beam CT
CCC	Clinical Care Classification System
CCU	μ μ
CDA	Clinical Document Architecture
CIS	 μ
CMRR	μ
CPT	Current Procedural Terminology
CRP	C-reactive protein
CT	μ
DARPA	Defense Advanced Research Projects Agency
DICOM	Digital Imaging and Communications in Medicine
ECRI	Emergency Care Research Institute
EDMA	European Diagnostic Manufacturers Association
FDG	
GC	μ
GMT	Good Microbiological Techniques

HDR	High Dose Rate
HL7	Health Level Seven
HPLC	μ
ICPC	International Classification in Primary Care
LC	μ
FA	μ
LIA-ILMA	μ
LOC	Lab-on-a-chip
LOINC	Laboratory Observation Identifier Names and Codes
LDR	Low Dose Rate
MDR	Medium Dose Rate
MRI	μ
N	
PDA _s	
PNL	Phoenix Nuclear Labs
POC	μ
ppb	part per billion
ppm	part per million
RFID	Radio Frequency Identification
SNOMED	Systematized Nomenclature of Human & Veterinary Medicine
SWOL	Standard Web Ontology Language
TE	μ μ μ
UPS	μ
W	μ μ
XML	extensible mark-up language

μ

American College of Radiology	μ
artefacts	
artifacts	
bar-code	μμ
Building Automation System, BAS	μ μ μ
baseline	μ μμ
batch analyzers	
Blood Bank Information Management System, BBIMS	μ μ
Boron Neutron Capture Therapy, BNCT	μ μ
bosons	μ
British Standards Institution – Bsi	
browser	μμ
bucky table	μ
Building Management System, BMS	μ
cardiomyocytes	μ
care plan	
Case based Reasoning, CBR	
central systems	μ
Clinical Care Classification, CCC	μ
clinical guidelines & pathways	μ
Coefficient of Skewness, SKEW	
collimator	
collimators	
comorbidities	
complaints	
complications	
Computed Radiography, CR	
Computed Tomography, CT	μ
Continuity of Care Record, CCR	μ
contrast	()
Cumulative Probability Distribution Function, CDF	μ
data base	μ
densitometer	μ μ
Diagnosis Related Groups, DRGs	μ μ
Diagnosis related Groups, DRGs	μ μ
digital angiography	

dispensing pipetes	μ μ
distortion	μ
distributed systems	μ μ μ
dual photon absorptiometry	μ
Electronic Health Record, R	
Electronic Health Record, R	
Enzyme Immuno Assay, EIA	μ μ
Enzyme Linked Immuno Sorbit Assay, ELISA	μ μ
European Committee for Standardisation Comité Européen de Normalisation, CEN	
fermions	μ
Fetal ECG, FECG, FEKG	μ μ
Food and Drug Administration, FDA	μ μ μ
fume hood	
fuzzy logic	
fuzzy logic	
gantry	μ μ μ μ
gantry	μ μ
genomics	μ
guidelines	
health informatics	
Hemodialysis, HD	μ (μ ,)
ospital nformation Systems, HIS	μ μ
Hot - Lab	
imagers	μ
Integrated Building Management System, IBMS	μ μ
interfaces	
International Classification in Primary Care, ICPC	μ μ μ
International Classification of Diseases, ICD	
International Electrotechnical Commission, IEC	
International Normalized Ratio, INR	μ
International Standards Organisation, ISO	μ
isodose curves	μ
Knowledge base	
knowledge management	
Laboratory nformation Systems,	μ

LIS	
Laboratory nformation Systems, LIS	μ
Laboratory nformation anagement Systems, LIMS	μ
light source	
Luminescence Immuno Assay / Immunoluminometric Assay, LIA/ILMA	o μ
Magnetic Resonance Imaging, MRI	μ μ
Magnetic Resonance Imaging, MRI	μ μ
Major Diagnostic Categories, MDCs	
medical expertise	" "
Micro-Electro-Mechanical Systems, MEMS	-μ μ μ
microfluidics	μ μ
modular systems	μ
monitored bays	
National Electronic Manufacturers' Association ACR-NEMA	
Neonatal Intensive Care Unit, CU	
Nuclear Magnetic Resonance, NMR	μ μ
Nuclear Medicine,	
operational policy	
pattern recognition	μ
Personal Digital Assistant, PDA	
Photomultiplier,	
Picture Archiving and Communication System, PACS	μ
post-mortem	μ
Pos tron Emission Tomog aphy,	μ μ
precision engineering	μ
Principal Diagnosis, PD	
quality assurance	
quartz	
Radio Frequencies, RF	
Radioimmunoassay/Immuno Radiometric Assay, RIA/ R	μ
Radioimmunoassay/Immuno Radiometric Assay, RIA/ R	μ
Radiology Information System, RIS	μ μ μ
Radiology Information System, RIS	μ μ μ
random access analyzers	

reference knowledge base	
Region Of Interest, ROI	()
resuscitation bays	
RF pulse	μ
secondary diagnosis	
sensor	
sensor	
server	
shunts	μ
Simple Treatment And Rapid Transport, S.T.A.R.T	()
simulators	μ
spark gap generator	μ
spatial resolution	()
Standard Operating Procedures, SOP	μ
Stereotactic Body Radiation Therapy, SBRT	
Stereotactic Radio Therapy, SRT	
Stereotactic Radiosurgery, SRS	
throughput	
traceability	μ
transducer	μ
treatment planning system	μ μ
triage	
triplex	
Ultra Violet radiation, UV	
Ultrasound, US	μ
UN Transport Code	μ
unique room classifier	
Ventricular Fibrillation, VF	μ μ
Ventricular Tachycardia, VT	
Web-service	
worklists	

(980 - 1037)

Philippus Aureolus Theophrastus Bombastus von Hohenheim (1493-1541).

1541.

1618 William Harvey (1578-1657)

Marie François Xavier Bichat (1771-1802)

Baron Guillaume Dupuytren (1777-1835), Jacques Lisfranc de St. Martin (1790-1847), Auguste Nélaton (1807-1873)

Alfred-Armand-Louis-Marie Velpeau (1795-1867)

1867 Sir James Young Simpson (1811-1870), Crawford Long (1815-1878), Horace Wells (1815-1848), William Morton (1819-1868)

Louis Pasteur (1822-1895)

Pasteur

[Redacted]

Hans Lippershey /

Sacharias Jansen

1595 Middelburg

Christopher

Wren (~1659),

150

1675 Anton van Leeuwenhoek

in vitro

[3]-[7].


[8]:

- Conrad Wilhelm Roentgen 1896, Wuerzburg

- Willem Einthoven, to 1903.

LASERS


-
-
-
-



1.1

20

Roentgen [40].



1.2

Willem Einthoven, to 1903 [39].

•
•

μ, μ, : μ

•
•
•
•

(, , , ,

) μ

μ :

, μ, , μ

μ, μ 19 , μ, μ μ

μ μ

μ μ
n vitro

μ μ

1.1 μ μ

1.2. Ε

μ, () μ, μ, μ

μ (μ, μ μ μ μ

.) μ (μ μ μ μ μ μ μ μ [12], [19].

μ μ μ μ μ :



1.4 μ

- Εσωτερική Ιατρική (πολυδύναμα παθολογικά)
- Χειρουργική
- Ορθοπαιδική
- Κλινική Φυσιολογία (καρδιολογία)
- Ουρολογία
- Μαιευτική και Γυναικολογία
- Παιδιατρική
- Οφθαλμιατρική
- ΩΡΛ
- Οδοντιατρική
- Ψυχιατρική κλπ.

μ (: .)

O, , μ in vivo , μ in vitro , μ μ μ :

-
-
-
-
-
-
-

μ μ
μ μ

μ μ .

— μ :
« μ » μ

μ , μ

-
-
-
-
-
-
-

μ

μ : μ μ

μ μ μ

μ « ».

« » μ μ

μ . μ μ μ μ μ μ μ μ μ μ μ μ μ μ .

O

(μ , .).

1 WC 20 .

μ μ μ ,

E :

, /

(standards). μ

μ μ (12 m², , .) μ μ

μ [11], [19], [20]:

-
-
-
-
-
-
-
-
-
-
-

130 x 75 x 80 (cm)

μ μ 5

μ (4 m)

/ ,

(, μ , μ .)

(couch) 180 x 60 x 75 (cm) μ μ

75 x 45 x 85 (cm)

μ μ

μ

μ μ

μ

μ

55 db [11], [19], [22]:

[12]. μ μ

- (): 3 - 4 /h
- : 7 - 8 /h
- : 3 - 5 /h
- : 6 - 8 /h
- : 5 - 8 /h
- μ : 4 - 6 /h
- : 6 - 8 /h
- μ : 6 - 8 /h
- : 2 - 4 /h



1.5

(: .) .


O μ :

μ , μ

μ , μ ,

μ /

μ μ μ [12]:



1.6

μ , μ

[19], [22].

_____ :
 _____ (ECG, EMG-ENG, _____, test _____, Holter _____, olter _____
 _____ (_____, _____). _____
 _____ (IEC
 60601) _____

_____ :
 _____, _____

 _____ :


_____ :
 _____, _____, _____ (_____, 2 - 4 m² _____).

 (EEG) _____
 _____ (_____, _____), _____, _____ Faraday _____

_____ : _____ « _____ » _____ 10 m² _____, _____;
 _____, _____ 6.5 m, _____
 _____ _____ LASER,



1.7



[26].



1.8 : [25]. (μ μ μ / μ).
 μ (3-5 m²)
 μ LASER μ
 μ / μ .




1.9 : μ μ (: μ).

_____ : « » μ μ 37-45 cm, μ , μ
 , μ : 150 lux , μ μ 400 lux , μ
 μ μ , μ « » , μ μ 6 m²,
 « μ » , μ μ μ
 , μ , 6-12 m². E
 , WCs, . μ ,

_____ : μ μ , μ μ
 , : μ . μ
 • .

- μ (. . . , . . .).
- μ (Video Processor).
- TV - Monitor
- (. . . Video Printer).
-
-
- μ (. . . , . . .), μ




1.10 μ μ μ [24].

-
- μ
 - μ
 - μ
 - μ (Triplex), μ μ Doppler.
 - μ

« » (μ , μ , multi - format camera, video).

	(min)	μ
	30 min	7
	20 min	10
	10 min	21
	30 min	7
	13 min	16
1.2		3.5 h ()

[24].




1.11 μ [24].

1.3. μ μ μ

75% , μ . μ , μ , μ , μ .

μ μ () μ , μ , [14], [15], [20],

[21].



1.12 μ μ [29].

μ μ μ , μ , μ , μ ,

μ (6/10000 μ « μ », μ , μ

μ , μ μ μ μ ,

μ μ

μ , μ , μ , μ
 [13], [16], [19], [20].



1.13 μ μ [29].

μ μ μ μ μ μ
 μ (. . μ) μ μ μ μ μ μ

7.0 x 13.5 m²,


3.3 x 4.5 m²

μ μ μ μ μ μ / μ μ [11].

- μ ()
- μ
- μ
- Mayo (, μ μ μ)
- μ μ μ « μ »
- μ μ μ , μ μ .

(μ μ μ « » , μ set μ μ) μ μ μ μ μ

), μ μ « » μ (. μ ,
).
 μ μ . μ μ μ μ , μ μ μ [15].



1.14 μ μ (Emergency Clinic) [29].



1.15 μ μ μ .



μ μ μ , [35].

_____ :
 μ .
 • μ

/ μ μ : μ
 μ μ monitor

arm) [13], [20], [21].

-
-
-
-
-
-




1.18

[31].

[5].

1.3.1.


.



1.22

$\mu \mu$

[37].



1.23

μ

μ

μ

μ

$\mu \mu$

[37].

4. Culver C.M. Gert B. *Philosophy in Medicine. Conceptual and Ethical Issues in Medicine and Psychiatry*. New York/Oxford: Oxford University Press, 1982.
5. King L. S. *Medical Thinking*. Princeton, N.J.: Princeton University Press, 1982.
6. . , : 1983.
7. Spyropoulos ., Papagounos G., “A theoretical approach to Artificial Intelligence Systems in Medicine”, *Artificial Intelligence in Medicine*, 7, (1995), 455-465.
8. Spyropoulos ., “Artificial Intelligence Systems in Medicine: Limits and Perspectives”, *Evening Workshop, 1996 AMIA Annual Fall Symposium*, October 26-30, 1996, Washington DC, p.27, W1.
9. Spyropoulos B., Papagounos G., “Decision making in a modern Hospital: Some theoretical and practical aspects”, *IEEE, Engineering in Medicine and Biology Society, 19th Ann. Intern. Conference*, Chicago, IL, October 30-November 2, 1997.
10. Spyropoulos B., “On-line Educational Means supporting the tutoring of the Physical Principles applied in modern Biomedical Equipment Technology, 1999, *Centennial Meeting of the American Physical Society, Atlanta 20-26 March, 1999, Bulletin of the American Physical Society*, UB20.04, Volume 44, (1999), No 1, Part II, p. 1425.
11. Badner B. (1981). “Outpatient Surgery Facilities”, : *Hospital Special-Care Facilities*. New York: Academic Press.
12. Burgun J.A. (1976). “Construction Considerations for Ambulatory Care Facilities”. *Hospitals*, 50,3,79.
13. Gastinger W., Plarre H.H. (1965). *Bau- und Funktionsformen eines Unfall-Ambulatoriums mit orthopaedischer Fachpraxis*. Medizinal-Markt, 6.
14. *Guidelines for Design and Function of a Hospital Emergency Department*. (1978). Am.Coll.Surg.Comm.Trauma.
15. Laufman H. (1981). *Planning the Emergency Department*, : *Hospital Special-Care Facilities*. New York: Academic Press.
16. Miles I.(1975). “Major Disasters: Hospital Admission Procedures”. *Br.J.Surg.* 63,731.
17. Moles T.M. (1977). “Planning for major Disasters”. *Br.J.Anaesth.*, 49, 643.
18. *Optimal Hospital Resources for Care of the Seriously Injured*.(1976). Bull.Amer.Coll.Surg., 9.
19. Puetshep E. (1979). *Modern Hospital*. London: Lloyd-Luke Ltd.
20. Rutherford R. (1973). “Organization-Design, Function and Operation of Outpatient Clinics and Emergency Rooms”, : *Outpatient Surgery*. Philadelphia: G.J.Hill & W.B.Saunders Company.
21. Spencer J.H. (1972). *The Hospital Emergency Department Springfield*: C.C.Thomas.
22. Teut A., Nedelikov G. (1973). *Die Gruppenpraxis*. Duesseldorf: Bertelsmann Fachverlag.
23. Weisz G.M. (1976). “Psychiatry and the Management of an Accident Service”, : *Modern Perspectives in the Psychiatric Aspects of Surgery*. New York: Brunner & Mazel.
24. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/142892/HBN_12-01_Suppa_DSSA.pdf Out-patient Care, Health Building Note 12-01: Consulting, examination and treatment facilities.
25. Joseph Caballero, https://commons.wikimedia.org/wiki/File:Echocardiography_%28Ultrasound_of_the_Heart%29.jpg Echocardiography (Ultrasound of the Heart).
26. BruceBlaus , https://commons.wikimedia.org/wiki/File:Blausen_0113_BrainMapping_Electrodes.png Blausen 0113 Brain-Mapping Electrodes.

27. <https://www.attainia.com/templates/room.cfm?U.S.-VA:-Outpatient-Clinic---Satellite-Community-Based+Exam-Room-%28Multi-Purpose-%28EXRG3%29&roomid=50284> U.S. Veteran Administration (VA) Satellite/ Community based Outpatient Clinic, Multi-Purpose Exam Room.
28. http://ergo.human.cornell.edu/ahprojects/hospital_ergonomics/emergencyroom.pdf Cornell Ergonomic Consultants, Hospital Emergency Room Ergonomic Evaluations & Recommendations.
29. <http://www.luxtica.com/emergency-room-floor-plans/> Emergency Room Floor Plans.
30. <http://emergencymedicalassociates.com/emergency-care/tour-emergency-care-department/Resuscitation/Trauma Room,> emergency medical associates ().
31. <http://www.annarbor.com/news/a-pediatric-resuscitation-room-in/> A resuscitation room in the pediatric emergency department in the C.S. Mott Children's Hospital.
32. <http://www.cdhb.health.nz/Hospitals-Services/Specialist-Care/Emergency-Department/Pages/default.aspx> Monitored / Resuscitation / Trauma: 10 monitored bays, 9 resuscitation bays and 1 trauma room.
33. <http://kxan.com/2014/04/29/doors-open-today-at-new-seton-psychiatric-emergency-department/>
34. <https://www.google.gr/search?q=resuscitation+room+emergency+department&source=lnms&tbn=isch&sa=X&ved=0CAcQAUoAWoVChMI8LudzaKtyAIVBokUCh1OmgJk&biw=1280&bih=699#tbm=isch&q=psychiatric+patient+room+emergency+department&imgsrc=Smrpgwj4Pi7VM%3A> Psychiatric patients are being warehoused in Portland's emergency rooms in growing number.
35. [https://www.aslimnica.lv/en/saturs/clinic-emergency-medicine-and-patient-admission#galerija\[g\]/0/](https://www.aslimnica.lv/en/saturs/clinic-emergency-medicine-and-patient-admission#galerija[g]/0/) Riga Latvia, East Clinical University Hospital, Clinic of Emergency Medicine and Patient Admission.
36. <http://yourhealth.asiaone.com/content/brain-disease-spurred-him-be-nurse> An observation ward at the Accident & Emergency (A&E) Department at Changi General Hospital (CGH).
37. http://www.systemswiki.org/index.php?title=Emergency_Department_Medical_Imaging_Interaction Emergency Department Medical Imaging Interaction.
38. <http://www.biomerieux.de/klinische-diagnostik/ihre-herausforderungen/aus-sicht-des-labors/time-result> Optimal workflow in the microbiology lab ensures rapid results and transmission to the patient bedside. See more at: <http://www.biomerieux.de/klinische-diagnostik/ihre-herausforderungen/aus-sicht-des-labors/time-result#sthash.CR4TrRi2.dpuf>
39. Einthoven, W. "Un nouveau galvanometer", Arch. Neer. Sci. ser. II 6, 625, 1901.
40. Edwin J. Houston - Retrieved December 22, 2014 from [Edwin J. Houston, "Elementary Electricity Ch. 13: The X-rays" in Popular Electricity magazine, Popular Electricity Publishing Co., Chicago, Illinois, Vol. 2, No. 1, May 1908, p. 6, fig. 87](#) on Google Books.

1

3

/

•

•

•

μ

2

3

/
•
•
•

.

3 μ

3

.


/
•
•
•

.

μ

.

• Ca^{++} μ .
 • Ca^{++} , $\mu \mu$.
 • μ - μ , , $\mu \mu$.
 • μ .
 • μ , μ $\mu \mu$, $\mu \mu$.
 • μ μ $\mu \mu$, μ , μ , μ .
 5 ms), μ μ μ ($\mu \mu$ $\mu \mu$)
 μ . μ μ μ μ , μ μ ,
 μ 10000 μ , 100 μs μ μ μ ,
 μ , 20000 , Na^+ K^+ μ 2000 .
 μ μ , μ , μ 0.5 - 1.0 ms, .





2.3 μ μ μ [2].

10 « » , μ 5 ms μ
 μ , μ 5 mV, μ
 μ μ (μ).
 μ μ μ - μ . μ
 μ , μ μ , μ (μ ,
 1 ms). , μ ms, μ ,
 μ , μ μ .
 μ μ μ . μ 1000 Hz.
 μ , μ , 8-30 Hz μ μ

2.2.

μ

μ , μ (μ ,) , μ (- ,) ,
 μ (μ) (μ) . μ μ (μ) . μ
 μ μ μ , μ 0.05-10.00 μm . μ μ μ μ (. . μ μ)



2.8 : μ μ μ , μ μ 12 standard , Einthoven, Goldberger Wilson [14]. : μ μ , Einthoven. RA, LA: μ (V), , LF: , P,Q,R,S,T: μ μ (μ) μ μ [15], [16].

μ μ μ , μ μ μ PQRSTU,

μ ():

- μ , μ , μ
- (μ) $\mu\mu$ PQ, μ His μ μ .
- μ Q,
- μ R, μ
- μ S,
- μ μ ST,
- μ
- μ U μ


μ μ PQRSTU,

μ Einthoven (, μ , Einthoven) [15]. μ μ (μ) P, Q, R, S & μ (, μ) , μ , μ μ , μ μ .

R , $0.1 - 0.3 \text{ mV}$,
 $60 - 80 \text{ min}^{-1}$.
 (μ) , μ

2.4.

Galvani, μ
 300 mV
 1 mV .
 $50 \mu\text{F/cm}^2$.
 (Galvani), μ



[17].

$\text{Ag} - \text{AgCl}$, μ
 μ

(Block),
 (. . . 8).
 (. . . 8),
 (. . .)
 (monitoring)
 «smart-phones»,
 Software,





2.11 To FDA (5-12-2013)



smart-phones Android [19],[20].


- [Macfarlane, 1979]:
- - line), (base .).
 - PQRSTU.
 - «μ μ», μ (averaging), μ
 - P, T & U μ P, QRS & T. O
 - $V(t)$ (μ) $dV(t)/dt$.
 -
 - (, μ).

μ μ μ μ μ (. . . , ACTH .), μ μ , μ μ , μ μ (Common Mode Rejection Ratio, CMRR).




2.13 μ $\mu\mu$ μ 32 [22], [23].


μ () μ , μ μ , μ :
 μ μ (μ) : μ , μ , μ , μ :
 μ , μ 0.65 0.43 mm. μ ()
 μ , μ , μ « » .
 μ , μ .




(a)




(b)



(y)



(d)



(e)

2.15 15.) μ μ μ :
 μ μ F) μ , μ μ μ :
 μ . F : μ , F : μ , : μ μ , S : μ (, μ μ μ)
 μ) .) μ μ , μ μ μ μ , : μ , : μ .)
 μ , μ , : μ , : μ μ μ , μ μ :
 μ μ , : μ , : μ (μ) , : μ .)
 μ μ μ μ μ μ μ [22].





μ , μ μ μ , μ . μ μ . μ ,
 μ 0.5 mm μ , μ μ μ , μ μ μ , μ ,
 μ :
 μ , « » ,
 μ () , « » , μ ,
 μ : μ μ μ μ 14 μ μ μ ,
 μ , μ μ . μ μ μ μ , μ μ ,
 μ / /- . μ μ μ 3-4 . μ μ μ ,
 μ : 2 μ μ , μ

(. . . , . . .) μ . μ

μ μ μ μ (. . . , . . .) . μ μ μ μ μ μ , μ μ



μ μ μ .
5 - 25 $\mu\text{V/cm}$
 μ .

, μ 5 μV ,



2.16 : μ &

μ μ [17], [26].




2.17 μ μ : a) $\mu\mu$ μ , b) μ , c) μ , d) [27].

μ (CMRR) μ 100 . μ μ 2 Hz-10 KHz. μ μ μ . μ μ μ μ . μ μ μ . μ μ μ .



- $\frac{\mu}{\mu} (\mu , EDG):$
 - $\frac{\mu}{\mu} (\mu , EGG):$
 - $\frac{\mu}{\mu} (\mu , EHG):$
 - $\frac{\mu}{\mu} (\mu , EOFG):$
 - $\frac{\mu}{\mu} (\mu , EAG):$
- (0 - 30000 Hz) (5 μ V - 130mV)

	μ	F (Hz)	U (mV)
EEG	μ (ECG)	0.2 - 200	0.1 - 3
	μ (EEG)	1 - 70	0.005 - 0.1
EEG (Cortex)		10 - 100	0.015 - 0.3
(EMG)	μ	10 - 1000	0.1 - 5
EMG ()	(ERG)	10 - 10000	0.05 - 5
	(EDG)	0.1 - 100	0.02 - 0.3
	(EMG)	0 - 1	0.1 - 5
	(EMG)	0 - 200	0.1 - 8
	(EGG)	0.02 - 0.2	0.2 - 1
2.3	μ	0 - 10000	50 - 130

-
- μ : Transducer, Messwandler
 - μ : Sensor, Messfühler,
 - μ : μ .
 - μ : μ .
 - μ : μ .
 - μ : μ .
 - μ : μ .
 - μ : μ .
 - μ : μ .



2.24 () , μ



, μ [17].

μ μ μ μ μ

μ μ μ μ μ μ



2.25 μ μ




μ [35].

() : μ μ μ μ

() μ μ μ

μ est : μ -Camera. μ μ



2.28 est [38].

in vivo : μ μ

in vivo :

- μ in vivo . μ .
- μ , μ μ μ μ .
- μ μ μ μ μ μ .

μ , μ μ μ μ μ [39].

μ in vivo ,

- « » :
- Medical electrical equipment: IEC60601.
 - Safety of laser products: IEC 61000.

μ μ μ [40].

Changes to the List of Recognized Standards
Standards Added
ISO 5840-3:2013 Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques
ISO 14117:2012-Ed.1.0 Active implantable medical devices - Electromagnetic compatibility - EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices
IEC 60601-1:2012-Ed.3.1 Medical electrical equipment – Part 1: General requirements for basic safety and essential performance
CAN/CSA-C22.2 NO. 60601-1:14 Medical electrical equipment – Part 1: General requirements for basic safety and essential performance
IEC 60601-1-11:2010-Ed. 1.0 Medical electrical equipment – Part 1-11: General requirements for basic safety and essential performance – Collateral Standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment
IEC 60601-2-57:2011-Ed.1.0 Medical electrical equipment – Part 2-57: Particular requirements for the basic safety and essential performance of non-laser light source equipment intended for therapeutic, diagnostic, monitoring and cosmetic/aesthetic use
IEC 62366:2007 Medical devices – Application of usability engineering to medical devices
ISO 13408-1:2008 Aseptic processing of health care products - Part 1: General requirements
ISO 13408-2:2003 Aseptic processing of health care products - Part 2: Filtration
ISO 13408-3:2006 Aseptic processing of health care products - Part 3: Lyophilization
ISO 13408-4:2005 Aseptic processing of health care products - Part 4: Clean-in-place technologies
ISO 13408-5:2006 Aseptic processing of health care products - Part 5: Sterilization in place
ISO 13408-6:2005 Aseptic processing of health care products - Part 6: Isolator systems

Revised Date: 2015/08/10; Effective Date: 2015/08/31

1

2.4 μ
 μ [39].

(Health Canada 2015)

ΚΑΝΟΝΙΣΜΟΙ	ΣΤΑΔΙΟ ΕΦΑΡΜΟΓΗΣ
Κοινοτική Οδηγία για τα Ενεργά Εμφυτεύσιμα Ιατροτεχνολογικά Προϊόντα - 90 / 385 / EEC	Υιοθέτηση: Ιούνιος 1990 Υιοθέτηση στην Εθνική Νομοθεσία: Αύγουστος 1994 Πλήρης Εφαρμογή: Ιανουάριος 1995
Κοινοτική Οδηγία για τα Ιατροτεχνολογικά Προϊόντα - 93 / 42 / EEC	Υιοθέτηση: Ιούνιος 1993 Υιοθέτηση στην Εθνική Νομοθεσία: Σεπτέμβριος 1994 Πλήρης Εφαρμογή: Ιούνιος 1998
Κοινοτική Οδηγία για τα In Vitro Διαγνωστικά - 98 / 79 / EEC	Υιοθέτηση: Δεκέμβριος 1998 Μεταβατική Περίοδος: Ιούνιος 2000 Πλήρης Εφαρμογή: Ιανουάριος 2004
Κατευθυντήριες Γραμμές για ένα Σύστημα Επαγρύπνησης Ιατροτεχνολογικών Προϊόντων	Έκδοση Τελικού Σχεδίου: Φεβρουάριος 1998 Προβλέπεται Αναθεώρηση το 2004
Κατευθυντήριες Γραμμές για την Κατάταξη των Ιατροτεχνολογικών Προϊόντων	5η Έκδοση: Μάρτιος 1996 Υπό Αναθεώρηση

2.5 μ μ μ

[40].

/

1. Evans W.F., *Anatomy and Physiology*, Prentice Hall, New Jersey, 1971.
2. <https://commons.wikimedia.org/wiki/File:Neuro-anatomy.jpg> Neurological tissue features.
3. Ruediger W., *Lehrbuch der Physiologie*, Volk & Geusndheit Verlag, Berlin 1976.
4. https://commons.wikimedia.org/wiki/File:1222_Action_Potential_Labels.jpg Polarization and Action Potentials.
5. μ ., μ , μ . . , 1979.
6. https://commons.wikimedia.org/wiki/File:Synapse_Illustration2_tweaked.svg
7. Geddes L.A., *Electrodes and the Measurement of Bioelectric Events*, Willey Interscience, New York, 1972.
8. Keidel W.D., *Kurzgefasstes Lehrbuch der Physiologie*, Georg Thieme Verlag, Stuttgart, 1967.
9. Cardiac resynchronisation therapy.
10. Eichmeyer J., *Medizinische Elektronik*, Springer Verlag, Heidelberg, 1983.
11. Heinecker R., *R:EKG - Fibel*, Georg - Thieme Verlag, Stuttgart, 1973.
12. Frank K., *An Accurate Clinical Practical System for Spatial Vectorcardiography*, Circulation XIII, 1956.
13. McFee R., Parungao H., "An orthogonal lead system for clinical electrocardiography", *Am. Heart. J.*, 62, (1961), 74.
14. ., 1985.
15. Lichtlen P., *Klinische Vektor - Elektrokardiographie*, Springer Verlag, Heidelberg, 1969.

16. Benchimol, A., Desser K.B., "Advances in clinical Vector-Cardiography", *Am.J.Cardio.*, 36, (1975), 76.
17. Kresse H. *Kompendium Elektromedizin*, Siemens A.G., Muenchen 1982.
18. Macfarlane P.W., "A critical appraisal of computer assisted ECG interpretation", *J.Med.Eng.&Tech.*, 3, (1979), 281.
19. <http://mobihealthnews.com/27865/fda-clears-android-based-continuous-ecg-monitor/> J. Comstock, FDA clears Android-based continuous ECG monitor, *MobiHealthNews*, Dec 5, 2013.
20. <http://www.medgadget.com/2013/06/new-android-ecg-system-to-let-patients-athletes-keep-a-close-eye-on-heart.html> New Android ECG System to Let Patients & Athletes Keep a Close Eye on Heart, June 21, 2013.
21. Jasper H., "The Ten - Twenty Electrode System of International Federation of Societies for EEG and Clinical Neurophysiology", *Clin. Neurophysiology*, 10, (1958), 371.
22. http://www.google.gr/imgres?imgurl=http://www.allometric.com/tom/courses/protected/ECK/CH12/figure-12-07b.jpg&imgrefurl=http://imagestack.co/96357307-skeletal-muscle-action-potential.html&h=412&w=632&tbnid=8GQRsjkVUASJxM&tbnh=181&tbnw=278&usq=__AeJ1Gm1kFZOnUKYRHg9BVLiclw=&docid=Yb27qZOEzgaGIM. Skeletal Muscle Action Potential.
23. https://www.google.gr/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0CAUQjhxqFQoTCN_vjOHQvcgCFcjSGody3gCUQ&url=http%3A%2F%2Fwww.slideshare.net%2Fmandarhaval%2Ffeeg-in-pediatric-dnb-pediatric&psig=AFQjCNET_ypV_1zt-F7B_7Zo8mnWi3FERQ&ust=1444762922079863
24. Caldwell Laboratories Inc., Technical Report for the Caldwell 5200A System, 1991.
25. Asynchronous-BCI-control-using-high-frequency-SSVEP-1743-0003-8-39-S1.ogv Author: Diez P, Mut V, Avila Perona E, Laciari Leber E (2011). https://commons.wikimedia.org/wiki/Category:Visual_evoked_potentials
26. https://upload.wikimedia.org/wikipedia/commons/8/88/Multielektrodov%C3%BD_EMG_grid.png Multielektrodový EMG grid.
27. Hon E.H., "The Electronic Evaluation of the Fetal Heart Rate", *Am. Obst. and Gyn.* 75, (1958).
28. Hon E.H., *An introduction to fetal heart rate monitoring*, Harty Press Inc., New Haven, 1971.
29. Hickl E. J., Riegel K., *Angewandte Perinatologie*, Urban & Schwarzenberg, Muenchen, 1974.
30. <http://www.neovanta.com/2012/10/new-publication-fetal-ecg-waveform-helps-differentiating-maternal-from-fetal-heart-rate/> Fetal ECG waveform: helping differentiating maternal from fetal heart rate.
31. https://commons.wikimedia.org/wiki/File:Cajal_Retina.jpg Cajal Retina.
32. <https://commons.wikimedia.org/wiki/Category:Retina#/media/File:ConeMosaics.jpg> Illustration of the distribution of cone cells in the fovea of an individual with normal color vision (left), and a color blind (protanopic) retina. The center of the fovea holds very few blue-sensitive cones.
33. Qdavis, https://en.wikipedia.org/wiki/Electroretinography#/media/File:2014_ERG_test.jpg Electroretinography.
34. <http://www.datasci.com/solutions/neuroscience/sleep-research> Location of EEG, EOG and EMG electrodes in humans.
35. <http://drakeeyecenter.com/ophthalmic-instruments/> Ophthalmic instruments.
36. <http://uk.safestb2b.com/hello-seoul-ent-medical-equipment-medstar-ad-21008> medical equipment.
37. <https://commons.wikimedia.org/wiki/File:Zahnarztbesuch.jpg> Zahnarztbesuch

38. https://commons.wikimedia.org/wiki/File:Stress_test.jpg Stress test system.
39. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/md-im/standards-normes/md_rec_stand_im_norm_lst-eng.pdf List of Recognized Standards for Medical Devices, Published by authority of the Minister of Health of Canada, Effective date: 31 AUG 2105.
40. http://www.ptapde.gr/projects/innact/ERGO_3.2.pdf μ , 2004.

1

3 μ .

/

- .
- .
- .

2

3 μ μ .

/

- .
- μ .
- .

3

3 μ « μ » / .

/

- μ .
- .
- est .

3: in vitro

μ

- μ :
in vitro .
- μ .
- μ μ .
- 20 a : μ μ .
- μμ μ
- μ μ μ in vitro
- μ .
- μ .
- 98/79/ μ .
- 21 a : μ ,
- Lab-on-a-chip (LOC).
- μ in vitro .
- μ μ μ μ
- μ .
- μ .
- μ on-line μ μ .
- μ μ RFID. μ μ .
- μ μ μ μ .

3.1. in vitro

3.1.1. μ

« » in vitro
1595 Middelburg μ Hans Lippershey / Sacharias Jansen
Christopher Wren (~1659). 150
μ in vitro
1675 Anton van Leeuwenhoek μ μ
μ [1]-[5].
1771), Giovanni Battista Morgagni (1682-
μ (post-mortem) μ μ μ μ
μ μ
μ « μ » [6], [7].
19 μ μ μ
Lavoisier (1743 - 1794), μ μ « μ »
μ μ μ μ μ μ
μ μ μ μ μ μ μ

Antoine Francois de Fourcroy (1755-1809),

Fourcroy [8].
Fourcroy
« »

Joens Jakob Berzelius (1779 – 1848)

19
2, 1806 1808),
[9], [10].
Berzelius
Berzelius,
« » (vis vitalis),
[11].

Friedrich Wöhler,


1828,
Berzelius,
vis vitalis

Justus Liebig (1803-1873)

Liebig
Justus Liebig
[12].
Giessen 19


Louis Pasteur (1822 –1895)

1857,
Liebig,
Liebig
Louis Pasteur (1822- 1895),



3.1 Justus Liebig Giessen (Trautschold von Ritgen 1840)
<https://de.wikipedia.org/wiki/Liebig-Museum>

(μ μ). μ μ Liebig μ Pasteur μ
 μ μ μ μ 1872 μ Pasteur
 μ μ μ μ μ Pasteur μ μ μ .



3.2 Justus Liebig () Louis Pasteur () μ μ
 μ . Unkown,

https://commons.wikimedia.org/wiki/File:Justus_von_Liebig_NIH.jpg Nadar,
https://commons.wikimedia.org/wiki/File:Louis_Pasteur_foto_av_F%C3%A9lix_Nadar_Crisco_edit.jpg

3.1.2. μ μ μ
 μ μ 19 μ «
 « », William Prout (1785-1850), »
 μ μ μ μ

Thomas Hodgkin (1798-1866)

Wuerzburg 1843 Johann Joseph Scherer (1814-1869) (klinisch-chemischen Laboratorium) "Chemische und Mikroskopische Untersuchungen zur Pathologie" (19) (titrimetric) *in vitro*

1870, 1896, Massachusetts General Hospital, Johns Hopkins 1893,

3.1.3. 20 :

- Otto Knut Folin (1867-1934), Jules Duboscq (1817-1886) (1904).
 - Donald Dexter Van Slyke (1883 - 1971), Folin Van Slyke (1917)
- 20 , 19 20 ,

in vitro

in Vitro	
	I -
	Outsourcing
	(POC)

3.1 in vitro

profiles).

IVD Product Market	IVD Sales 2003 (\$ million)	Market Share (%)	IVD Sales 2008 (\$ million)	Market Share (%)	Average Annual Growth Rate
Clinical chemistry	6735	24	7100	18	1
Nonisotopic immunoassays:	—	—	—	—	—
Infectious diseases	1860	7	2990	8	10
Other immunoassays	3000	11	4465	11	8
Blood bank screening	510	2	580	1	3
Hematology	1340	5	1430	4	1
Microbiology (ID/MIC)	1800	7	2100	5	3
Radioimmunoassays	300	1	290	1	-1
Coagulation	600	2	800	2	6
Histology and cytology	1650	6	2290	6	7
Nucleic acid assays	2125	8	4980	13	19
Blood grouping and typing	320	1	375	1	3
Flow cytometry	650	2	1300	3	15
POC testing:	—	—	—	—	—
Over the counter	3950	14	6510	17	11
Professional or hospital	2850	10	4100	10	8
Total	27,690	100	39,310	100	7

3.4 in Vitro (2003-2008) [15].

800%.

, μ μ « μ » . ,
 , μ μ . ,
 μμ μ ,
 μ . μ μ
 . μ μ
 (μ , , μ μ , μ , /),
 μ (/) μ , μ , , UPS, μ / .
 μ / μ , μ . μ , μ .
 μ μ μ μ μ . μ μ μ
 μ , μ μ μ μ . μ μ μ
 μ μ , μ μ μ μ ,
 (μ , UPS) μ .

IN VITRO		N	
	(m ²)	(m)	
μ	12	3.0	- μμ - μ 2-4 m ²
μ	10	2.5	, μ WC
WC	4	1.5	μ
	16	3.0	μ
	16	3.0	, ,
	4	1.5	
	4	1.5	
	16	3.0	- μ
	16	3.0	
	4	1.5	
	4	1.5	
	16	3.0	μ
	16	3.0	
	4	1.5	
	4	1.5	
	16	3.0	μ
			μ .

Equipment Specifications

Item **Description**

I0B01 **AUTOMATED CLINICAL CHEMISTRY ANALYZER, MEDIUM CAPACITY**

Random access system to perform the following tests: Routine Chemistries, Therapeutic Drugs Monitoring Drugs of Abuse, Immunoassays, electrolytes. Fully open system with stat capability. Throughput more than 200 photometric tests per hour, more than 300 tests per hour with ISE. Reagent positions for at least 20 different test in cooled reagent places. Minimal and controlled reagent consumption. Sampler capacity for at least 70 patient sample. Cuvettes with low operation costs. Bar code for samples/reagents. Automatic calibration-automatic reagent delivery and dilution, automatic Q.C. Automated daily maintenance procedures. Multiwavelength grating photometer . To include water purifying until, printer and up to date computer. Available interface with common LIS (Laboratory Information System)

I0C00 **IMMUNOLOGY-HORMONES ANALYZER**

Fully automated immunoassay analyzer. Continuous random access providing a throughput of at least 120 test per hour. The system can simultaneously run > 18 different tests per sample. The assay technology not to be radioisotopic. The assay menu to include hormones, thyroid, fertility tumor markers, proteins, and infectious diseases. To be upgradable for new tests. Sample capacity not less than 70 samples. Stat samples can be loaded at any time at any position and are processed with priority. Stored calibration, long time stability. Automatic reagent management system, autoreruns, autodilutions. Barcode for sample/ reagent. Liquid level detection. Quality control and auto daily maintenance. To include colour monitor and printer. Networking capability.

I0F00 **ANALYSER, PH/BLOOD GAS, ELECTROLYTES**

For the measurement of pH, pO2, pCO2, Hct on whole blood samples and the calculation of at least 6 parameters. To perform glucose, lactate, K, Na, Ca. Sample volume to be less than 160iL. All consumable should be contained in multi use cartidge and not use gas cylinders. Automatic calibration, self diagnosis, QC software, automatic reagent management bar code compatibility. To include printer and interface for co-oximeter.

3.8

μ (μ) μ μ μ in vitro [22].

μ μ μ μ , μ , μ ,

μ μ 20 [23], μ μ μ μ , μ μ

μ (kitchen-labs).

μ , μ μ μ μ , μ /

μ μ μ in vitro μ , μ μ μ

μ , μ , μ μ « μ » μ , μ μ μ μ , μ , μ , μ μ .

μ , μ , μ .

3.3.1.7.

μ μ μ μ in vitro

(Outsourcing). μ μ :

- μ .
- μ μ .
- μ μ μ μ μ μ μ μ .

μ μ μ μ , μ μ .

μ μ μ μ μ , μ μ .


3.3.2.

/ (/) in vitro

- $\mu\mu$: 70-80 %
- $\mu\mu$: 5-10 %
- $\mu\mu$: 5-10 %
- $\mu\mu$: 10-20 %

3.3.3.4. μ μ

μ μ (μ) ,
 100%
 (Batch Analyzers), μ μ μ (1 - 5),
 μ , μ , μ , μ ,
 μ , μ .
 μ 70 - 80 μ
 μ
 (Random Access Analyzers), . . . R 500/ R
 1000 Technicon Corporation, Tarrytown, New York, μ . . . (. . . 80), μ μ ,
 μ (12 - 18), menu μ , μ ,
 μ , , μ .



3.10 μ L.T. Skeggs [24] (Single channel Auto Analyzer, 1957, Technicon Corporation, Tarrytown, New York,) μ (test-pack) μ ACA IV (stat) (P CT) μ
 Du Pont de Nemours μ ().

μ menu,
 μ , μ ,
 μ μ μ "data manager", μ LIS.

Technicon, Skeggs, Boehringer Mannheim, Hitachi, « »

“Consortium”, “hardware”, “marketing”

« » - « »

Boehringer-Hitachi

« »

in vitro

“outsourcing”

Kalorama Information « » 4.8

2007, 12% 15%, [25].

Westergard


Levey-Jennings [26].

[27].

5. 2 – 4 m « »


autosampler

		ISE (Ion Selective Electrode), Conductivity Electrode, Glucose Oxygen Sensor, Colorimetric, Immuno-turbidimetric, Enzyme Immunoassay, Rate, Endpoint
(Cartridge chemistry detector)		Multi-wavelength, diffraction grating spectrophotometer, Light source: Pulsed xenon lamp, Detector: Diode array for 340, 380, 410, 470, 520, 560, 600, 650, 670, 700 nm wavelength
		NIPIA detector, Type: Light emitting diode, Detector: Photo diode array for 940 nm wavelength
		Modular detectors: ISE, Electrochemical, Colorimetric
(Throughput)		1400 tests/hour maximum 8-11 (stat) 45 sec (ALB, BUN, CALC, CO ₂ , Cl, CRE, GLU, PHOS, K ⁺ , Na ⁺ , P, UREA)
		Reaction Carousel Temp. Cuvette methods 37°C (± 0.2°C)
		Cup Module Temperatures: 37°C & 41°C, method dependent
		ISE Method Temperatures: In ambient operating environment
		Cartridge Reagent Compartment Temp. 2°C - 8°C
		70 μ, 60 cartridge chemistries, 2 - 5 ISE, 6 modular chemistries
(Chemistry Menu)	tests	100 preprogrammed bar-coded methods. On-board data storage 100 user-defined methods
(Bar-Coded)	μ μ μ	μ : μ tests, μ tests, μ/ Lot number, μ μ (Calibration expires)
(Calibration Types)	μ μ	Single-point, 2-point, multi-point Linear and non-linear models (chemistry method dependent)
(Sample Management/Capacity)	μ μ	100 samples input queue, continuous loading 150 samples total
		μ μ Bar code: Code 3/9, Code 128, Interleaved 2/5, Codabar
		μ (Sample volume) μ 3 μl. : μ Haemolysis, Lipaemia, Icterus Sample probe obstruction detection & correction
		Serum, Plasma, Urine, CSF, Whole blood hemolysate
		BD Hemogard, Greiner, Sarstedt 10.25 X 64 mm (3 ml), 13 X 75 mm (5 ml), 13 X 100 mm (7 ml), 16 X 75 mm (7 ml), 16 X 100 mm (10 ml)
		Weight/Volume: pg/ml, ng/ml, μg/ml, pg/dl, ng/dl, μg/dl, mg/dl, g/dl, mg/l, g/l.
		Mass/Volume: nmol/l, μmol/l, mmol/l
		Volume and miscellaneous units: mEq/l, nKat/l, μKat/l, μIU/l, IU/ml, U/l, IU/l, mA, mA/min, %, nIU/dl, mIU/ml
(Communication Modes)		Unidirectional, bidirectional, bidirectional with true Host Query RS-232C Serial
		0.6 l/minute peak flow rate, 16 l/hour minimum continuous flow rate,



3.12 μ , μ μ μ μ μ

[34].



3.13 μ , μ (1:50) μ , in vitro μ μ [: Philipp Holzmann AG, 1985].

-
-
-
- μ 100% μ μ (μ) . μ (μ 8 5 h/w)
- 7 24 h/w).
- μ
- μ μ (μ μ μ)
- μ (μ . POCT μ μ).

UNIVERSITÄTSHOSPITAL JOHANNINA 440303112 05.12.85
60 - 4

ROOM - NO. : 19-1412

11	2 32 30 923-0	
	ANALYSER FOR SODIUM/POTASSIUM, INCL. ION-SELECTIVE ELECTRODES, - SAMPLE VOLUME 135 OR 65 MICROLITRES, - BIO-OUTPUT/SERIELL/ASCII 2862 MOD. 614	1
12	2 35 73 511-1	
	THROMBOCOUNTER SYSTEM INCL. THROMBOCOUNTER C AND THROMBOFUSS 0652 9965034	1
13	2 32 22 874-5	
	HEMATOLOGICAL SYSTEM PROVIDES 6 PARAMETERS: RBC, WBC, HB, MCV, HCT AND PLATELETS, INCL. - DUAL DILUTER, - HEMOGLOBINOMETER, - RCV/HCT ACCESSORY, - IF AND ROLLER MIXER, START-UP KIT, 0652 2F6 SYSTEM/9965066	1
14	2 30 00 015-3	
	LABORATORY MICROSCOPE FOR CLINICAL ROUTINE ANALYSES 0537 490537-STANDARD-16	1

3.14 μ μ (*Room by Room List*) μ , *in vitro*
 μ μ [*Hospitalia International GmbH,*
1985].

μ , μ μ . μ *in vitro*
 μ « » μ « »
 μ , μ « μ μ , μ , μ ,

(Room by Room List) : <http://www.medicalequipmentplanningonline.com>.

in vitro

in vitro

LIS.

3.4.2. 98/79/

in vitro 98/79/ 27 1998

in vitro. 98/79/ *in vitro* (CE)

98/79/	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	CE
17	CE
18	
19	
20	
21	
22-24	

3.4 24 98/79/

[35].
 (Food and Drug Administration, FDA)
 [36].
 [37] Biochips
in vitro
 [38], [43], [40] «μ »
 (International Normalized Ratio, INR)

μ	μ μ μ FDA
486 Alcohol, Breath	027 Luteinizing Hormone (LH)
392 Allergen Specific IgE / Allergen Panel	090 Methadone
041 Amphetamines	092 Methamphetamine/Amphetamine
103 Barbiturates	100 Methamphetamines
101 Benzodiazepines	256 Methylenedioxyamphetamine (MDMA)
409 Bilirubin, Urine	003 Microalbumin
084 Cannabinoids (THC)	143 Morphine
171 Chloride	087 Opiates
161 Cholesterol	030 Ovulation Test (LH) Visual Color Comparison Test
086 Cocaine Metabolites	285 Oxycodone
159 Creatinine	408 pH, Urine
494 Estrone-3 Glucuronide	085 Phencyclidine (PCP)
274 Fecal Occult Blood	245 Protein, Total (Urine)
249 Fern Test, Saliva	364 Semen
026 Follicle Stimulating Hormone (FSH)	246 Tricyclic Antidepressants
184 Fructosamine	021 Triglyceride
122 Glucose	188 Uric Acid
116 Glucose Monitoring Devices	448 Urinary Protein, Qualitative
072 Glucose, Fluid	186 Urine Dipstick Or Tablet Analytes
422 Glucose, Urine	125 Urine hCG Visual Color Comparison Tests
208 Glycated Hemoglobin, Total	264 Urine Qualitative Dipstick Bilirubin
172 Glycosylated Hemoglobin (Hgb A1c)	265 Urine Qualitative Dipstick Blood
261 hCG, Serum, Qualitative	266 Urine Qualitative Dipstick Glucose
370 hCG, Urine	001 Urine Qualitative Dipstick Ketone
121 HDL Cholesterol	268 Urine Qualitative Dipstick Nitrite
016 Hemoglobin	269 Urine Qualitative Dipstick pH
460 Hemoglobin A1	270 Urine Qualitative Dipstick Protein
124 Ketone, Blood	271 Urine Qualitative Dipstick Urobilinogen
352 Ketone, Urine	410 Urobilinogen, Urine
024 Lactic Acid (Lactate)	042 Vaginal pH

3.6) FDA *in vitro* ([39].) (Warfarin),
 INR
 [41],[42],[43],[44].
in vitro

3.5.2. Lab-on-a-chip (LOC)

3.5.2.1. « chip»

« chip» (Lab-on-a-chip, LOC) picoliters (pl). LOC (Micro-Electro-Mechanical Systems, MEMS), chip. (Microfluidics),
 1975
 S.C. Terry, LOC Stanford 90, LOC
 90, LOC
 (Genomics) (Capillary Electrophoresis) DNA Micro-Arrays.


DARPA (Defense Advanced Research Projects Agency),
 « - », « » "Lab-on-a-chip (LOC)".

- LOC
-

-
-

in vitro

LOC, 1
 (nm), (μm)
 « DNA»,



3.15
 and detector and method”

Stanford
 LOC [48].

US 4471647 A “Gas chromatography system
 μ μ

3.5.2.2.

LOC

LOC h
 μ μ μ

[45].

-
-
-
-
-
-
-
-

μ μ μ
 μ μ μ
 μ (etching) μ μ μ


Polydimethylsiloxane (PDMS).

μ μ


μ μ μ μ μ

LOC μ (Precision Engineering).

Bo μ μ μ



3.16 μ LOC [46].



3.17 μ LOC « (Shrinky Dink) (PDMS) [47].

3.5.2.3. μ LOC


μ LOC, μ CD4 [48], μ CRP (C-reactive protein) [49]. μ (gold standard methods),

LOC [50] μ μ μ μ μ

μ	μ		μ	
pH	2<pH<12	Glass Electrode	+/- 0.02 pH R ₂ = 0.99 Correlation	Serum, buffer
Ca(II)	10 ⁻⁷ -10 ⁻³ M	ISE	R ₂ = 0.999 for dose dependant curve	Serum, buffer
CRP	10-105 ng/ml	ELISA	0.987	Human serum
CRP	10-104 pg/ml	ELISA	N/A	Human saliva
DNA-18 mer	10 ⁻¹³ M	PCR	N/A	Buffer
CD4, CD3, CD8, CD45 Cells	50-15000 cells/ μ l	Flow Cytometry	R ₂ = 0.98	Human serum
Bacillus Spores	500	Culture	N/A	Bioaerosol samples

3.7 [50]. μ LOC μ μ (golden standard methods) μ

μ LOC (μ , μ , μ , μ), μ



3.18 LOC μ μ μ μ [51].

μ « » μ μ (cardiomyocytes), LOC μ
 μ chip. LOC, μ
 μ μ - μ - μ , μ ,
 μ μ , μ μ μ
(... - μ *in vitro*), μ μ


3.6. μ in vitro

(~ 287 – 212 . . .)
 Ludolph van Ceulen 32x109 , 1610 , 17 , 35
 (~3 . . .)
 « » (~276-195 . . .)
 500 , (19-07-2012)
 US2012/0185177: “Harnessing high throughput sequencing for multiplexed specimen analysis”.
 :
 •
 • μ (, μ).


μ	-T/	μ μ	T/
	25/443	μ Euler Path	0/1
μ	7/1154	μ Hamilton Path	0/2
μ μ μ	28/598	Splicing (μμ , .)	2/66
μ wavelets	26/984	μμ	5/180
	0/11	μ - (Clustering and Trees)	5/55
	26/984	μμ (Sequence-DB)	0/16
μ μ	0/11	μμ Markov	193/1040
μ	1/58		1/1
μ μ	0/0	μ	5/165
μ	9/129		20/189
μ	0/3	μ (&)	0/5
	8/79	« » μ	0/9
	0/0	μ μ μμ μ	219/1953
μ	1/2	μ « »	3/11
μ μ μ	1/8	Machine Learning	1001/3757
μ	2/51	Randomized Algorithms	3/17

3.8

μ μ (, :) & μ (')
 μ . : μ (, :) & μ (')
 μ μ μ J. Radon (1917) μ μ , μ μ μ
 μ μ μ CT μ μ
 μ μ (-) μ μ μ
 μ μ μ μ μ / μ μ μ
 μ μ μ μ μ , μ .



3.19 μ μ μ μ [55].



3.20 μ μ [55].

(interactively)

μ μ μ μ « μ μ μ μ [58]-[62]. μ μ μ μ μ μ (LAN), μ μ μ μ μ μ

ΕΘΝΙΚΗ ΥΠΗΡΕΣΙΑ ΑΙΜΟΔΟΣΙΑΣ
ΣΤΑΘΜΟΣ ΑΙΜΟΔΟΣΙΑΣ ΠΕΡΑΙΑΣ
Π.Γ.Ν.Π. - ΤΖΑΝΕΙΟ -

ΠΕΡΑΙΑΣ 12/9/99

136

ΔΕΛΤΙΟ ΑΙΜΟΔΟΤΗ

Α. ΣΤΟΙΧΕΙΑ ΑΙΜΟΔΟΤΗ (προσπελάσιμα συμπληρώματα)

ΕΠΩΝΥΜΟ: Σαράντζης ΟΝΟΜΑ: Βασιλίου
ΟΝΟΜΑ ΠΑΤΡΟΣ: Παπαγιάννης ΕΠΑΓΓΕΛΜΑ: ΥΠΟΤΕΙ
ΕΤΟΣ ΓΕΝΝΗΣΗΣ: 1952 ΤΟΠΟΣ: Αθήνα
ΔΕΥΤΕΡΗ ΟΔΟΣ: Ομότιμη Αριθμός: 116 Στοιχεία: Π.Θ.Σ.Α.Υ.Α.
Πόλη: Αθήνα Τ.Κ.Π.562 Τηλέφωνο: 9811964

ΕΧΕΤΕ ΚΑΡΤΑ ΕΒΕΛΑΝΤΗ ΑΙΜΟΔΟΤΗ ΝΑΙ ΟΧΙ
(αν έχετε) Α.Μ. κάρτας αλλοδαπής υπηκότου ΝΑΙ ΟΧΙ

ΘΕΛΕΤΕ ΝΑ ΓΙΝΕΤΕ ΕΒΕΛΑΝΤΗΣ ΑΙΜΟΔΟΤΗΣ ΝΑΙ ΟΧΙ

ΟΝΟΜΑ ΑΣΘΕΝΟΥΣ γι τον οποίο δίνετε αίμα: Δ.Ε.Π.Π. Αθηνών
ΝΟΣΟΚΟΜΕΙΟ: Ζήνωνος Τμήμα: Β7

ΣΥΝΑΓΩΓΟΣ ΕΒΕΛΑΝΤΩΝ: ΕΛΕΥΘΕΡΟΣ ΕΒΕΛΑΝΤΗΣ

ΠΑΡΑΚΑΛΟΥΜΕ ΑΣΤΑΝΤΕΣ ΣΤΟ ΕΡΩΤΗΜΑΤΟΛΟΓΙΟ ΤΗΣ ΠΙΣΤΟ ΣΕΛΙΔΑΣ

Β. ΣΤΟΙΧΕΙΑ ΙΑΤΡΙΚΗΣ ΕΞΕΤΑΣΗΣ (συμπληρώνεται από το Γενικό)

Μέρος σώματος: ΑΡ. 12/95 Σπρίντ: 78
ΗΒ: 14.5 g% 4 HT

ΓΕΝΙΚΗ ΕΝΤΥΣΙΣΗ: α.κ.

Γ. ΕΙΔΙΚΟΣ ΜΟΝΑΔΑΣ ΑΜΑΤΟΣ (συμπληρώνεται από το Εργαστήριο)

ΟΜΑΔΑ Α Β Β (0) RHESUS (+) ΦΑΝΟΤΥΠΟΣ
HbA1c (-) HCV (+) HIV 1-2 (-) HTLV 1-2 (-) HEPATITIS (-)

ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ ΚΑΙ ΠΡΟΦΥΛΑΞΗΣ
ΠΕΡΙΦΕΡΕΙΑΚΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΑΣ
«Ο ΕΥΑΓΓΕΛΙΣΜΟΣ» - Π.Π.Α.Α.
ΕΤΟΣ ΙΔΡΥΣΗΣ 1884
ΣΤΑΘΜΟΣ ΑΙΜΟΔΟΣΙΑΣ

Αθήνα

ΔΕΛΤΙΟ ΑΙΜΟΔΟΤΗ

ΕΠΩΝΥΜΟ: ΟΝΟΜΑ
ΠΑΤΡΟΝΥΜΟ: ΕΤΟΣ ΓΕΝΝΗΣΗΣ
ΕΠΑΓΓΕΛΜΑ
ΔΕΥΤΕΡΗ ΟΔΟΣ: ΑΡΙΘ.
ΠΟΛΗ: ΤΑΧ. ΚΩΔ. ΑΡ. ΤΗΛ.

ΑΣΘΕΝΗΣ γι τον οποίο προσκομίζετε το αίμα

ΕΠΩΝΥΜΟ: ΟΝΟΜΑ
ΤΜΗΜΑ:
ΑΡ. ΓΕΣΗΣ-ΜΕ: ΜΗ: ΣΥΣΤΕΣ: ΟΜΗ:
ΟΡΜΟΝΟΡΡΟΦΙΑ: ΑΜΑΤΟΚΡΗΤΗΣ: % ΑΜΟΞΟΡΡΟΦΙΑ: g%

ΓΕΝΙΚΗ ΕΝΤΥΣΙΣΗ: ΝΑ
ΟΜΑΔΑ ΑΜΑΤΟΣ
ΓΕΝΙΚΗ ΕΝΤΥΣΙΣΗ

Κλινικά στοιχεία:	ΝΑΙ	ΟΧΙ	ΝΑΙ	ΟΧΙ
Εργαζομαι για 6000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 12000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 18000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 24000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 30000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 36000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 42000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 48000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 54000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 60000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 66000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 72000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 78000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 84000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 90000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 96000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 102000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 108000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 114000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Εργαζομαι για 120000 ώρες	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

ΠΡΟΣΟΧΗ
ΠΟΙΟΣ ΔΕΝ ΠΡΕΠΕΙ ΝΑ ΔΕΙΤΕ ΑΙΜΑ


Ονομα: Εργαζομαι για 6000 ώρες από το 1997
Ονομα: Εργαζομαι για 12000 ώρες από το 1997
Ονομα: Εργαζομαι για 18000 ώρες από το 1997
Ονομα: Εργαζομαι για 24000 ώρες από το 1997
Ονομα: Εργαζομαι για 30000 ώρες από το 1997
Ονομα: Εργαζομαι για 36000 ώρες από το 1997
Ονομα: Εργαζομαι για 42000 ώρες από το 1997
Ονομα: Εργαζομαι για 48000 ώρες από το 1997
Ονομα: Εργαζομαι για 54000 ώρες από το 1997
Ονομα: Εργαζομαι για 60000 ώρες από το 1997
Ονομα: Εργαζομαι για 66000 ώρες από το 1997
Ονομα: Εργαζομαι για 72000 ώρες από το 1997
Ονομα: Εργαζομαι για 78000 ώρες από το 1997
Ονομα: Εργαζομαι για 84000 ώρες από το 1997
Ονομα: Εργαζομαι για 90000 ώρες από το 1997
Ονομα: Εργαζομαι για 96000 ώρες από το 1997
Ονομα: Εργαζομαι για 102000 ώρες από το 1997
Ονομα: Εργαζομαι για 108000 ώρες από το 1997
Ονομα: Εργαζομαι για 114000 ώρες από το 1997
Ονομα: Εργαζομαι για 120000 ώρες από το 1997

ΜΗΝ ΓΙΝΕΤΕ ΟΜΩΣ ΑΙΜΟΔΟΤΗΣ

Ο Γενικός Επιμεταστάτης
Ο Αρμόδιος

3.26

(μ) μ μ



3.27

μ μ [63], [70] - [74].

μ IBSB-128 μ , :

- μ μ μ μ
- μ μ μ μ μ μ
- μ μ μ
- μ $\mu\mu$ μ
- μ
- μ μ μ μ μ μ μ μ /
- μ , $\mu\mu$ μ , μ
- μ , μ μ μ :
- μ
- μ
- μ .
- μ

(barcoding)



1		2	
W1234 02 123456A W		5100	
Accurate Blood Center Anywhere, Worldwide			
<small>Properly Identify Intended Recipient See Circular of Information for indications, contraindications, cautions and methods of infusion. This product may transmit infectious agents.</small>			
R only VOLUNTEER DONOR			
3		4	
E0291V00		0022062359	
		Expiration Date JULY 31 2002	
RED BLOOD CELLS ADENINE-SALINE (AS-1) ADDED		Special Testing bar code goes here	
<small>From 450 mL CPD Whole Blood</small>			

3.28 μ μ ISBT 128 μ [62].

3.7.3.

μ

μ

μ μ μ μ μ μ μ μ μ HTML μ

μ μ [52]-[54], μ μ μ μ μ

μ , μ μ



μ	μ	μ
μ	μ	μ
μ	μ	μ
μ	μ μ	μ

3.9 μ μ [52]-[54].

μ

,


:




3.30 : RFID $\mu\mu$ PC RS232 « » . :
 μ : « » RFID
 ,) .

μ RFID μ μ 7.5 « » RFID
 μ : μ RS 232. μ μ ~180 m.
 • μ μ μ μ μ μ μ
 • μ / RF 433.92 MHz, μ μ μ

Transmitter (#27980)




Receiver (#27981)



3.31 μ μ μ μ μ RF- μ / Parallax 433.92
 MHz (μ ~ 180 m) [75].

BIMS
RFID (ISBT 128)


RFID BBIMS. RFID, BBIMS, bar-code BBIMS, ISBT128. 2 \$/RFID-tag 100-300 \$ on-line




3.32

« » μ μ RFID [70]. μ ,

Office. : MS-Access, / Nikon 50 i.





3.35 μ



(: Cell Dyn 1800 : HeCo).

CellDyn HeCo),



3.36 μ μ μ [64]-[68].

/

1. , .. , , , 2000.
2. Kay P. Jankrift: *Mit Gott und schwarzer Magie. Medizin im Mittelalter*. Theiss Verlag, Stuttgart 2005; ISBN 3-8062-1950-8
3. Michael Embach: *Die Schriften Hildegards von Bingen. Studien zu ihrer Überlieferung und Rezeption im Mittelalter und in der frühen Neuzeit*. Akademie, Berlin 2003, ISBN 978-3-05-003666-3. (Erudiri Sapientiae. Band 4).

4. *Avicenna and the Visionary Recital*. Princeton University Press, 1960.
5. *Histoire de la philosophie Islamique*. Gallimard, 1964.
6. D. Craig Brater and Walter J. Daly (2000), "Clinical pharmacology in the Middle Ages: Principles that presage the 21st century", *Clinical Pharmacology & Therapeutics* 67 (5), p. 447-450 [448].
7. Cartwright F. *A Social History of Medicine*, London: Longman, 1977.
8. http://nobelprize.org/educational_games/physics/microscopes/timeline/index.html. L uis Rosenfeld, Clinical Chemistry since 1800: Growth and Development, *Clinical Chemistry*, (2002), 48:1, 186–197.
9. *Wolfgang Eckart: Geschichte der Medizin*. Springer Verlag Berlin, Heidelberg 1990. ISBN 3-540-51982-3.
10. Bechtel W, Richardson RC, Vitalism. (1998). *Routledge Encyclopedia of Philosophy*. E. Craig (Ed.), London ([http:// www.rep.routledge.com/article/Q109](http://www.rep.routledge.com/article/Q109)).
11. L uis Rosenfeld, "Justus Liebig and Animal Chemistry", *Clinical Chemistry*, (2003), 49:10, 1696–1707.
12. Jürgen D. Kruse-Jarres, "Entwicklung der Klinischen Chemie und Laboratoriums-medicin in Deutschland", *Laboratoriums Medizin*, (2005), Volume 29, Issue 3, Pages 198–212
13. L uis Rosenfeld, "A Golden Age of Clinical Chemistry: 1948–1960", *Clinical Chemistry* 46:10 1705–1714 (2000).
14. Leonard T Skeggs Jr., "Persistence and Prayer: From the Artificial Kidney to the AutoAnalyzer" *Clinical Chemistry*, 2000; 46:1425-1436.
15. Kalorama New York (<http://www.device-link.com/ivdt/archive/04/09/ivdt0409p39b.jpg>).
16. Kalorama New York (<http://www.device-link.com/ivdt/archive/04/09/ivdt0409p39c.jpg>).
17. Iowa State University Facilities Planning and Management, Genetics Building Room List (<http://www.fpm.iastate.edu/maps/buildings/rooms.asp?building=GEN%20LAB>).
18. Alexander K. Wing, "Laboratory Automation and Optimization: The Role of Architecture", *Clinical Chemistry* (2000) 46:5 784–791.
19. *Boehringer Mannheim GmbH. Complete Laboratory Concepts*, Mannheim 1984.
20. . . . , μ . . . μ , 2000, . 34-37.
21. B. Spyropoulos, Introduction to Hospital Organization and Biomedical Technology Management, 100p. Patras 1997
22. . . 517/91, ' 202/24.12.1991.
23. Reinhard Kattermann R., *Naturwissenschaft und Medizin: 75 Jahre Klinische Chemie, Pathobiochemie und Mikrobiologie in Mannheim 1910-1985*, Fakultät fuer Klinische Medizin der Universität Heidelberg, 1985.
24. Technical Manual, Stat and routine Analyzers (1980), *Du Pont de Nemours Medical Products*, Wilmington DE, USA.
25. B. Spyropoulos. N. Koufogiannis, "Experimental Determination of the Aging of Biochemistry Analyzer Working Reagent Solutions depending on the Conservation Conditions", 17th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine, 3-7 June 2007, Amsterdam, The Netherlands.
26. http://www.esiap.gr/esiap_FLcontent.htm
27. 1014 () 94, 216 6/3/2001.

28. B. Spyropoulos, C. Tsatsi, D. Pyrgou, C. Alepi, B. Panagopoulou, L. Dadiotis, "A Haematology Laboratory specific Medical Record and associated Educational Means", *Proceedings of Euromedlab 2009*, Innsbruck, Austria, 7-11 June 2009.
29. . . . : « μ μ » μ μ MEDIC-EXPO 2009, ,4 2009.
30. Bronzino J.D., *Management of Medical Technology*, Butterworth-Heinemann, Boston 1992.
31. Laufman H. *Hospital Special-Care Facilities*, Academic Press, New York 1981.
32. Puetsch E., *Modern Hospital*, Lloyd-Luke, London 1979.
33. <http://www.medicalequipmentplanningonline.com>
34. 98/79/ 27 1998 μ , L331, 07.12.1998.
35. List of the FDA approved home test kits sold over the counter, www.fda.gov/cdrh/ode/otclist.html.
36. F.D.R. Hobbs, M. G. Broughton, J. E. Kenkre, et al. "Comparison of the use of four desktop Analyzers in six urban General Practices", *British Journal of General Practice*, 42 (1992) 42, 317-321
37. J.J. Lavigne, S. Savoy, M.B. Clevenger, J.E Ritchie et al. "Solution-based analysis of multiple analytes by a sensor array: toward the development of an "electronic tongue" ". *J Am Chem. Soc* 120 (1998) 6429– 6430.
38. Goodey, Lavigne JJ, Savoy SM, Rodriguez MD, Curey T, Tsao A, et al. "Development of multianalyte sensor arrays composed of chemically derivatized polymeric micro spheres localized in micro machined cavities". *J Am Chem Soc* 123 (2001) 2559–2570.
39. S.L. Wiskur, P.N. Floriano, E.V. Anslyn, J.T. McDevitt, "A multi-component sensing ensemble in solution: differentiation between structurally similar analytes". *Angewandte Chemie International Edition* 42 (2003) 2070–2072.
40. J. Hambleton, "Home Monitoring of Anticoagulation", *Journal of Thrombosis and Thrombolysis* 16 (2003) 39–42.
41. V. Marzinotto, P. Monagle, A. Chan, M. Adams, P. Massicotte, M. Leaker, M. Andrew, "Capillary Whole Blood Monitoring of Oral Anticoagulants in Children in Outpatient Clinics and the Home Setting", *Pediatr Cardiol* 21 (2000) 347–352.
42. S Mähönen, P Riikonen, R-L Väätäinen, T Tikanoja. "Oral anticoagulant treatment in children based on monitoring at home", *Acta Paediatrica* 93 (2004), 687–691.
43. C. P. Price, "Point of care testing", *BMJ* 322 (2001)1285-1288.
44. US Patent Nr.4 471 647, September 18th, 1984.
45. Myers FB, Lee LP. "Innovations in optical microfluidic technologies for point-of-care diagnostics". *Lab Chip* 2008; 8:2015-31.
46. Grimes et al. *Lab Chip*, 2008, 8, 170–172.
47. P. N. Floriano, N. Christodoulides, D.K Romanovicz et al. "Membrane-based on-line optical analysis system for rapid detection of bacteria and spores", *Biosens Bioelectron* 20 (2005) 2079–2088.
48. N. Christodoulides, P. N. Floriano, S. A. Acosta et al., "Toward the Development of a Lab-on-a-Chip Dual-Function Leukocyte and C-Reactive Protein Analysis Method for the Assessment of Inflammation and Cardiac Risk", *Clinical Chemistry* 51 (2005) 2391-2395.
49. McDevitt Research Labs: http://www.tastechip.com/labchip/research_comparisons.html
50. Y Tanaka et al., *Lab Chip*, 2006, 6, 362 – 368.
51. Jungyul Park, Il et al. *Lab Chip*, 2007, 7, 1367 – 1370.

66. ... 20 ... 4-7
 ... 2009.
 ... « n-line
 ... ISO 9001:2000 ...
 ... MEDIC-EXPO 2009, ,4 2009.
67. ... AxSYM-Abbott 2007 ... HBsAg, HIVI/IIAb & HCVA b
 ... « ... »». ... MEDIC-EXPO 2009, , 4
 2009.
68. ... MEDIC-EXPO 2009, ,4 2009.
69. ... MEDIC-EXPO 2009, ,4 2009.
70. ... MEDIC-EXPO 2009, ,4 2009.
 ... RFID». ... n-line
 MEDIC-EXPO 2009, ,4 2009.
71. B. Spyropoulos, P. Lagga, K. Liakos, T. Manetzi, E. Oikonomi, M. Tzoka, “An Industrial Property Document based estimation about the perspective of innovative techniques for blood-transmissible agents (top 5% poster)”, 2011 AABB Annual Meeting, October 22-25, 2011, San Diego, CA, USA.
72. B. Spyropoulos, “Blood inactivation Perspectives as reflected on recent patent applications”, *Innovation in Medical Biology (JIB) Conference*, CNIT 7-9 November 2012, Paris, France.
73. B. Spyropoulos. P. Diakoumi-Spyropoulou, “Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine”, *Proceedings of the 20th IFCC-EFCC European Congress of Clinical Chemistry*, Milano 19-23 May 2013.
74. B. Spyropoulos, “Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine”. *Innovation in Medical Biology (JIB) Conference*, CNIT 6-8 November 2013, Paris, France.
75. <https://www.parallax.com/>

1

in vitro

/

• μ μ

- μ
- μ
- μ (μ ,)
- μ (PCR, TMA)



2 μ ;

- /
- μ
 - μ μ μ
 - μ μ μ

3

μ μ μ **RFID.** μ μ

- /
- RFID μ
 - RFID reader
 - Blood Bank Information System



4.1

μ

μ

μ

μ

Compton.

μ

Raleigh.

μ

1.02 MeV,

μ

μ

511 keV

Compton,

μ

•

•

μ

μ

μ) μ , μ ,

4.2.

film, film

430 nm, Compton

μ μ

$D = dE/dm$ μ μ

1 Gray = 1 Joule /1 kg.

(ucky), μ


- μ
- μ
- μ
- μ



4.2 μ (



):




(ucky), & μ [2].

μ , μ , μ , μ

(ZnS:CdS:Ag). μ , μ , μ


μ , μ μ , μ film, μ film,
 $\mu Ag^+ + e^- Ag^0$




4.3

[3].

- : μ μ
- μ (ZnS:CdS:Ag) (CsI),
- μ μ μ μ μ μ (Wehnelt),
- μ 25-35 kV, μ μ
- μ (ZnS:CdS:Ag),
- μ





4.4



4.6 Over-table Under-table μ [2].

μ μ μ μ , μ (Contrast).



4.7 μ μ μ [6].

μ μ μ μ C (C-arm), μ μ (-arm). μ μ , μ μ , μ . μ : μ • μ .

• μ μ μ film, μ μ
 $m \times n$ (m, n μ μ) μ , μ μ ,
 μ μ μ μ - Video, μ μ
 , μ (4). μ “ $m \times n$ ”
 μ , μ μ μ $m \times n$,
 μ (4). μ μ
 μ , μ μ μ , μ
 μ μ , μ μ μ , μ μ
 μ μ . μ μ μ films,
 μ μ , μ μ μ μ μ μ μ
 μ , μ μ μ .





4.8

[7].


4.3. μ (CT)

μ μ μ film
 μ μ μ μ 30 μ μ μ μ film.
 film μ film μ film μ μ μ
 μ μ film μ μ , μ μ



4.10 CT 1 4 [8]-[10].


μ , μ μ μ μ μ μ
 μ , μ μ μ μ μ
 μ : μ (Gantry).
•
•
•
•
Gantry μ , μ μ CT:
• μ μ μ μ μ μ ,
 μ μ μ μ , μ μ
 μ μ μ , μ μ μ 180 μ 180
• μ μ , μ μ μ 5 μ μ μ
 μ μ , μ μ μ μ 1 μ μ μ




4.12 Cone Beam CT (CBCT)



[12], [13].



4.13



[14], [15].

4.4.

kV.

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ



μ

(Dual Photon Absorptiometry),

^{153}Gd (μ 153).




(μ), ^{80}Sm , ^{140}Nd , ^{137}Ce ,

μ 40 kV 70 kV.



Bone Densitometry Scan

4.14 : $\mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu$ [16].



4.15 : $\mu \mu 40 \text{ kV} 70 \text{ kV.} : \mu \mu 80 \text{ kV} \mu$
 $400 \text{ mg/cm}^2 \text{ Ce.} : \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu$ [16].

NaI(Tl),

4.5.

Henri Becquerel (1852-1908). 1896

Marie Curie, Pierre Curie (1859-1906).

Marie Curie Sklodowska (1867-1934), Pierre Curie (1859-1906).

Jacques, Curie Becquerel

1903 Ernest Rutherford (1871-1937)

1911. Ernest Rutherford (1871-1937) Soddy

1903 Rutherford Soddy

Ernest Rutherford (1871-1937) Cavendish Laboratory

Frederick Soddy 1908

He,


(),

(),

(),

()

Einthoven, Roentgen, Fermi, (standard model), quarks spin, (fermions), spin, (bosons), Bose-Einstein, Fermi-Dirac, Pauli.



4.17 : : μ - μ - μ - Quark.

Fermions		Bosons	
Leptons Quarks	Spin $\frac{1}{2}$	1	Carrier Bosons γ, W^+, W^-, Z^0, g
Baryons (qqq)			Mesons (q \bar{q})
	$\frac{1}{2}, \frac{3}{2}, \frac{5}{2}, \dots$	0, 1, 2, ...	

Interaction	Carriers	act on	Fundamental Particles
Gravitation	Graviton		
Weak	W^+, W^-, Z^0		Leptons*
Electromagnetic	Photon		Quarks
Strong	Gluon		Quarks

*Note: Neutral leptons (neutrinos) do not have electromagnetic interactions

4.18 μ : : Quarks μ μ .

http://pdg.web.cern.ch/pdg/cpep/fermion_boson_chart.html

The Larmor frequency is the frequency of the precession of the magnetic moment around the external magnetic field. It is given by the equation:

$$\omega = \gamma B$$

where ω is the angular frequency, γ is the gyromagnetic ratio, and B is the external magnetic field. The Larmor frequency is directly proportional to the external magnetic field.


For example, in a magnetic field of 10 000 Gauss (1 Tesla), the Larmor frequency for a proton is approximately 42,57 MHz.

NMR (Nuclear Magnetic Resonance) was discovered by Felix Bloch at Stanford in 1946 and by Edward Purcell at Harvard in 1946.


In NMR, a pulse of radio frequency (RF) is applied to the sample, causing the magnetic moment to flip. The resulting signal is detected and processed to obtain the NMR spectrum.

The relaxation time (T1 and T2) is a measure of the time it takes for the magnetization to return to its equilibrium state after the RF pulse.

μ : μ μ μ μ μ μ μ



4.24 μ , μ (μ), μ , μ μ [5].



4.25 « » (RF) μ RI Siemens: : [24]. [25].

μ μ μ μ μ μ μ μ μ MR : μ .

1. Johns H.E., Cunningham J.R., *The Physics of Radiology*, C. C. Thomas, Springfield IL, 1978.
2. Becker J., Kuhn H.M., Wenz W., Willich E., *Radiologie und Strahlenschutz*, Springer Verlag, Berlin, Heidelber, New York 1976.
3. Hoxter E.A., *Roentgenaufnahmetechnik*, Verlag Siemens AG, Berlin & Muenchen 1978.
4. Krestel E., *Bildgebende Systeme für die medizinische Diagnostik*, Verlag Siemens AG, Berlin & Muenchen 1980.
5. Krestel E., *Imaging Systems for Medical Diagnostics*, Verlag Siemens AG, Berlin & Muenchen 1988.
6. Elizabeth George et. al., https://commons.wikimedia.org/wiki/Category:Angiography#/media/File:Preoperative_catheter_angiography_for_hand_transplantation.jpg
7. https://commons.wikimedia.org/wiki/Category:Angiography#/media/File:KH_St_Elisabeth_RV_2013_Radiologie_Angiographie.jpg St. Elisabeth Krankenhaus Ravensburg, Abteilung Radiologie, Angiographie (2013).
8. Alexander J., Kalender W., Linke G., *Computertomographie*, Verlag Siemens AG, Berlin & Muenchen 1985.
9. „ μ », μ : μ . . .
(μ .), μ , μ , μ , μ , μ ,
, 1995.
10. http://www.snipview.com/q/Spiral_computed_tomography Spiral computed tomography.
11. http://www.lookfordiagnosis.com/mesh_info.php?term=multidetector%20computed%20tomography&lang=1 Multidetector computed tomography: Types of spiral computed tomography technology in which multiple slices of data are acquired simultaneously improving the resolution over single slice acquisition technology.
12. Aron Saar, https://commons.wikimedia.org/wiki/File:Cone_Beam_CT_principle.png Cone Beam CT principle.
13. https://commons.wikimedia.org/wiki/File:NAOMI-CT_CBCT_scanner.jpg NAOMI-CT CBCT scanner.
14. https://en.wiki2.org/wiki/Electrical_impedance_tomography Electrical impedance tomography.
15. G. Angelopoulos, C. Tsigkas, A. Tzavaras, B. Spyropoulos, “Digital Multiplexer supported scanning Data Collection Method to be employed in Electrical Impedance Tomography simulation measurements”, *ESCR 2010 Meeting*, Prague, Czech Republic, October 28-30, 2010.
16. https://commons.wikimedia.org/wiki/File:Blausen_0095_BoneDensitometryScan.png Bone Densitometry Scanner. The image is donated by Blausen Medical.
17. <https://upload.wikimedia.org/wikipedia/commons/d/de/12sdfsfsf34.jpg> A nuclear medicine gamma camera by Siemens Medical Systems.
18. https://commons.wikimedia.org/wiki/File:Block_Diagram_of_a_Gamma_Camera-de.svg Block Diagram of a Gamma Camera.
19. https://commons.wikimedia.org/wiki/File:KH_St_Elisabeth_RV_2013_Radiologie_PET-CT.jpg KH St Elisabeth RV 2013 Radiologie PET-CT.
20. <https://commons.wikimedia.org/wiki/File:Pet-ct-images-or.jpg> Excerpt of PET-CT clinical images from a 69-yrs old female with metastases in the pelvic area, evidenced by hypermetabolic spots, one near the sigmoid colon (at right), another in a lymphatic node (at left). Obtained with a Philips PET-CT device in the Cancer Hospital of São Paulo. Patient identification is not shown.

21. https://commons.wikimedia.org/wiki/File:Sarkoidose_Leber_und_Milz_-_36jm_-_CT_und_PET-CT_axial_001.jpg Extrapulmonale Sarkoidose bei einem 36-jährigen Mann. Befall von Leber und Milz sowie der Lunge. Die Computertomographie axial zeigt multiple hypodense Herde, die primär an ein Malignom denken ließen, zumal die Befunde in der PET-CT stark stoffwechselaktiv waren.
22. <http://www.diagnosticimaging.com/pet-ct/petmri-reflections-two-years-after-fda-approval> PET/MRI: Reflections Two Years after FDA Approval: Philips Ingenuity TF PET/MRI.
23. http://www.rad-planning.com/newsletter/2011/1109_3_PET_MRI_hybrid.html Siemens Biograph PET/MRI: The New Kid On The Block
24. https://upload.wikimedia.org/wikipedia/commons/8/8c/Antenne_neuro-vasculaire_IRM.JPG Antenne Volumique de type neuro-vasculaire de marque Siemens destinée à l'imagerie par résonance magnétique.
25. https://commons.wikimedia.org/wiki/Category:Magnetic_resonance_imaging_equipment#/media/File:Atenne_surfacique_IRM.JPG Antenne surfacique de marque Siemens destinée à l'imagerie par résonance magnétique.
26. <http://www.news-medical.net/news/20130403/Handheld-ultrasound-devices-an-interview-with-Warren-Ortmann-Signostics.aspx> andheld Ultrasound device.
27. <http://www.jultrasoundmed.org/content/23/4/473/F6.expansion> Four-Dimensional Ultrasonography of the Fetal Heart Using Color Doppler Spatiotemporal Image Correlation.

1

μ .

/

- Bucky.
- .
- .

2

3

.

/

- -Camera.
- PET.
- PET-CT


3

2

μ .

/

- PET-CT
- PET-MRI



Pos. A. Equipment room Pos. B Examination room Pos C. Control room

- | | | |
|---------------------------|-----------------------------------|-----------------------|
| 1. Floor stand cabinet | 6. Floor stand | 10. Imaging System |
| 2. Generator | 7. Patient table | 11. Control console |
| 3. Cable cabinet (option) | 8. DCS PRO | 12. Measuring station |
| 4. System control cabinet | 9. Floor stand overhead carriage | 13. Hardcopy |
| 5. Cooling unit | 14. LAF Ceiling | |
| 15. USV | 16. Flexible radiation protection | |

5.1

o

μ

μ [1].

μ μ μ μ μ μ

, μ μ μ μ μ μ

• μ μ μ

• μ μ μ μ μ μ

μ μ μ μ μ

• μ μ μ μ μ :

• μ μ μ μ μ

• μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ μ μ

- m^2 . μ μ 10
- μ $6 m^2$.
- μ $9 m^2$.

⋮

- μ $8 m^2$
- μ $6 m^2$ μ $12 m^2$ μ
- $10 m^2$, 2 μ $18 m^2$.
- X μ $20 m^2$. μ $8 m^2$ μ $2 - 3$ μ $12 m^2$.

μ

- μ $25 m^2$ μ
- $10 m^2$.


- $6 m^2$ μ
- μ $12 m^2$ μ $12 m^2$ μ 5 μ $2 m^2$ μ

- μ $(\mu \mu \mu \mu)$ $3 m^2$ μ $day-light$.
- μ $6 m^2$ μ
- μ $6 m^2$.
- μ $8 m^2$.

- μ μ μ μ 3 μ $7 m^2$
- $-$ $-$ (μ) μ $10 m^2$.
- $4 m^2$, μ

⋮

- μ , μ μ μ . μ [25]. μ
- μ μ μ μ μ [26]. μ
- μ (μ , μ μ μ μ μ μ μ) μ μ , μ μ .




5.7 : μ $\mu\mu$ [38]. : "Apollo", Dräger Medical Inc. Telford, PA, USA [39].

μ μ , μ μ μ μ μ μ μ , μ μ μ μ μ : μ (. . . CG, μ , , 2, c 2).

- μ μ (μ μ μ , μ , μ).
- μ μ .
- μ Monitors, μ [27], [28].



5.8 : *monitor* [40]. : *monitor* [41].



- μ μ μ : μ μ μ :
- μ μ μ μ C-arm. μ μ , 4
- μ μ 5000 μ μ .
- μ μ (μ) μ (. . . Day-
- light μ) , μ μ . [29], [30].



5.9 : μ μ μ μ : [42].

- μ μ μ , μ μ : μ sets.

- μ μ .
- (. . . μ).
- μ , μ :
- μ 132 C.
- (μ .
- μ 250-300 C.
- μ μ 2 2.



5.10

μ



[2].



5.11



μ

μ


[43].

μ , μ μ Containers , μ , μ μ . [31]-[34].



μμ μ (PoCT) μ [35]-[37].

- : μ .
- μ : , μ , μ .
- μ : μ , μ , μμ , .

μ , μ , μ μ μ 10 - 20
 μ (spark gap generator), μ μ LC μ 3-70 kHz. 1945,
 μ , μ μ μ , μ μ (300-3000 kHz), μ
 μ $\mu\mu$, [44-46]. μ



5.12 : μ μ μ μ () . [44-46].




5.13 : μ US6203541B1 [47]. : [48]. μ μ


LASERs
 1700
 LASER, 50
 arc-lamp Ruby LASER
 1961. Charles Campbell Institute of Ophthalmology, Columbia- Presbyterian Medical Center
 Charles Koester American Optical Corporation Ruby LASER Photo-coagulator
 Ruby LASER Photocoagulator
 LASER
 LASER
 LASER

	LASER
	Excimer, Nd:YAG, Argon, Ho:YAG, CO2
/	CO2, CV, PLDL, Ruby, Alexandrite
	Sharplan CO2
	Nd:YAG
	Nd:YAG, CO2, KTP
	Nd:YAG, CO2, KTP
	CO2, KTP, Argon
	Argon, Nd:Yag, Krypton
	Ho:Yag
	CO2, KTP, Argon
	CO2, Argon, , Nd:YAG

5.1 LASER



5.14 : (1970-2010). : 1960-2010.



5.15 : LASER»
 59% LASER



5.17



[53], [54].

μ

μ video,

Erich M he 1985 [68]

1990 μ Philippe Mouret 1987 [69].

μ trocars.


μ video-

(CO₂)

(Light source) μ



5.18



[71].

5.3. « μ »

μ da Vinci

μ

μ DaVinci

FDA μ

μ

μ

μ μ

800

μ μ

μ

Johns Hopkins University Research Center for Computer

Integrated Surgical Systems and Technology

μ

μ

(FDA)

μ

Intuitive Surgical,

μ

μ μ

μ μ :

- μ μ
- T
- T



5.19

μ da Vinci

μ

[57].

μ μ μ

,

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

μ μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ video cameras,

μ

μ

μ

, video monitor

2000 μ

μ

μ

μ

350

μ

μ

μ



μ μ μ

,

μ

μ

video monitor da Vinci 1995



5.23 : μ . : μ μ μ μ 3:30 [59].

5.5.

ISO-9000. [61],
 «on-line»
 «»

Step	Tasks and actions
Awareness and interest	Recognition of the need, introductory meetings and readiness survey.
Implementation Team Development	Selection of a cross-disciplinary implementation team, training of internal Quality auditors, implementation coordinators, approval of an implementation plan.
Policy Clarification	Quality Manual drafted, operating procedures drafting and approval.
Present Procedure Documentation	Operating Procedures finalized and distributed,
Work Instruction Documentation	Work Instruction writing, reviewed and approved.
Internal Audit	Conduct internal Quality System Audit, corrective actions issued.
System Improvements	Implementation of corrective actions, confirmation of their effectiveness.
Pre-Assessment Audit	External auditors pre-assessment, findings reported and corrective actions are issued.
Non-conformity Resolution	Resolution of known nonconformities
Certification Audit	3 rd party certification audit, report, non-conformances correction, Certification.
Follow-up	Semi-annual internal audits and annual external audits.

5.2 [61].

ISO 9000: 2008

web-based (XML),

μ μ μ

μ ()


μμ

The image displays three medical forms from the Hellenic Republic's Ministry of Health. The first form on the left is titled 'ΠΡΟΕΓΧΕΙΡΗΤΙΚΗ ΚΑΙ ΜΕΤΕΓΧΕΙΡΗΤΙΚΗ ΕΚΤΙΜΗΣΗ ΑΣΘΕΝΟΥΣ' (Pre- and post-operative patient evaluation). The middle form is 'ΑΝΑΙΣΘΗΣΙΑ ΕΞΕΤΑΣΗ ΚΑΙ ΔΙΑΓΡΑΜΜΑΤΑ' (Anesthesia evaluation and diagrams), featuring a large grid for recording vital signs and anesthetic agent usage. The third form on the right is 'ΜΕΤΕΓΧΕΙΡΗΤΙΚΗ ΕΚΤΙΜΗΣΗ ΑΣΘΕΝΟΥΣ' (Post-operative patient evaluation). A purple watermark 'Pre- and post operative patient evaluation' is overlaid across the forms.

5.24

μ

μ μ [61].




5.25

μμ

μ

μ

μ (μ , μ) μ
 μ μ « μ », μ
 μ μ ISO, μ
 μ μ



5.26 .

[61].

ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ ΚΑΙ ΚΟΙΝΩΝΙΚΗΣ ΑΣΦΑΛΙΣΤΙΚΗΣ
 Δ.Υ.ΓΕ.
 ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ

Ημερ/νία: _____

ΕΝΤΥΠΟ ΥΠΟΒΟΛΗΣ ΠΑΡΑΠΟΝΩΝ

ΣΤΟΙΧΕΙΑ ΑΡΡΕΤΟΝΟΜΟΥ
 Ονοματεπώνυμο παραπονούμενου: _____
 Ιδιότητα παραπονούμενου: Ασθενής / Συναγής ασθενούς / Άλλο _____
 Διεύθυνση: Τ.Κ.-Π.Ω.Π.: _____

ΣΥΜΠΤΩΜΑΤΑ (Παραπονών)
 Πάθη ή νόσος (παρά): _____

Complain Form

Το ενδιαφέρον εστιάζεται στα τα δελτία του θύματος.

Διευκρίνιση ή διερεύνηση παραπόνου: _____

ΔΙΑΚΡΙΣΗ ΠΑΡΑΠΟΝΟΥ (Συνεπείκρινση από τον υπεύθυνο)
 Τύπος Νοσηλείας/Διαμνητέρας: _____
 Κατηγορία παραπόνου: Φαρμάκων / Εργασίας / Εξοπλισμού / Άλλου Προκείμενου Τυχήματος: _____

Διαθέτουμε ή διαθέτουμε παραπόνου: _____

Επιτελέθηκε ο παραπονούμενος: ΝΑΙ / ΟΧΙ / Με νέο τρόπο: _____
 Ονοματεπώνυμο: _____

ΣΤΟΙΧΕΙΑ ΕΠΙΧΕΙΡΗΣΙΑΚΩΝ ΔΕΔΕΓΜΕΝΩΝ - Τ.Κ. - Π.Ω.Π. - ΤΗΛ. - FAX

5.27

ΤΜΗΜΑ ΜΑΙΕΥΤΙΚΗΣ	ΠΑΡΑΡΤΗΜΑ Γ' ΕΠΙ-ΕΠΙΧΕΙΡΗΣΙΑΚΩΝ ΙΣΤΟΡΙΩΝ	Έγκριση Διεύθυνση Νοσηλείας ημερομηνία Έγκρισης: 2/6/2011 Έκδοση η Υπεύθυνος Ποιότητας Σελίδα: 2 από 3
------------------	--	--

ΒΗΜΑΤΑ ΠΡΙΝ ΤΗΝ ΕΠΕΜΒΑΣΗ

ΕΛΕΓΧΟΣ	ΕΛΕΓΧΟΣ
Επιβεβαίωση ταυτότητας ασθενή	
Επιβεβαίωση είδους επέμβασης	
Συγκατάθεση ασθενή	
Έλεγχος αναισθησιολογικών συσκευών	
Έλεγχος απορριπτικών φαρμάκων	
Γνωστή αλλεργία του ασθενή	

ΚΑΣΑΡΗΝΗ ΤΟΜΗ

ΕΛΕΓΧΟΣ/ΠΑΡΑΤΗΡΗΣΕΙΣ
Ανασθησία
Τύπος
Εξαγωγή νεογνού
Ροπή κεφί

Delivery Procedure Instruction Form

ΦΥΣΙΟΛΟΓΙΚΕΣ ΤΟΚΕΤΙΣ

ΕΛΕΓΧΟΣ/ΠΑΡΑΤΗΡΗΣΕΙΣ
Ανασθησία
Στάδιο διαστολής
Στάδιο εξόδου
Στάδιο υπερτοκίας

μ μ

ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ ΚΑΙ ΚΟΙΝΩΝΙΚΗΣ ΑΣΦΑΛΙΣΤΙΚΗΣ
 Δ.Υ.ΓΕ.
 ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ

Ημερ/νία: _____

ΑΝΑΦΟΡΑ ΣΥΜΒΑΝΤΟΣ Ή ΑΤΥΧΗΜΑΤΟΣ

ΣΥΜΠΡΑΒΗ ΕΠΕΜΒΑΣΗΣ

Τραυματισμός από αναισθησία	Καταστροφή εξοπλισμού	Παρελάκι
Τραυματισμός από μήτρα	Καταστροφή εξοπλισμού	Ανάλυση ή σκληρή αντιμετώπιση
Άλλο	Διασπορά υαλινών οστών	Επίθεση κατά ασθενή(ους) ή σωματίων

Το συμβάν αφορά: _____

Παραγραφή: _____

ΣΤΟΙΧΕΙΑ ΕΠΕΜΒΑΣΗΣ - ΣΤΟΙΧΕΙΑ ΜΑΡΤΥΡΩΝ & ΑΝΑΦΕΡΟΝΤΟΣ

Κύριος: Ονόματι/Διεύθυνση: _____ Ορόστος: _____ Τύπος: _____

ΣΤΟΙΧΕΙΑ ΜΑΡΤΥΡΩΝ:

1. Ονοματεπώνυμο:	Ιδιότητα:	Τμήμα:
2. Ονοματεπώνυμο:	Ιδιότητα:	Τμήμα:
3. Ονοματεπώνυμο:	Ιδιότητα:	Τμήμα:

ΣΤΟΙΧΕΙΑ ΑΝΑΦΕΡΟΝΤΟΣ:

Ονοματεπώνυμο: _____ Ιδιότητα: _____
 Ημερ/νία: _____ Τύπος: _____ Υπογραφή: _____

ΑΙΤΙΟΛΟΓΙΑ ΤΟΥ ΕΥΧΑΙΡΙΣΤΟΥ ΚΑΙ ΕΜΠΕΡΙΣΤΟΤΗΤΑ ΤΩΝ ΣΤΟΙΧΕΙΩΝ

Αιτιολογία: _____

Εμπειρία υπεύθυνου: _____

ΣΤΟΙΧΕΙΑ ΕΠΙΧΕΙΡΗΣΙΑΚΩΝ ΔΕΔΕΓΜΕΝΩΝ - Τ.Κ. - Π.Ω.Π. - ΤΗΛ. - FAX


[61].

/

1. http://www.ctsnet.org/portals/endovascular/nutsbolts/Nollert_HybridOR_fig5 Hybrid Operating Room (OR) example. Cardiovascular Hybrid OR: Clinical and Technical Considerations. CTSNet.
2. <http://frandsenarchitects.com/gmc-or10/> Gwinnett Medical Center - Neurological Operating Room #10, Frandsen Architects, Location: 1000 Medical Center Blvd Lawrenceville, GA 30046, USA.
3. '202/24.12.1991
4. Ruhrfisch, https://commons.wikimedia.org/wiki/File:Cardiac_operating_room.jpg Cardiac operating room.
5. Klebanoff G. *Bull. Am. Coll. Surg.* 64 (1979) 6.
6. Laufman . *m. J. Surg.* 122 (1971) 332.
7. Moore J.S., Spencer W. J. *J. Am. Hosp. Assoc.* 49 (1975) 115.
8. Laufman H. *Med. Instrum.* 7/8 (1967).
9. Beck N.C. *Am. J. Surg.* 140 (1980) 327.
10. DIN 5035, Teil 3.
11. Claywell J. *Ill. Eng.* 12 (1967) 654.
12. <http://www.alamy.com/stock-photo-scialytic-lamp-67543135.html> Scialytic lamp.
13. <http://www.aviga.lt/produktai.php?f=1&gr=196>
14. <http://www.bioblog.it/2008/05/26/lampada-scialitica-a-led/20082938> Power LED 500, Maquet, Germany.
15. <http://www.google.com/patents/US6464383> Fiber optic ceiling supported surgical task light system with optical commutator and manual zoom lens, US6464383.
16. <http://technomedindia.tradeindia.com/halogen-operation-theatre-lights.html> Halogen Operation Theatre Lights.
17. VDE 0750.
18. <http://www.mizuhosi.com/products/spine/proaxis/> Spinal Surgery Tables.
19. https://www.google.gr/search?q=surgical+tables&source=lnms&tbm=isch&sa=X&ved=0CAcQ_AUoAWoVChMIyO3GzZLZyAIVS7gaCh2S5wAa&biw=1280&bih=699#imgrc=GdKEHdXtO9Zy9M%3A Pre-owned Surgical Table Accessories: Bariatric Table Extenders Complete Set w/ 4.
20. Conway C. M. *Brit. J. Anaesth.* 57 (1985) 649.
21. Mapleson W.W. *Brit. J. Anaesth.* 26 (1954) 323.
22. Bruce D.L., Linde H.W. *Anaesth.* 60 (1984) 342.
23. White D.C. *Brit. J. Anaesth.* 57 (1985) 658.
24. Gray W. M. *Brit. J. Anaesth.* 57 (1985) 685.
25. Gale . et al. *Hospimedica* 4 (1986) 41.
26. Greenbaum R. *Brit. J. Anaesth.* 57 (1985) 709.
27. CNEH *Cahier* . 3.
28. CNEH *Cahiers* . 11, 12, 13.
29. Berci G, Steckel R. *Arch. Surg.* 107 (1973) 577.


30. Berci G. Seyler A. *Am. J. Roentg.* 90 (1963) 1290.
31. CNEH *Cahiers* . 2 , 16.
32. DIN 58946, *Teile* 2, 4, 6.
33. ISO/DIS 7741.
34. DIN 58 298.
35. CN *Cahier* . 1.
36. *Medizin Geraete Verordnung* (MedGeV), Bundesgesetz Blatt Teil1,NV2/19.01.1979 s.93.
37. Nebe G. *Medizintechnik* 4 (1985) 137.
38. http://medind.nic.in/iad/t13/i5/IndianJAnaesth_2013_57_5_472_120143_f1.jpg Safety features are incorporated into every single component of the machine.
39. <http://www.udmercy.edu/crna/agm/images/apollo.jpg> The Anesthesia Gas Machine “Apollo”, Dräger Medical Inc. Telford, PA, USA.
40. <http://www.medicalexpo.com/prod/maquet/product-69182-541855.html> Multimedia data management module for integrated operating theatre
41. <http://www.ramalaser.com/know/RFsurgery/Electrosurgery.htm> Principles of Electrosurgery.
42. <http://hybridoperatingroom.com/hybrid-operating-room-angiography-imaging-systems/> Hybrid-OR-Operating-Room-Toshiba-C-Arm-Skytron
43. http://www.symbolmachine.com/pafiledb/symimages/S_Getinge_HS6606_Turbo_Steam_Sterilizer.rfa.jpg Getinge Steam Sterilizer.
44. Czerny V., *Ueber die Blitzbehandlung des Krebses*, Verh. Dtsch. Ges. Chir., 1908.
45. Keibel W., Seelinger E., “Radiotom 611, ein Universalgeraet fuer Elektrochirurgie”, *SRW Nachrichten*, (1957), 2.
46. Kresse H., *Kompendium Elektromedizin: Grundlagen, Anwendungen, Geraete.*, Siemens A.G., Muenchen 1982.
47. <http://www.google.com/patents/US6203541> Automatic activation of electro-surgical generator bipolar output, US 6203541 B1.
48. <http://www.cehjournal.org/article/electrosurgical-units-how-they-work-and-how-to-use-them-safely/> “Electrosurgical units: ow they work and how to use them safely”, *Comm Eye Health* Vol. 28 No. 89 2015 pp 15-16, 08 June 2015.
49. B. Spyropoulos, “50 years LASERS: in vitro diagnostics, clinical applications and perspectives”, *Clinical Laboratory*, 2011, 57(3-4):131
50. <http://www.paragonmed.com/laser30Watt.shtml> The Cutting Edge 30 Watt CO2 Laser System.
51. <http://www.medidirect.net/brymill/cryosurgery.html>
52. <http://www.atlasofpelvicsurgery.com/4Cervix/9CryosurgeryOfCervix/chap4sec9.html>
53. https://commons.wikimedia.org/wiki/File:Pacific_Partnership_Ends_Years_of_Darkness_for_Little_Girl_DVIDS95126.jpg
54. https://www.google.gr/search?q=surgical+diode+laser&biw=1280&bih=699&source=lnms&tbm=isch&sa=X&ved=0CAYQ_AUoAWoVChMImYnEsZjbyAIVwl4UCh2SOwAv#tbm=isch&q=surgical+microscope&imgsrc=yFF7frOBwILD_M%3A
55. https://commons.wikimedia.org/wiki/Category:Laparoscopy#/media/File:Blausen0602_Laparoscopy_02.png
56. <https://commons.wikimedia.org/wiki/Category:Laparoscopy#/media/File:Appendectomy2.jpg>

57. https://commons.wikimedia.org/wiki/Category:Surgical_robots#/media/File:Laparoscopic_Surgery_Robot.jpg .
58. <http://roboticmedicaltechnology.weebly.com/about-da-vinci.html> Da Vinci Robotic Medical Technology: System Overview.
59. Improving Patient Flow and Throughput in California Hospitals Operating Room Services, *Program for Management of Variability in Health Care Delivery*, Boston University Health Policy Institute, 53 Bay State Road, Boston, MA 02215.
60. Litvak E. "Optimizing Patient Flow by Managing its Variability." In Berman S. (ed.): *Front Office to Front Line: Essential Issues for Health Care Leaders*. Oakbrook Terrace, IL: Joint Commission Resources, 2005, pp. 91-111.
61. Basile Spyropoulos, Kostas Lefteriotis, Eftychia Nassioka, Alexandros Tsouni, Eleftherios Papalexis and Aris Tzavaras, "A Web-based System Supporting the Certification of a Surgical Department in a General Hospital", *EMBEC 2011*, Budapest 14-16 September 2011.




Conventional Radiotherapy

Interaction with water generates limited number of electrons



Radiotherapy with NanoXray

Interaction with Hafnium oxide nanoparticles generates large number of electrons



Much more photon are absorbed then much more electrons generated at the same dose of radiation and, hence, more cell killing activity

6.2

μ

[3].

μ

HfO_2

μ

μ

μ

μ

μ

(treatment planning)

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ


μ

μ

(treatment planning)


μ

μ



6.3

μ



DNA

μ

[4].

[5].

100 Angstrom.

μ (. . DNA)

μ

μ

μ



μ IMRT (IMRT) μ μ μ IMRT IGRT, (μ μ $\mu\mu$ μ , μ μ , μ . μ μ μ , μ , μ , μ) . μ (μ .. , μ) . μ , μ , μ , μ , μ , μ , μ , μ . μ (μ , μ) , μ , μ , μ . μ μ μ . μ μ μ , μ . μ 50% μ , 40% . :

-
- μ (μ) .
 - μ .
 - μ (μ μ) .
 - μ μ (Hodgkin μ non- Hodgkin μ μ) .
 - μ & (μ) ,

-
- μ μ .
 - μ .
 - μ & μ .
 - μ .
 - μ μ .
 - μ .
 - μ μ μ (μ , μ) .
 - μ μ μ .
 - μ .
 - μ .

6.2. H

μ . μ , μ 1896, μ , μ 1910. Emil Grubbe, μ , μ , Rose Lee, μ μ , Grubbe μ , μ [8]. μ



6.5 : μ μ 1910 (1920)

[11]. : μ μ
[12].

μ μ , Claude Regaud, μ μ μ ,
 μ μ [9]. μ , μ Henri Coutard, μ μ μ)
 μ μ μ , μ μ 1934 [10], μ ,
 μ μ μ . μ μ 1898 μ ,
 μ μ μ μ , μ 1900 Otto
Walkhoff, μ μ « μ Becquerel». 1901, Henri
Becquerel μ , μ μ μ ,
 μ μ Ernest Besnier, μ μ ,
 μ μ μ . Curie, μ μ . , Besnier
 μ μ μ ,
 μ μ , μ μ μ) .
 μ μ , μ Vincenz Czerny μ μ μ) .
 μ μ 1877 Czerny μ μ 1908
(Samariterhaus). μ μ μ - μ μ 47 μ μ ,
 μ μ μ , μ μ ,
 μ μ , μ μ Friedrich Dessauer (1881-

1963) Boris Rajewsky (1893-1974) μ

6.3. : Betatron μ '80

Betatron « μ » Donald Kerst μ Illinois 1940.
 Rolf Widerøe, μ , μ
 Max Steenbeck, '40,

$$\theta_0 = 2\pi r_0^2 H_0,$$

where

θ_0 is the flux within the area enclosed by the electron orbit,

r_0 is the radius of the electron orbit, and

H_0 is the magnetic field at r_0 .

In other words, the magnetic field at the orbit must be half the average magnetic field over its circular cross section:



$$\Leftrightarrow H_0 = \frac{1}{2} \frac{\theta_0}{\pi r_0^2}.$$

This condition is often called *Widerøe's condition*.^[8]

6.6

Widerøe

Betatron.



6.7

: Donald W Kerst

Betatron

Betatron[14].

: Rolf Widerøe

6.4.

'90

μ μ T

, (⁶⁰C, ¹³⁷Cs) μ

μ μ T

⁶⁰C

¹³⁷Cs,

μ

μ

90

μ

μ

μ

μ

⁶⁰C

¹³⁷Cs

SRS)

(Stereotactic Radio Therapy SRT). SRT


(-Knife Stereotactic Radio-Surgery,

μ μ

μ

μ μ

.




Original – A radiation teletherapy capsule:
 A.) an international standard source holder (usually lead),
 B.) a retaining ring, and
 C.) a teletherapy "source" composed of
 D.) two nested stainless steel canisters welded to two
 E.) stainless steel lids surrounding an
 F.) internal shield (usually uranium metal or a tungsten
 alloy) that protects a
 G.) cylinder of radioactive source material, often but not
 always cobalt-60. The diameter of the "source" is 30mm.

6.10

μ ⁶⁰C

⁶⁰C [26].



6.11 : ^{60}Co -Knife μ 192 μ ^{60}C , [24].

Gamma Knife
1950,


Lars Leksell,

1967


Karolinska,

Gamma Knife

DNA





6.13 [28].



6.14 [30] [31]


(Bremsstrahlung).
 magnetron klystron. (. . . , Wo).




6.17 : μ [38]. e^- [37]. : μ

(flattening filter),
 (flattening filter free).
 (collimator).
 (jaws)
 (multileaf)



μ , μ μ



6.18 μ $\mu\mu$ [38].



6.19 μ μ μ μ μ [39]



6.20 : lock-diagramme LINAC [40].

RT IGRT[41].

LINAC

μ 4-5 $\mu\mu$

- Microtron μ 50 MeV X-rays e^- .
- (14 MeV).
- M

Microtron

25MeV,



μ μ , μ . 1945 Vladimir Veksler μ ,
 Microtron, μ , μ , μ ,
 Microtron, μ μ (1),
 μ μ μ (2).
 μ (3), μ ,
 μ (4). μ μ ,

$E = mc^2$,
 (5).

, μ , μ AC μ . ,
 μ , μ μ μ ($E_0 = m_0c^2$)
 , μ , μ AC,

Veksler 1944,
 Edwin McMillan, μ



μ , μ Scanditronix Wellhoefer, μ MM50 Racetrack
 Microtron .



6.21 :

Microtron [42]. :



Race Track Microtron [43].



6.22 H μ RTM 100 Microtron[44].

National Laboratory : μ μ μ Lawrence Berkeley :
 • D-D (2.5 MeV).
 • D-T (14 MeV).
 • - (0-9 MeV).
 μ μ μ , μ , μ :
 • μ μ (Boron Neutron Capture Therapy).
 • μ -
 • μ
 • μ μ μ μ μ .

MeV
 μ
 K (D+Be) $\mu\mu$ (p, n).
 μ , s
 Seattle, WA, Detroit MI Batavia, IL. 2
 μ (Be). T
 Batavia Fermilab μ $\mu\mu$



6.23 Scanditronix Racetrack Microtron μ [45].




6.24 :



University of Washington [46]. :
 Phoenix Nuclear Labs (PNL) [47].



1×10^{11} (D-D), 5×10^{11} n/s. 3×10^{11} D-D n/s, Phoenix Nuclear Labs (PNL) [47].



6.25 [48].

The text in this section is highly garbled and contains numerous symbols and fragments that are difficult to decipher. It appears to be a corrupted or heavily redacted version of a document. Some recognizable fragments include:

- PNL
- M
- 1947.
- 1949
- 1935
- « »
- M



6.27 : $\mu \mu \mu$ Bragg.

: μ [51]. Bragg μ

$\mu \mu \mu$ Bragg,

μ , μ ,

μ

μ Bragg,

Bragg μ

μ

26 (),

μ ,

$\mu \mu$ Bragg.

μ .

«

μ , μ

()

)

.

,

« μ »,

, μ

6.27 () μ

μ

μ

μ

()

,

.

μ

μ

μ

μ , μ

.

,

,

$\mu \mu$

μ ,

μ .

μ .

μ


1950

μ .

μ μ

.

μ ,




6.28


University of Florida Proton Therapy Institute [51].

μ . μ μ , μ , μ , μ , μ , μ , μ .
 μ μ , μ , μ , μ .
 μ μ , μ .
 μ , μ μ , μ .
 μ , μ , μ , μ , μ .
 μ , μ , μ , μ , μ .
 μ μ , μ , μ , μ .
 μ μ μ , (μ μ μ , μ ,
 Ernest Lawrence 1934).
 μ , μ , μ , μ , μ , μ ,
 μ , μ , μ .
 μ μ , μ μ , μ μ .

70-250 MeV,



6.29 μ . . US 1948384 A Ernest Lawrence 1934 [52].



The Nozzle

Brass aperture
The aperture is cut to the outline of the tumor to prevent the radiation from damaging the surrounding tissue.

Lucite compensator
Various depths are cut out of Lucite to squeeze the beam's penetration to the shape of the tumor.

Proton radiation therapy


By adjusting the speed of the protons, a physician can control how deep they will penetrate into the body. The protons then release their energy at the tumor and cause less damage to the surrounding tissue.

Conventional X-ray therapy

Because conventional radiation doesn't release its energy at a specified depth, as it travels through the body it can cause more damage to the tissue surrounding the tumor.

6.30 : « μ : Bragg (SOBP, μ $\mu\mu$ μ $\mu\mu$) μ μ [53]. : μ Bragg μ μ [54].



by side (Treatment Planning). movie loop, (ROI – Region Of Interest). (Distortion)




6.32 (3-D CRT) [57].

(Treatment planning) (isodose curves). Gy rad

μ, ύμ
 •
 • μά
 • μ
 ά μ μ, μύ
 μό, ό ύ έ ί μέ ί ί ό ί .



6.33 μό ί μ ή ό ί μή [58].



6.34 : $\mu\mu$ - $\mu\mu$: μ [60].

(TCP, tumor Control Probability) μ (NTCP, normal tissue
 Complication Probability), μ issue
 , Suk Lee μ .
 RTOG, μ QUENTEC, μ Emami μ μ
 , μ μ , μ μ
 Martin Ebert $\mu\mu$ - (DVHs, Dose-Volume
 Histograms), μ Suk Lee 15 $\mu\mu$
 μ μ μ μ μ μ


Index	Formula	Concept	Value = 1	Value <1 or value >1
PITV (prescription isodose to target volume)	$PITV = \frac{PIV}{TV}$			
CI (conformity index)	$CI = \frac{PTV_{PD}}{PIV}$			
TCI (target coverage index)	$TCI = \frac{PTV_{PD}}{PTV}$			
CN (conformity number)	$CN = TCI \times CI = \frac{PTV_{PD}}{PTV} \times \frac{PTV_{PD}}{PIV}$			
HI (homogeneity index)	$HI = \frac{D_{max}}{PD}$			
MHI (modified homogeneity index)	$MHI = \frac{D_{95}}{D_5}$			
COSI (critical organ scoring index)	$COSI = 1 - \sum_i W_i \frac{V_i(OAR) \geq tol}{TC}$			

Index: = PTV (planning target volume) = PIV (prescription isodose surface volume)
 = TV (target volume) = OAR



6.35

μ

[59].



6.36 $\mu \mu \mu \mu$ [59]. μ



6.37 : $\mu \mu \mu$ [61]. : μ [62]-[64].

6.10.

, $\mu \mu$ $\mu \mu$ $\mu \mu \mu$ μ ,


ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΑΚΤΙΝΟΘΕΡΑΠΕΙΑΣ			
ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΠΕΡΙΟΧΗ ΠΛΑΘΕΡΑΠΕΙΑΣ			
Αποδστήρια	2X1.5=3		Πλήσιον εγκαθιστάσας θεραπείας
Αίθουσα Γραμ. Επιτηρητική	38	5.8	Καθαρός χώρος μημη- νηματος χώρος των διαδρομο-προβόλιμο
Διηλεκτρολογικοί χώροι υποστήρι- ξης του γραμμα- τικού επιτηρητή (χώρος γύωση νε- ρού και χώρος πίνα από την καρδιά) με την βάση του παραπροσφικού συστήματος κ.α)			Αναλόγως του τύπου του εγκαθιστημένου μημηνηματος σύμφωνα με τις εντύπες οδηγίας του κατασκευαστή
Χειριστήριο γ.ε.	7	2.3	Σε επαφή με την αι- θουσα του γραμματικού επιτηρητή μέσω κλειστού κωδωκίματος TV & με δυνατότητα αμφίδρομης ομιλίας
Αποδστήρια γ.ε.	2X1.5=3	1.3	Πλήσιον της εισόδου της αίθουσας γ.ε.
Εργαστήριο Φυσικής κόψης	10		
Εργαστήριο Ηλεκτρονικών	7		
Βοηθητικός χώρος	9		
Αποθήκη περιοχής Τηλεθεραπείας	5		

6.39

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΑΚΤΙΝΟΘΕΡΑΠΕΙΑΣ			
ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΠΕΡΙΟΧΗ ΕΡΧΥΘΕΡΑΠΕΙΑΣ			
Δομάτιο εφαρμογής	24		Αεριοποιημένη αέριουσα υγραυγεία. Απαραίτητη ακτινο- λογική εγκατάσταση για τον έλεγχο της ουστής γεωμετρικής τοποθέτησης των εφαρμογών.
Δομάτιο θερα- πείας	12		Με το κρεβάτι και και την συσκευή μεταφοράς Εφόσον χρησιμοποι- ούνται τεχνικές με- ταφοράς υψηλού ρυθμού δόσεων το δομάτιο θεραπείας μπορεί να ταυτίσει με το δομάτιο εφαρμογής
Προβόλιμο-ηλε- χειριστήριο συ- σκευής μεταφοράς	6		Αν τα δομάτια θερα- πείας είναι 2 μπε- ρονίνα είναι στην αι- τιο προβόλιμο. Εξοπλισμό δυνατό για τις αμφίδρομης ομιλίας. Για συστήματα υψηλού ρυθμού δόσεων και οπτική παρακολούθηση
Χώρος υγιεινής	4		Σε επαφή με το δομάτιο θεραπείας
Ανάληψη	9		Εφόσον χρησιμοποι- ούνται θεραπευτικές μέθοδοι που απαιτούν γωνιακή επιπέδωση
Αποθήκη απο- στηραμμένου υλικού	5		Εφόσον χρησιμο- ποιούνται θεραπευ- τικές μέθοδοι που απαιτούν γωνιακή επιπέδωση

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΑΚΤΙΝΟΘΕΡΑΠΕΙΑΣ			
ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΓΕΝΙΚΟΙ ΧΩΡΟΙ			
Είσοδος Γενική αναμονή ασθενών	16		Εύκολη προσπέλαση
Αναμονή φορέων	7		Δίπλα στη γενική αναμονή αλλά αθέατη από αυτή.
W.C. ασθενών- επισκεπτών	2X3=6		
Υποδοχή-Γραμματεία	16		Εύκολη προσπέλαση από την είσοδο και σε επαφή με την Γενική αναμονή η περιοχή της αναμονής.
Αρχειό	10		Σε άμεση σχέση με την Γραμματεία.
Γραφείο υπεύ- θυνου Ιατρού του τμήματος	10		
Εξεταστήριο	12		
Γραφείο για πε- ρισσότερους από δύο γιατρούς.	6/Γατρό		
Δομάτιο σχεδιασμού θεραπείας (planning Room)	12		Εξοπλισμένο με ηλεκτρονικά μέσα υπολογισμών. Άμεση σχέση με αζονικό τομογράφο για την παροχή διαγνωστικών στοιχείων
Δομάτιο προσωπικού	8		
Αναυκτήριο Αποδυτήρια-W.C. προσωπικού	2X8=16		
Γενική αποθήκη τμήματος	6		
Συγκέντρωση ακαθάρτων	2		

6.40



μ

/

1. <http://www.nanobiotix.com/technology-products/#intro> *he limited therapeutic window concerning the total dose governing the use of Radiotherapy.*
2. <http://www.nanobiotix.com/en/wp-content/uploads/2008/10/ILLUSTRATION04-e1347359007211.jpg>
3. <http://www.nanobiotix.com/en/wp-content/uploads/2008/10/How-its-work2.png>
4. <http://simplyrejuvenation.com/causeandsymptoms.html> *Free radicals are basically oxygen atoms with a missing electron, or molecules with unpaired electrons.*
5. <http://radiating.oncology.ox.ac.uk/all-about-radiation/radiation-damages-dna-1.html> *Radiation damages DNA.*
6. http://www.slideshare.net/vandana_rt/cell-survival-curve Multi-target model.
https://www.google.gr/search?q=tumor+cell+death+curves&biw=1280&bih=699&source=lnms&tbn=isch&sa=X&ved=0CAYQ_AUoAWoVChMI6OfNqdzuyAIVxrQaCh2XtAMo#tbn=isch&q=tumor+cell+survival+curves&imgc=b8O5SFwGuo4xAM%3A
7. <http://clincancerres.aacrjournals.org/content/16/7/2076/F1.expansion.html> *n vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762.*
8. https://en.wikipedia.org/wiki/Emil_Grubbe Emil Herman Grubbe (1875-1960).
9. <http://www.whonamedit.com/doctor.cfm/2025.html> Claude Regaud (1870-1941).
10. <http://www.ncbi.nlm.nih.gov/pubmed/15417771> Henri Coutard (1876-1950).
11. N.M.Eberhardt https://en.wikipedia.org/wiki/History_of_radiation_therapy#/media/File:X-ray_treatment_of_tuberculosis_1910.jpg X-ray treatment of tuberculosis in 1910.
12. https://en.wikipedia.org/wiki/History_of_radiation_therapy
13. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520298/> “Early victims of X-rays: a tribute and current perception”. *Dentomaxillofac Radiol*.40(2); 2011 Feb PMC3520298.
14. <http://www.google.co.ug/patents/US2497891> US 2497891 A: Betatron injector structure.
15. <https://quizlet.com/12327283/clinical-radiation-generators-flash-cards/> Betatron operation.
16. http://www.ph.unimelb.edu.au/museum/index.php?state=item_view&pm_item=52 The School of Physics Museum, Univ. of Melbourne, AU.
17. https://www.google.gr/search?q=betatron&biw=1280&bih=699&source=lnms&tbn=isch&sa=X&sqi=2&ved=0CAYQ_AUoAWoVChMIusqfrePvyAIVgtMaCh1Fpwae#imgc=YdekiTIfgpl02M%3A Betatron Siemens 42 MeV.
18. https://www.google.gr/search?q=betatron&biw=1280&bih=699&source=lnms&tbn=isch&sa=X&sqi=2&ved=0CAYQ_AUoAWoVChMIusqfrePvyAIVgtMaCh1Fpwae#imgc=ISRIJPeMSvf4eM%3A 45-MeV-Betatron der Firma Brown und Boveri.
19. Hassib G.M., Spyropoulos B.: “Neutron leakage characteristics in high energy medical accelerators, Radiation Protection Dosimetry”, Vol.3, No1/2, 1982,pp. 67-70.
20. Fehrentz D., Hassib G.M., Spyropoulos B.: *Neutrone erschmutzung in Roentgenstrahlenbuendel von Elektronenbeschleunigern*, Strahlentherapie 159, (1983), s. 703-712.
21. Koutroumbas S., Spyropoulos B., Proimos B.: *New shielding materials for the treatment suites of radiotherapy devices*, Intern. Conf. Med. Phys. & Biol. Eng., Helsinki 1985.

22. Spyropoulos, B., "Radiological Protection Policy Aspects Concerning the Preliminary Design and Operation Modus of the Athens Racetrack Microtron Facility", *Bulletin of the American Physical Society*, 40, (1995), 1094.
23. Spyropoulos, B., I. Marnieris, "On-line Educational Means on Radiological Protection and Accelerator General Safety Policy in Radiotherapy and Industrial Sterilization Facilities", *WEP 124*, 1999 Particle Accelerator Conference New York City, March 29th - April 2nd, 1999.
24. https://upload.wikimedia.org/wikipedia/commons/0/00/Gamma_Knife_Graphic.jpg NRC Graphic of the Leksell Gamma Knife.
25. Nevit Dilmen, https://commons.wikimedia.org/wiki/File:MRS_131720_135.png MRS, in a 48yo M patient with Lung ca, + Gamma Knife RT for brain metastasis, showing double inverted peaks between 1 & 2 ppm.
26. https://en.wikipedia.org/wiki/File:Teletherapy_Capsule.jpg A diagram of a typical teletherapy radiation capsule.
27. , « » , 1 , .39 , , 2010.
28. https://en.wikipedia.org/wiki/Brachytherapy#/media/File:Clinical_applications_of_brachytherapy.jpg Body sites in which brachytherapy can be used to treat cancer.
29. http://www.hygeia.gr/services.aspx?p_id=678 μ μ μ
μ μ .
30. <http://www.radiotherapy.gr/page.asp?ID=116>
31. <http://www.athensradiotherapy.gr/treatments/Vraxotherapeia/>
32. http://www.bacancercentre.org/photo_gallery.html
33. <http://www.gloshospitals.nhs.uk/en/Wards-and-Departments/Departments/Medical-Physics/Radiotherapy/Brachytherapy/> Brachytherapy.
34. Frank C., Fritz P., Spyropoulos B., Trinh S., Flentje M.: "Verstaerkung des Kontakteffektes nach LDR - Bestrahlung versus HDR - Bestrahlung in V 79 Sphaeroiden", *Jahrestagung der Oesterreichischen Gesellschaft fuer Radioonkologie*, Feldkirch, 11 - 12.10.1991.
35. Fritz P., Spyropoulos B., Frank C., Flentje M.: *Strahlenbiologische Aspekte bei der gepulsten Brachytherapie*, Deutsche Brachytherapie Konferenz, Koeln, Juni 1992.
36. <http://www.pedsoncologyeducation.com/RadiotherapyBasicsWhatisXRT.asp> cross-sectional diagram of a linear accelerator. The dotted line is the stream of electrons that are accelerated before they hit the tungsten target.
37. http://link.springer.com/referenceworkentry/10.1007%2F978-3-540-85516-3_37 Linear Accelerators (LINAC).
38. <http://ojs.ujf.cas.cz/~mitja/presentations/AV04/08.htm> The schematic drawing of the linear accelerator and the schematic drawing of the linac's head.
39. Sigamani Ashokkumar et al., "Comparison of Head Scatter Factor for 6MV and 10MV flattened (FB) and Unflattened (FFF) Photon Beam using indigenously Designed Columnar Mini Phantom", *J. Med. Phys.*, 2014, Volume: 39, Issue: 3, Page: 184-191. <http://www.jmp.org.in/article.asp?issn=0971-6203;year=2014;volume=39;issue=3;page=184;epage=191;aulast=Ashokkumar>
40. <http://www.slideshare.net/khlarsen/21-ex-qa> Linear Accelerator Block Diagram.
41. <http://www.mygenesishealth.com/treatment-options/genesis-prostate-cancer-center/igrt-imrt-for-prostate-cancer.html> IGRT / IMRT for Prostate Cancer.
42. <https://en.wikipedia.org/wiki/Microtron> The Microtron.
43. <http://www.isa.au.dk/facilities/astrid/electrons/microtron.asp> 100 MeV Race-Track Microtron (RTM).

44. P. Lidbjork, J. Astrom, "A 100 MeV Racetrack Microtron", *IEEE*, 1993, Page: 2068 - 2069
45. F.M. Khan, "The Physics of Radiation Therapy", Lippincott Williams & Wilkins, Baltimore, 2010.
46. Ikiwaner, https://en.wikipedia.org/wiki/Fast_neutron_therapy#/media/File:UW_Therapy_room.jpg Patient treating room for neutron radiation therapy, University of Washington.
47. http://phoenixnuclearlabs.com/product/high-yield-neutron-generator/?gclid=CJzLiu_bg8kCFcLnwgod06YHXw PNL's High Yield Neutron Generator is the highest yielding deuterium-deuterium (D-D).
48. <http://phoenixnuclearlabs.com/solution/neutron-radiography/> Neutron radiography and tomography.
49. <https://www.google.gr/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0CAUQjhxqFQoTCLHq9oD3g8kCFQpZFAodS2oMwg&url=http%3A%2F%2Fslideplayer.com%2Fslide%2F7287%2F&psig=AFQjCNFZ7C7tJH17HLi0UtQ9fiPzPAsBqQ&ust=1447175083651079> Pi Meson (Pion) Therapy.
50. http://www2.kek.jp/proffice/archives/kek-news/vol1no2/image/05_1.gif Meson Science Laboratory (started in 1980 in KEK).
51. <https://www.medlook.net/%CE%9A%CE%B1%CF%81%CE%BA%CE%AF%CE%BD%CE%BF%CF%82%CF%80%CE%BD%CE%B5%CF%8D%CE%BC%CE%BF%CE%BD%CE%B1/2796.html> μ . <http://www.floridaproton.org/what-is-proton-therapy>.
52. <http://www.google.com/patents/US1948384> Method and apparatus for the acceleration of ions .US 1948384 A.
53. http://www.nytimes.com/interactive/2007/12/14/business/20071217_PROTON_GRAPHIC.html?_r=0
54. https://upload.wikimedia.org/wikipedia/commons/3/37/Comparison_of_dose_profiles_for_proton_v._x-ray_radiotherapy.png
55. https://www.google.gr/search?q=radiotherapy+simulator&source=lnms&tbm=isch&sa=X&ved=0CAcQ_AUoAWoVChMIyYGO58yKyQIVRr0aCh0IAwZC&biw=1280&bih=699#tbm=isch&q=radiotherapy+simulator+varian&imgsrc=GZcA2IEfljZrZM%3A Varian Acuity Simulator 14C54.
56. http://www.myradiotherapy.com/general/ct_planning/Simulators/radiotherapy_simulators.html
57. <http://aktinotherapeutis.gr/wp-content/uploads/2012/07/3d-sxediasmos2.jpg> μ , 3-D CR .
58. . , $\acute{\epsilon}$ $\acute{\epsilon}$ $\acute{\iota}$, . 514-517.
59. Suk Lee, Yuan Jie Cao, Chul Yong Kim, "Physical and Radiobiological Evaluation of Radiotherapy Treatment Plan", in: *Evolution of Ionizing Radiation Research*, Sep. 17, 2015. <http://www.intechopen.com/books/evolution-of-ionizing-radiation-research/physical-and-radiobiological-evaluation-of-radiotherapy-treatment-plan>
60. Martin Ebert, "Ranking radiotherapy treatment plans: physical or biological objectives?", *Radiol Oncol* 2001; 35(3): 215-24.
61. <http://cancer.ucsd.edu/care-centers/radiation-oncology/pediatric/Pages/default.aspx> Radiation Therapy For Pediatric Cancers.
62. B. Spyropoulos, D. Papanagioutou, J. Anagnostopoulos, "A System facilitating Physical and Biological Risk Management in Radiotherapy", *Second Regional Mediterranean Congress on Radiation Protection*, IRPA, Tel-Aviv, Israel, November, 16-20 1997.
63. . , . , « $\mu\mu$ μ μ , . 78, 9-13 1995.

64. . , . (NTCP) , « μμ μ μ (TCP) » , 7 24-25 μ 1996.

1
3 .
 /
 • ^{60}Co .
 • μμ e^- .
 • p^+ .

2
3 μ .
 /
 • ^{192}Ir .
 • ^{137}Cs .
 • ^{60}C .

3 .
3
 /
 • μμ (3D-CRT).
 • μ μ (IMRT).
 • μ (IGRT).

μ, μ μ, μ μ μ (μ μ μ) μ μ μ μ μ μ



7.3

μ [5]. μ

μ μ μ μ μ μ μ



7.4

μ « » monitors μ «Mercy». μ [6].

μ μ monitors μ

12 m^2 in vitro 6 3 m^2 WC 3 m^2



7.5 $\mu \mu$ R. Priseman 2004 [7].

12 m^2 9 m^2

, WC Dousche, 6m²
 10 m².
 6 m²,
 (monitors)
 (lockers)
 , WC, Dousche
 8 m²

WC
 (air-sluiice)
 6 m²
 15 m²,
 WC
 517/91 [6

7.3.

(ICU),
 6

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΜΟΝΑΔΑΣ ΕΝΤΑΤΙΚΗΣ ΘΕΡΑΠΕΙΑΣ 6 ΚΛΙΝΩΝ

ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΝΟΣΗΛΕΙΑ - ΧΩΡΟΙ ΑΣΘΕΝΩΝ			
Θάλαμος 5 κλινών	100		
Μόνωση 1 κλίνης	20		
Βάση - Εποπτεία	12		Μέχρι 12 κλίνες
Εργαστήριο	4		
Ακάθαρτα	4		
Σκοραμίδες			
WC ασθενών	3		Μόνο Πολυδύναμη, Εμφραγμάτων, Παιδιατρική.
Κινητό Ακτινολ/κό	2		
Λινοθήκη-Ιματισμός			Ερμάριο 0.6 m
Είδη καθαρισμού	4		
ΧΩΡΟΙ ΠΡΟΣΩΠΙΚΟΥ			
Γραφείο γιατρών	12		6 m ² ανά γιατρό
Ανάπαυση προσωπικού	9		πλησίον κουζίνας
Διανυκτέρευση	6 m ² /κλίνη		συν 3 m ² WC/D
Αποθήκη εξοπλισμού και αναλωσίμων	10		
Συντήρηση	6		
Κουζίνα	8		
Αποδυτήρια	8		
ΧΩΡΟΙ ΕΠΙΣΚΕΠΤΩΝ			
Υποδοχή/Αλλαγή Ενδυμασίας	6		
Παραμονή συγγενών και W.C.	15		Παιδιατρικές 20

7.1 μ

6 .

μ μ

(CCU)

μ

μ μ μ

, μ

μ .


μ μ

.

μ μ μ μ μ μ .



7.9 Kinderkrankenhaus 10-'80 "Oskar-Ziethen", [10].



7.10 μ μ μ . . US 20100168502 [11].

μ μ μ μ μ μ μ μ (boxes) μ
 (, ,). : μ μ μ
 • 3 m² / (μ) 1.0 m μ
 (μ).

- - μ μ μ ,
- μ μ μ μ
- μ μ μ
- μ μ
-
-
-

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΝΕΟΓΝΙΚΗΣ ΜΟΝΑΔΑΣ

ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΚΥΡΙΑ ΝΟΣΗΛΕΙΑ			
Προθάλαμος θαλάμου νοσηλείας	7		Αλλαγή ρούχων πλύσιμο χεριών
Θάλαμος νοσηλείας	60-80 (110-250)		παροχή ρεύματος Λήψεις O ₂ , πεπεσμένου, κενού, νιπτήρες, παγκοι εργασίας
Απομόνωση	7-14		Επίπεδα II & III
ΒΟΗΘΗΤΙΚΟΙ ΧΩΡΟΙ ΥΠΟΣΤΗΡΙΞΗΣ			
Είσοδος - Αναμονή	6		
Γραφείο Διευθυντή	9		
Γραφείο Γιατρών	12		
Στάση Εργασίας	15		Πάγκος, ντουλάπια
Εργαστήριο	15		Εργαστηρικοί πάγκοι
Χώρος ανάπαυσης	6		
WC/D Ιματιοθήκες	12		
Κουζίνα-γαλ/μείο	6		Ντουλάπια, πάγκος εργασίας με νεροχύτη, αποστειρωτήρας, γάλακτος και σκευών
Χώρος Ακτ/κού	3		
Χώρος θηλασμού	5		Προθάλαμος, νιπτήρας
Αποθήκη θερμοκ/δων			Αναλόγως μεγέθους
Χώρος πλύσης	6		
Αποθήκη υλικών	6		
Χώρος ακαθάρτων	6		

7.2 μ

7.5. μ
 μ

- μ μ μ μ :
- (3 Eindhoven).
- μ .
- μ μ .
- μ (μ) μ .
- 2 C 2 ().



7.12 : Monitor μ : μ [13].




7.13 μ μ μ μ [5].

7.6. μ


μ μ

μ




7.14 : Galileo Gold, Hamilton Medical [14]. : μ [15].

μ (μ , μ . Hemodialysis) μ μ
 μ , μ μ μ μ
 μ μ μ μ (. .) μ .



7.15 μ




μ [17], [18].



7.16 μ μ μ [19].



μ μ μ μ μ μ μ μ μ μ μ (home hemodialysis). μ μ



7.17 : μ μ



(1980) [19]. μ μ [20].



7.18

μ

μ

μ

μ

[21].

μ [22].

μ

μ

μ

μ
17.

7.7.

μ

μ

μ

μ

μ

μ

μ

μ

μ

±2%

μ

μ

μ

μ

μ

1 cm.

μ

μ

μ

μ

μ

(C-arm)

μ

μ

μ

30 cm.

μ

μ

μ

μ μ



μ

μ

μ

μ μ

- 3.1 .
- 3.2 .
- 3.3. .
- 3.4. .
- 4.
 - 4.1 μ .
 - 4.2 .
 - 4.3 .
 - 4.4 .
 - 4.5 μ .
 - 4.6 , .
 - 4.7 .
- 5.
 - 5.1 μ .
 - 5.2 μ .
- 6. :



7.20

μμ μ [31]-[33].


7.9. μ

ISO 9001:2008 μ

, μ μ

μ μ μ

μ



7.21 [34] I (μ μ μ μ μ μ)

Έντυπο καταγραφής συμβάντων

ΗΜΕΡΟΜΗΝΙΑ : / / 2013 ΩΡΑ: 7-15 15-23 23-7

ΦΑΡΜΑΚΑ	ΕΞΟΠΛΙΣΜΟΣ	ΓΡΑΜΜΕΣ - ΚΑΘΗΤΗΡΕΣ ΔΕΡΑΤΩΓΟΙ	ΑΦΑΙΡΕΣΗ	ΑΠΟΣΥΝΔΕΣΗ	ΑΠΟΦΡΑΣΗ
Οδηγία	ΑΝΑΠΝΕΥΣΤΗΡΑΣ	Αρτηριακή Γραμμή 1			
1. Λάθος φάρμακο	ΑΝΑΠΝΕΥΣΤΗΡΑΣ ΜΕΤΑΦΟΡΑΣ	Κεντρ. Φλεβ. Γραμμή			
2. Λάθος δόση	ΑΝΤΑΙΑ ΦΑΡΜΑΚΟΥ	Swan - Ganz			
3. Μη εκτέλεση οδηγίας	ΑΝΤΑΙΑ ΤΡΟΦΗΣ	Καθετήρες Αιμοδιήθησης			
4. Λάθος αντιγραφής κάρτας	ΦΙΑΤΡΟ ΝΕΦΡΟΥ	Περιφερική φλέβα			
5.	ΑΠΙΝΙΔΩΤΗΣ	Θωρακική Παροχέτευση			
	ΕΝΔΟΚΡΑΝΙΟ MONITORING	Κοιλιακή παροχέτευση			
	ΤΡΟΧΗΛ./ ΒΑΛΙΤΣΑ ΕΠΕΙΓΟΝΤΩΝ	Ενδοκράνια παροχέτευση			
Χορήγηση	ΚΟΥΒΕΡΤΑ ΘΕΡΜ/ ΨΥΞΗΣ	Ενδοκράνιοι καθετήρες			
1. Λάθος φάρμακο	MONITORS	Τραχειοσωλήνας			
2. Λάθος δόση	RICCO	Τραχειοστομία			
3. Λάθος γραμμή χορήγησης	CCO (SWAN-GANZ)	Folley			
4. Διακοπή ροής αντλίας	ΥΤΡΑΝΣΗ O2	Levin			
5.	ΝΕΦΕΛΟΠΟΙΗΣΗ	PEG			
Άλλο συμβάν <input type="checkbox"/> :					
ΚΩΔΙΚΟΣ 1: ΚΑΤΑΣΤΑΣΗ	ΚΩΔΙΚΟΣ 2: ΠΑΡΑΓΟΝΤΕΣ	ΑΞΙΟΛΟΓΗΣΗ ΣΥΜΒΑΝΤΟΣ			Επεξηγήσεις Σημειώσεως:
Σ ΣΤΡΩΣΙΜΟ	1. ΕΠΙΚΟΙΝΩΝΙΑ	0	όχι επικίνδυνο για τον ασθενή		
ΕΣ ΕΙΣΑΓΩΓΗ	1.α. Προφορικά 1.β. Γραπτά	1	δυστηρά επικίνδυνο		
ΕΞ ΕΞΙΤΗΡΙΟ	2. ΑΠΡΟΣΕΣΙΑ	2	σοβαρό συμβάν καμία βλάβη για τον ασθενή		
Μ ΜΕΤΑΦΟΡΑ	3. ΦΟΡΤΟΣ ΕΡΓΑΣΙΑΣ	3	σοβαρό συμβάν δυνητική βλάβη για τον ασθενή		
Κ ΚΡΙΣΗ	4. ΑΣΘΕΝΗΣ ανήσυχος, διεγερτικός	4	σοβαρό συμβάν μόνιμη βλάβη για τον ασθενή		
ΚΝ ΚΙΝΗΤΟΠΟΙΗΣΗ	5. ΤΕΧΝΙΚΟ ΠΡΟΒΛΗΜΑ	5	σοβαρό συμβάν θάνατος		
P ΡΟΥΤΙΝΑ	6. Μη τήρηση Διαδικασίας / Οδηγίας				
Κωδικός:					

PNAXD ICU E01D08.doc

Συντάσσεται από:

Ελέγχεται από:

Ελεγγόμενο αντίγραφο
Απαγορεύεται η αντιγραφή
Εγκρίθηκε από:

7.22

μ μ

[34].

	2010	2011	2012	2013	2014 1/1 - 30/8
Ασθενείς	283	256	282	360	208
Κάλυψη κλινών	75%	71%	72%	70%	74%
Ηλικία	60 ± 18	59 ± 19,3	62,8 ± 18	61,5 ± 18,5	62 ± 16
Άρρενες %	62,5	62	64,5		
Μέρες νοσηλείας (average)	7,3	9,1	7,5	5,6	7
Νοσηλευτές σε βάρδια- (average)	31,4	24,9	21,6	18,5	
ΑΡΑΧΕ II- (average ± SD)	23,4 ± 11	23,9 ± 9,5	22,3 ± 9,7	20,8 ± 10,8	22,4 ± 11,5
Θνητότητα %	34,7	36,3	34,7	29,1	35
Προβλεπόμενη θνητότητα % (ΑΡΑΧΕ II-based)	-	49,3	43,5	38,2	44,30
Standardized mortality ratio - SMR	-	0,74	0,79	0,76	0.79
VAP (1/3-31/8)					7,9/1000/vds/{6%}

7.23

μ μ

[34]

5

μ ISO 9001:2008.

/

1. http://www.hektoeninternational.org/index.php?option=com_content&view=article&id=689 he Sarah Morris Children's Hospital, Chicago IL, was housed in this building (1913-1968).
2. <http://amhistory.si.edu/polio/howpolio/ironlung.htm> 1927 Philip Drinker and Louis Agassiz Shaw, at Harvard University, devised a version of a tank respirator that could maintain respiration artificially, until a person could breathe independently.
3. https://en.wikipedia.org/wiki/Walter_Dandy
4. <http://www.medvarsity.com/Articles/Dr.%20Sweena.html> Layout of an Intensive care unit.
5. <http://www.iatrikodiavalkaniko.gr/en/monades-entatikhs-diavalkanikou>
6. https://commons.wikimedia.org/wiki/File:US_Navy_060502-N-1577S-003_A_look_at_the_Intensive_Care_Unit_%28ICU%29_ aboard_the_Military_Sealift_Command_%28MSC%29_hospital_ship_USNS_Mercy_%28T-AH_19%29.jpg US Navy 060502-N-1577S-003 A look at the Intensive Care Unit (ICU) aboard the Military Sealift Command (MSC) hospital ship US NS Mercy (T-AH 19)
7. https://commons.wikimedia.org/wiki/File:An_intensive_care_unit_in_a_hospital._Wellcome_L0075034.jpg An intensive care unit in a hospital. Oil painting by R. Priseman, 2004.
8. https://commons.wikimedia.org/wiki/File:Kapiolani_Neonatal_ICU.jpg The Neonatal Intensive Care Unit (NICU) at Kapiolani Medical Center in Honolulu, Hawaii.
9. https://commons.wikimedia.org/wiki/Neonatal_care#/media/File:Tahril-neonatal.jpg
10. https://en.wikipedia.org/wiki/Neonatal_intensive_care_unit#/media/File:Bundesarchiv_Bild_183-1989-0712-025,_Berlin,_Krankenhaus_%22Oskar-Ziethen%22,_Kinderkrankenhaus.jpg Oskar-Ziethen Kinderkrankenhaus, Berlin, 1989.
11. <http://www.google.com/patents/US20100168502> Modular neonatal intensive care system, US 20100168502 A1.
12. https://commons.wikimedia.org/wiki/Category:Neonatal_intensive-care_units#/media/File:US_Navy_090814-N-6326B-001_A_mock_set-up_of_the_new_pod_design_in_the_Neonatal_Intensive_Care_Unit_%28NICU%29_at_Naval_Medical_Center_San_Diego_%28NMCSD%29_is_on_display_during_an_open_house.jpg Neonatal Intensive Care Unit (NICU) at Naval Medical Center San Diego.
13. https://commons.wikimedia.org/wiki/Category:Intensive-care_medicine#/media/File:Dash_5000_Medical_monitor.jpg Medizinischer Multi-funktionsmonitor Dash 5000.
14. Intensiv-respirator Galileo Gold, Hersteller: Hamilton Medical
15. Stefan Bellini, https://commons.wikimedia.org/wiki/Category:Intensive-care_medicine#/media/File:Respirator_Galileo_Gold.jpg Intensivrespirator *Galileo Gold*, Hersteller: Hamilton Medical
16. https://commons.wikimedia.org/wiki/Category:Intensive-care_medicine#/media/File:Mittlererarteriellerdruck.png Darstellung des mittleren arteriellen Drucks (MAD) in einer typischen Blutdruckkurve peripherer Gefäße in mmHg.
17. National Institutes of Health, https://commons.wikimedia.org/wiki/Category:Hemodialysis#/media/File:Guy_getting_hemo.gif , Guy getting hemodialysis

18. National Institute of Diabetes and Digestive and Kidney Diseases, https://commons.wikimedia.org/wiki/Category:Hemodialysis#/media/File:Hemodialysis_schematic.gif , Schematic of a hemodialysis circuit
19. https://commons.wikimedia.org/wiki/Category:Hemodialysis#/media/File:Hemo_11-16-17.jpg , Stanbridge College - Hemodialysis Skills Lab
20. https://commons.wikimedia.org/wiki/Category:Hemodialysis#/media/File:Filtro_per_emoialisi.JPG Filter for hemodialysis year 1980.
21. <https://commons.wikimedia.org/wiki/Category:Hemodialysis#/media/File:CentralDialysatedelivery.JPG> dialysis unit's central dialysate delivery system (2008).
22. Van Meurs, K, Lally, KP, Peek, G, Zwischenberger, Extracorporeal Life Support Organization, Ann Arbor 2005. https://commons.wikimedia.org/wiki/Category:Intensive-care_medicine#/media/File:Schematic_of_silicone_membrane_oxygenator.jpg Right internal jugular vein drainage and right carotid artery infusion.
23. Van Meurs, K, Lally, KP, Peek, G, Zwischenberger, *Extracorporeal Life Support Organization*, Ann Arbor 2005.
24. https://commons.wikimedia.org/wiki/Category:Intensive-care_medicine#/media/File:Venoarterial_%28VA%29_ECMO_for_cardiac_or_respiratory_failure.jpg
25. μ , . . . , 2009.
26. Teut A., Nedelkov G., *Die Gruppenpraxis*, Bertelsmann Fachverlag, Duesseldorf 1973.
27. Kinney J.M., Walter C. W., *The Design of an Intensive Care Unit*, Saunders, Philadelphia 1977.
28. Puetsep E., *Modern Hospital*, Lloyd-Luke, London 1979.
29. Carr J. J., Brown J. M., *Introduction to Biomedical Equipment Technology*, John Wiley & Sons, New York 1981.
30. Laufman H. (Editor), *Hospital Special-Care Facilities*, Academic Press, New York 1981.
31. . . 517/91, ' 202/24.12.1991.
32. Bronzino J.D., *Management of Medical Technology*, Butterworth-Heinemann, Boston 1992.
33. The Intensive Care Society, *UK Standards for Intensive Care Units (1997)*, Intensive Care Society, May 1997
34. Society of Critical Care Medicine, *Guidelines for Intensive Care Unit Design (1995)*.
35. D.R.Thompson, Guidelines for intensive care unit design, *Crit Care Med* 2012 Vol. 40, No. 5 pp.1586-1600.
36. μ , : « ISO 9001:2008 ».

1

3 .

/

- μ .
- .
- μ μ .

3 **2**
 μ .
 /
 • .
 • .
 • μ

3 **3**
 .
 /
 • Monitor .
 • .
 • μ μ .

8:

•
•
•

μ : μ .

8.1.

μ

μ , μ

μ , μ μ , μ

« μ » μ [2].

[3]. μ μ μ 70 , 350 . .

μ μ μ , μ

μ μ μ [2].


[4]. μ μ μ Æsculapius (μ), μ μ (291 . .) μ

400 . .




8.1

[4]. μ



8.4 μ Hôtel-Dieu de Paris (~1500) μ « μ » () [17].



8.5 M μ Florence Nightingale William Simpson, 21 1856 [18].

Florence Nightingale (1820–1910) was a nursing pioneer and statistician who founded the first nursing school (Nightingale School for Nurses) in London in 1860. She is credited with the development of modern nursing practice. [15]

Nightingale's influence on nursing practice is profound. [16]

8.2.

()



8.6 Hospital ward, 1900 [19].


- -
 -
- 40.

- : 1-2 () 12 μ μ 45 dB.



8.8 μ μ μ [21].

- _____ : , 40 μ
- μ μ μ , _____
- μ - μ : μ .
- _____ : μ , μ
- _____ : μ 40 μ WC, 1-2 μ μ



8.9 : «μ μ» μ μ [22]. ; μ μ μ μ inden μ 1888.

- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$ (μ) ;
- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$ (μ) ;
- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$;
- $\frac{\mu}{\mu} = \mu$;



8.10 μ , μ (: . μ) .



8.11 : μ μ μ μ μ [23]. , : μ μ μ « »
 μ μ μ μ μ [24]. : μ μ μ μ μ ,
 μ μ μ [25].

- $\frac{\mu}{\mu} :$ μ μ .
- $\frac{\mu}{2} :$ μ μ μ μ ($\frac{\mu}{\mu WC}$) μ μ .



8.12 : μ (: .) . : μ μ μ

8.3.

μ μ μ μ , . 517/1991 ('202/ 24.12.1991) [27]-[31]. μ
 μ μ 40 , μ μ .



8.13

μ

(μ) .

(Bed-head Unit).

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΓΕΝΙΚΗΣ ΝΟΣΗΛΕΥΤΙΚΗΣ ΜΟΝΑΔΑΣ

ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΚΕΝΤΡΙΚΗ ΕΞΥΠΗΡΕΤΗΣΗ			
Χώρος εξέτασης θεραπείας	12	π3.30	
Λουτρό ασθενών1*	12	π2.50	
Οφίς φαγητού *	10		
Λινοθήκη	6		Γιά 40 κλίνες ερμάριο βάθους 0.60 m
Ακάθαρτα- Σκωραμίδες	8		
Χώρος καθαρι- ότητας	4		
Αποθήκη*	8		Στάση φορείου- τροχήλατου εσοχή στο διάδρομο

ΣΗΜΕΙΩΣΕΙΣ: π=πλάτος, μ=μήκος, υ=ύψος.

8.1

μ

[27].

ΠΙΝΑΚΑΣ ΜΕΤΡΙΚΩΝ ΣΤΟΙΧΕΙΩΝ ΓΕΝΙΚΗΣ ΝΟΣΗΛΕΥΤΙΚΗΣ ΜΟΝΑΔΑΣ

ΑΠΑΡΑΙΤΗΤΟΙ ΧΩΡΟΙ	ΕΛΑΧΙΣΤΗ ΩΦΕΛΙΜΗ ΕΠΙΦΑΝΕΙΑ m ²	ΕΛΑΧΙΣΤΕΣ ΩΦΕΛΙΜΕΣ ΔΙΑΣΤΑΣΕΙΣ m	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΘΑΛΑΜΟΙ			
Θάλαμος 1 κλίνης	11	π3.30 μ2.70 υ2.80	εκτός ερμαρίου W.C.
Προθάλαμος θαλάμου Πολυτελείας	5		
Χώρος υγιεινής με προθάλαμο	4.5		
Θάλαμος 2 κλινών	15	π3.30 μ4.50 υ2.80	χωρίς τον χώρο υγιεινής, προθάλαμο και ερμάριο
Θάλαμος 3 κλινών	21	π3.30 μ6.30 υ2.80	χωρίς τον χώρο υγιεινής προθάλαμο και έρμάριο
Θάλαμος 4 κλινών	24	π5.30 μ4.50 υ2.80	χωρίς τον χώρο υγιεινής, προθάλαμο και ερμάριο
Χώρος διημέρευσης	1 m ² / κλίνη		
ΧΩΡΟΙ ΠΡΟΣΩΠΙΚΟΥ			
Στάση αδελφής-χώρος εργασίας	15	ελεύθερο πλάτος πίσω από τον πάγκο 1.20 m	
Γραφείο προϊσταμένης	6		
Χώροι υγιεινής	6		
Γραφείο γιατρών	12		
Κοιτώνας γιατρών επί πλέον 3m ² WC-DOUCHE για 1-2 κλίνες	6 m ² / κλίνη & ιατρό		

1. Risse, G.B. *Mending bodies, saving souls: a history of hospitals*. Oxford University Press, 1990. p. 56 Books.Google.com
2. Askitopoulou, H., Konsolaki, E., Ramoutsaki, I., Anastassaki, E. "Surgical cures by sleep induction as the Asclepieion of Epidaurus. The history of anaesthesia". In José Carlos Diz, Avelino Franco, Douglas R. Bacon, J. Ruprecht, Julián Alvarez (eds.), *Proceedings of the 50th International Symposium*, . Elsevier Science B.V., *International Congress Series* 1242(2002), p.11-17. Books.Google.com.
3. Roderick E. McGrew, *Encyclopaedia of Medical History* (Macmillan 1985), pp.134-5.
4. Heiko Gorski, https://en.wikipedia.org/wiki/History_of_hospitals#/media/File:Kos_Asklepeion.jpg View of the Askleipion of Kos, the best preserved instance of a Greek Asklepieion.
5. <http://www.newadvent.org/cathen/07480a.htm> Catholic Encyclopedia.
6. James Edward McClellan and Harold Dorn, *Science and Technology in World History: An Introduction* (The Johns Hopkins University Press, 2006), p.99, 101.
7. <http://kassiani.fhw.gr/constantinople/Forms/fLemmaBody.aspx?lemmaId=10860> -
μ .
8. <http://kassiani.fhw.gr/constantinople/Forms/fMediaItem.aspx?lemmaId=10903&multiId=189906>
9. <http://kassiani.fhw.gr/constantinople/Forms/fMediaItem.aspx?lemmaId=10903&multiId=189907>
10. "The Hospital in Islam", [Seyyed Hossein Nasr, *Islamic Science, An Illustrated Study*], (World of Islam Festival Pub. Co., 1976), p.154.
11. Toby E. Huff, *The Rise of Early Modern Science: Islam, China and the West*, Cambridge University Press, USA, 2007.
12. http://fourriverscharter.org/projects/Inventions/pages/muslimworld_hospitals.htm Chelsea Wills, Middle-Ages Technologies, Muslim Hospitals.
13. http://www.google.gr/imgres?imgurl=http://www.onislam.net/english/oimedia/onislam/en/images/heal thscience/2013/10/Medieval-Islamic-Hospitals-Medical-Schools-1.jpg&imgrefurl=http://www.snipview.com/q/Medieval_Hospitals_in_Spain&h=399&w=300&tbnid=qZg1DpZtEmAZmM&tbnh=259&tbnw=195&usq=__cuf_Jcd-gxJjfSU1q0CusCOjA0I=&docid=PTGkfUaprFRysM Bimaristan del Sultan Qalaun, El Cairo S. XIII.
14. "España Sagrada", XIII, 539; Heusinger, "Ein Beitrag" in "Janus", 1846, I.
15. Kathy Neeb (2006). *Fundamentals of Mental Health Nursing*. Philadelphia: F.A. Davis Company.
16. Nightingale, Florence (August 1999). *Florence Nightingale: Measuring Hospital Care Outcomes*. ISBN 0-86688-559-5. Retrieved 13 March 2010.
17. https://commons.wikimedia.org/wiki/File:Mediaeval_hospital_ward_with_religious_nursing_orders._Wellcome_M0013376.jpg Medieval hospital ward with religious nursing orders. Wellcome M0013376.jpg
18. https://en.wikipedia.org/wiki/History_of_hospitals#/media/File:%27One_of_the_wards_in_the_hospital_at_Scutari%27._Wellcome_M0007724_-_restoration,_cropped.jpg A ward of the hospital at Scutari where Florence Nightingale worked and helped to restructure the modern hospital. William Simpson (artist, 1823–1899); E. Walker (lithographer, lifespan unknown, working for Day & Son); Publishers: Paul and Dominic Colnaghi, London; Goupil & Cie, Paris; Otto Wiegel, Leipzig; Restoration by Adam Cuerden.
19. https://commons.wikimedia.org/wiki/File:Gibraltar_Colonial_Hospital_ward.jpg A typical ward at the old Colonial Hospital (now St Bernard's Hospital) in Gibraltar, around 1900.

20. https://en.wikipedia.org/wiki/Hospital_bed Hospital bed.
[https://commons.wikimedia.org/wiki/File:Shower, double-vault urine-diverting dry toilet %28UDDT%29 and waterless urinal in Lima, Peru.jpg](https://commons.wikimedia.org/wiki/File:Shower,_double-vault_urine-diverting_dry_toilet_%28UDDT%29_and_waterless_urinal_in_Lima,_Peru.jpg) Shower, double-vault urine-diverting dry toilet (UDDT) and waterless urinal in Lima, Peru.

21. https://upload.wikimedia.org/wikipedia/commons/1/1c/Canteen_kitchen.jpg Modern restaurant food preparation area.

22. https://en.wikipedia.org/wiki/List_of_laundry_topics#/media/File:Industrial_laundry_sorting.jpg Industrial laundry sorting.

23. https://en.wikipedia.org/wiki/List_of_laundry_topics#/media/File:Industrial_laundry_linen_press,_exit.jpg A part of a press in industrial laundry which dries the linen.

24. https://en.wikipedia.org/wiki/List_of_laundry_topics#/media/File:Jensen_Supercentro_feeder.jpg A feeder where linen is placed and which takes the linen to the ironer and folder

25. <http://www.medicaexpo.com/medical-manufacturer/automatic-bedpan-washer-1338.html>

26. 517/91, '202/24.12.1991.

27. Bronzino J.D., *Management of Medical Technology*, Butterworth-Heinemann, Boston 1992.

28. Laufman H. (Ed.), *Hospital Special-Care Facilities*, Academic Press, New York 1981.

29. Puetsep E., *Modern Hospital*, Lloyd-Luke, London 1979.

30. Teut A., Nedelkov G., *Die Gruppenpraxis*, Bertelsmann Fachverlag, Duesseldorf 1973.

1

μ .

/

• μ μ μ .
 • μ μ μ μ μ μ μ μ μ
 • μ μ μ μ μ μ μ μ μ . 40.

2

μ .

/

• μ .
 •
 •
 • μ .

3

μμ .

/
 •
 •
 •
 •
 •
 •
 •
 •

—
 .
 .
 ().
 — μ .

_____ :


-
-

_____ :

-
- μ , (μ) .
-
-
-
-
-
- μ .

_____ :

- μ μ .
- μ . (μ , ,) .
- μ - . μ (, μ ,) .
- (,) .



9.3

[3].



9.4

– μ μ [4].



9.5

[5].




9.6

(. . μ ,



,


.) [6].



9.7 μ μ μ

[7].

- μ μ μ μ ,
- μ :
- μ () .
- μ () .



9.8 μ μ μ

[8].

•
 • μ μ μ
 • μ μ μ μ μ
 • μ μ μ μ μ
 • μ μ μ μ μ
 • μ μ μ μ μ



9.10 μ (: . , μ μ 1999). , μ

μ , . μ , μ ,
 μ μ μ μ μ
 , μ μ μ μ μ
 • μ
 • μ



9.12



90.

(: . , μ 1999). /

μ μ μ [11]-

[15].

μ μ μ
μ

/

1. <http://www.healthandfitness101.com/new-physical-therapy-clinic-opening/> Hurting people are going to start coming to Alpine Physical Therapy, North.
2. <http://www.mosaicpt.com/> Mosaic Physical Therapy is an experienced group of health care professionals dedicated to providing the highest quality care in a comfortable and relaxed atmosphere.
3. http://64.37.58.134/arnoldpalmerhospital/OurMedicalSpecialties/ped_phys_med_and_rehab.aspx?pid=6588 Pediatric Physical Medicine and Rehabilitation.
4. <https://www.youtube.com/watch?v=S31sK54qynM> Stroke from Car Crash Rehabilitation in HydroWorx Physical Therapy Pool.
5. <https://www.rainbowrehab.com/programs/> Rainbow Rehabilitation Center, Vocational and independent living Rehabilitation.
6. http://nhwc.ca/so_electro.html Electrotherapy involves the application of a therapeutic electrical current to the area of injury, inflammation, dysfunction, or pain.
7. <http://www.wired.com/2013/10/is-this-brain-controlled-bionic-leg-the-future-of-prosthetics/> The control traditional and advanced of prosthetic legs.

8. <http://medicine.missouri.edu/pmr/map.html> Physical Medicine and Rehabilitation layout.
9. <http://arquitectura.estudioquagliata.com/tag/stockholm/page/5> HELIX, Forensic Psychiatric Clinic of Stockholm / BSK Arkitekter.
10. , μ (μ)
μ
2012.
11. Laufman H. (Editor), *Hospital Special-Care Facilities*, Academic Press, New York 1981.
12. Puetsch E., *Modern Hospital*, Lloyd-Luke, London 1979.
13. Teut A., Nedelkov G. *Die Gruppenpraxis*, Bertelsmann Fachverlag, Duesseldorf 1973.
14. et al. « μ μ μ », 19 , 1993 .
52.
15. , μ μ (μ μ ;)
, (ISSN: 1109-3927), μ 1, . 191-203,
University Studio Press, 2002.

1


3
/
•
•
•

2

3
/
• μ μ (μ , ,).
• (,).
•


3

3 μ μ « »
/
•
•
•



10.2 μ $\mu\mu$ μ μ () [34].

μ (Eindhoven Semiconductor@). μ I-III) μ μ μ (C-programmable controller Rabbit JFET μ TL074 μ 300 Hz μ 433 MHz μ) μ /



10.3 μ μ μ [35]



TABLE I. PROBLEMS WITH THE USE OF CPAP COMPUTER INTERFACE FOR TELEMETRY

No	Problem statement	Discussion
1	Communication protocols depend on manufacturer	Communication software should adapt to different manufacturers. Therefore there cannot be a universal system. Data encryption should be implemented by the communication device.
2	Number and quality of measured data depends on manufacturer's technology	CPAP devices detect snoring either by airway's pressure vibrations or flow vs. time curves [4] and airflow is detected either by transducers or estimated based on blower's speed [4].
3	Respiratory events identification is dictated by the algorithms developed by device's manufacturer	A Hypnoea criterion is the magnitude reduction of the flow signal below 50% of basal value [17]. Similarly apnea are marked when flow drops below 10% of basal value [17]. However as Otero et al. [17] argues, basal value is not adequately defined and it does not remain constant during sleep


TABLE II. DESIGN SOLUTIONS ON CPAP COMPUTER INTERFACE PROBLEMS FOR TELEMETRY

No	Problem statement	Proposed Design Solutions
1	Communication protocols depend on manufacturer	The system transmits wirelessly and encrypted to a computer, the measured data utilizing a standard XBee (IEEE 802.15.4) protocol [26]. Data are quasi real time transmitted and stored in European Data Format (EDF) [27]. Furthermore the use of 802.15.4 protocol incorporates networking capabilities, thus enabling simultaneously communication of more than one XBee devices.
2	Number and quality of measured data depends on manufacturer's technology	Pressure and Flow measurement is performed by calibrated and temperature compensated piezo-resistive transducers; flow utilizes a differential pressure flow transducer.
3	Respiratory events identification is dictated by the algorithms developed by device's manufacturer	Data are transmitted as raw data, allowing further processing with the utilization of custom software. This feature allows the extraction of respiration related parameters, such as respiration volume and frequency as well as the application of custom respiratory events detection algorithms.



10.4 μ CPAP-PC Interface μ [36]




10.5 μ μ [36].





Πίεση




Ροή



CO₂




O₂





10.6 μ μ

(),

CO₂ O₂() [36]



Clinical Guidelines
Decision Support



$\mu_{10.7} : \mu \quad \mu$

(Fuzzy-rules) [37].


μ	μ	μ	μ	μ	μ
μ	μ	μ	μ	[10]	μ
μ	μ	μ	μ	μ	μ
μ	(Universitätsklinikum Mannheim) [11]	μ	μ	μ	μ
127	μ			127	μ
μ	52.6%	μ	μ	μ	116 (91.3%)
μ	μ	μ	μ	μ	12

Κατάλογος εμπορικά διαθέσιμων Διαγνωστικών Δοκιμασιών οι οποίες έχουν εγκριθεί από το FDA για κατ' οίκον εφαρμογή			
486 Alcohol, Breath	184 Fructosamine	027 Luteinizing Horm one (LH)	021 Triglyceride
392 Allergen Specific IgE / Panel	122 Glucose	090 Methadone	188 Uric Acid
041 Amphetamines	116 Glucose Monitoring Devices	92 Methamphetamine / Amphetamine	448 Urinary Protein, Qualitative
103 Barbiturates	072 Glucose, Fluid	100 Methamphetamines	186 Urine Dipstick: Or Tablet Analytes
101 Benzodiazepines	422 Glucose, Urine	256 Methylene dioxymethamphetamine (MDMA)	125 Urine hCG By Visual Color Comparison Tests
409 Bilirubin, Urine	208 Glycated Hemoglobin, Total	008 Microalbumin	264 Urine Qualitative Dipstick: Bilirubin
084 Cannabinoids (THC)	172 Glycosylated Hemoglobin (HgbA1c)	148 Morphine	265 Urine Qualitative Dipstick: Blood
171 Chloride	261 hCG, Serum, Qualitative	087 Opiates	266 Urine Qualitative Dipstick: Glucose
161 Cholesterol	370 hCG, Urine	030 Ovulation Test (LH) Visual Color Comparison	001 Urine Qualitative Dipstick: Ketone
086 Cocaine Metabolites	121 HDL Cholesterol	285 Oxycodone	268 Urine Qualitative Dipstick: Nitrite
159 Creatinine	016 Hemoglobin	408 pH, Urine	269 Urine Qualitative Dipstick: pH
494 Estrone-3 Glucuronide	460 Hemoglobin A1	085 Phencyclidine (PCP)	270 Urine Qualitative Dipstick: Protein
274 Fecal Occult Blood	124 Ketone, Blood	245 Protein, Total (Urine)	271 Urine Qualitative Dipstick: Urobilinogen
249 Fern Test, Saliva	352 Ketone, Urine	364 Semen	410 Urobilinogen, Urine
026 Follicle Stimulating Hormone (FSH)	024 Lactic Acid (Lactate)	246 Tricyclic Antidepressants	042 Va ginal pH

10.1 FDA, [12], [13].

[15]-[17].

CD₄



10.9 lab-on-a-chip (LOC).



Doppler,

μ , μ μ μ .




10.11 : Courtesy of Siemens Product: Acuson P10
<http://www.technologyreview.com/tomarket/411046/first-pocket-ultrasound/>


, μ μ , μ μ (. . , μ , μ , μ , μ),
 μ μ μ μ μ . μ μ μ μ .




10.12 *in vivo*



(μ) [38]



in vitro



10.13

μ

: μ phantom [39].

10.6.

μ

I

-

,

μ

μ

μ

,

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

,

μ

,

μ

μ

:

,

•

,

μ

,

μ

.

μ

,

•

,

μ

.

,

μ

•

,

μ

μ

μ

.

μ

μ

μ

μ

,

μ

μ

.

μ

μ

,

μ

μ

,

μ

μ

μ

,

μ

μ

μ

μ

μ

μ

,

μ

•

μ

.

•


μ

.

•

-

.



10.14

[40].

μ μ μ :

• ABCDE (Airway, Breathing, Circulation, Disability, Exposure) (, , ,)

• μ :

• μ μ μ (, , ,) .

• (, , , , ,) .

• μ () .

μ , μ μ

- Transport – S.T.A.R.T), (Simple Treatment And Rapid Transport – S.T.A.R.T),
-
-



in vitro

10.7.

(Continuity of Care Record - CCR)
 ASTM, E2369-05, (Continuity of Care Record - CCR) [28].

CCR

XML (extensible mark-up language), XML CCR XML HL7 CDA (Clinical Document Architecture).



10.15 : μ μ μ ; ANSI-E2369 (CCR), ISO 13606-1 prEN. : μ μ [41].

XML μ μ , μ CCR μ CCR μ CCR μ CCR μ CCR μ CCR μ




10.8.

CCR.

(Care Plan)

CCR,

(Care Plan)



10.16

[42].

CCR

CCR
 ASTM E2369-05, XML.

(International Classification of Diseases Version 10 – ICD10).
 Australian Refined Diagnosis Related
 Groups (AR-DRGs). (Clinical Care Classification - CCC) [29].

CCR,
 ATC
 [9]
 (audio-video
 networking systems)
 SMS

(SpO₂),

μ,

μ

μ
μ

μ

μ

μ

,

μ

(dSpO₂)

μ

μ

μ

,

μ

,

μ

.

,

μ

μ

.

μ

μ

μ

dSpO₂

μ

.

10.9. μ μ

μ

μ

μ

μ,

μ

μ

μ,

μ

,

μ

,

μ

μ

,

μ

,

μ

μ

.

μ

,

μ

,

μ

μ

μ

μ

.

μ

μ

μ

μ,

μ,

μ

in vivo

in vitro

,

,

μ

μ

μ

,

μ

,

μ

μ

•

,

μ

μ

μ:

,

•

.

,μ

,

.

•

,

μ

,

.

•

,

,μ

μ

μ,

,

μ

μ

μ

μ

,μ

,

μ

.

,

μ

μ

μ

μ

μ

μ

μ,

μ

μ

μ

,

,

μ

,

μ

μ

.

μ

μ

.

/


1. G.S. Meyer, R.V. Gibbons, "House calls to the elderly - a vanishing practice among physicians", *N Engl J Med* 337 (1997) 1815-1820.


2. C. M. A. Frederiks, M.J.M. te Wierik, H.J.L. van Rossum et al. "Why do Elderly People seek Professional Home Care? Methodologies Compared", *Journal of Community Health* 17 (1992) 131-141.
3. L. Gilman, "A Doctor in the House", *Time* Sep. 24 (2006).
4. P. Aylin, A.F. Mazeed, D.G. Cook, "Home visiting by general practitioners in England and Wales", *BMJ* 313 (1996) 207-210.
5. G. Peppas, G. Theocharis, E. A. Karveli, M.E. Falagas, "An analysis of patient house calls in the area of Attica, Greece", *BMC Health Svcs Res* 6 (2006) 112 <http://www.biomedcentral.com/1472-6963/6/112>
6. M. Dailey, J. Newfield, "Legal Issues in Home Care: Current Trends, Risk-Reduction Strategies, and Opportunities for Improvement". *Home Health Care Management & Practice* 17 (2005) 93-100.
7. K.E. Steinhauer, N.A. Christakis, E.C. Clipp, M. McNeilly, L. McIntyre, J.A. Tulsky, "Factors considered important at the end of life by patients, family, physicians, and other care providers". *JAMA* 284 (2000) 2476-2482.
8. R. S. Morrison, D. E. Meier, "Palliative Care", *N Engl J Med* 350 (2004) 2582-2590.
9. Editorial: "Can House Calls Survive?". *N Engl J Med* 337 (1997) 1840-1841.
10. H.Genzwürker, H. Iovic, T. Finteis, J.Hinkelbein, C. Denz, J. Gröschel, K. Ellinger,, "Ausstattung von Notarztbesetzten Rettungsmitteln in Baden-Württemberg", *Anaesthesist* 51 (2002) 367-373.
11. H.Genzwürker, H. Iovic, T. Finteis, J.Hinkelbein, C. Denz, J. Gröschel, K. Ellinger, "Erhebliche Unterschiede bei der Ausstattung von notarztbesetzten Rettungsmitteln", *Notfall & Rettungsmedizin* 5 (2002) 441-447.
12. C. Lewis, "Home Diagnostic Tests: The Ultimate House Call?". *U.S. Food and Drug Administration Consumer magazine* 11/12 (2001) www.fda.gov
13. List of the FDA approved home test kits sold over the counter, <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm> .
14. F.D.R. Hobbs, M. G. Broughton, J. E. Kenkre, et al. "Comparison of the use of four desktop Analyzers in six urban General Practices", *British Journal of General Practice*, 42 (1992) 42, 317-321
15. J.J. Lavigne, S. Savoy, M.B. Clevenger, J.E Ritchie et al. "Solution-based analysis of multiple analytes by a sensor array: toward the development of an "electronic tongue"". *J Am Chem. Soc* 120 (1998) 6429- 6430.
16. A. Goodey, Lavigne JJ, Savoy SM, Rodriguez MD, Curey T, Tsao A, et al. "Development of multianalyte sensor arrays composed of chemically derivatized polymeric micro spheres localized in micro machined cavities". *J Am Chem Soc* 123 (2001) 2559-2570.
17. S.L. Wiskur, P.N. Floriano, E.V. Anslyn, J.T. McDevitt, "A multi-component sensing ensemble in solution: differentiation between structurally similar analytes". *Angewandte Chemie International Edition* 42 (2003) 2070-2072.
18. P. N. Floriano, N. Christodoulides, D.K Romanovicz et al. "Membrane-based on-line optical analysis system for rapid detection of bacteria and spores", *Biosens Bioelectron* 20 (2005) 2079-2088.
19. N. Christodoulides, P. N. Floriano, S. A. Acosta et al., "Toward the Development of a Lab-on-a-Chip Dual-Function Leukocyte and C-Reactive Protein Analysis Method for the Assessment of Inflammation and Cardiac Risk", *Clinical Chemistry* 51 (2005) 2391-2395.
20. J. Hambleton, "Home Monitoring of Anticoagulation", *Journal of Thrombosis and Thrombolysis* 16 (2003) 39-42.
21. V. Marzinotto, P. Monagle, A. Chan, M. Adams, P. Massicotte, M. Leaker, M. Andrew, "Capillary Whole Blood Monitoring of Oral Anticoagulants in Children in Outpatient Clinics and the Home Setting", *Pediatr Cardiol* 21 (2000) 347-352.

22. S Mähönen, P Riikonen, R-L Väätäinen, T Tikanoja, “Oral anticoagulant treatment in children based on monitoring at home”, *Acta Paediatrica* **93** (2004), 687–691.
23. C. P. Price, “Point of care testing”, *BMJ* **322** (2001)1285-1288.
24. J.B. Seward, P.S. Douglas, R. Erbel et al. “Hand-carried cardiac ultrasound (HCU) device: recommendations regarding new technology. A report from the Echocardiography Task Force on New Technology of the Nomenclature and Standards Committee of the American Society of Echocardiography”. *J Am Soc Echocardiogr* **15** (2002) 369-373.
25. G. M. Goodkin, D.M. Spevack, P.A. Tunick, I. Kronzon I.” How useful is hand-carried bedside echocardiography in critically ill patients?”. *J Am Coll Cardiol* **37** (2001) 2019-2022.
26. K.T. Spencer, A.S. Anderson, A. Bhargava et al. “Physician-performed point-of-care echocardiography using a laptop platform compared with physical examination in the cardiovascular patient”. *J Am Coll Cardiol* **37** (2001) 2013-2018.
27. B. Puschendorf, J. Mair, “Cardiac Diseases”, in: Thomas L. (Ed.) *Clinical Laboratory Diagnostics, 101-119*, TH-Books, Frankfurt/Main, 1998.
28. ASTM E2369-05 Standard Specification for Continuity of Care Record www.astm.org
29. V.K. Saba, *Home Health Care Classification of Nursing Diagnoses and Interventions*, Georgetown University, Washington DC, 1994.
30. R.E. Hillberg, C.J. Douglas, “Non Invasive Ventilation”, *N Engl J Med* **337** (1997) 1746-1752.
31. A.K. Simonds, “Home ventilation”, *Eur Respir J* **22** (2003) Suppl. 47 38s–46s.
32. J. Kohorst, “Transitioning the Ventilator-Dependent Patient From the Hospital to Home”, *Medscape Pulmonary Medicine* **9** (2005)
33. B. Spyropoulos, A. Tzavaras, M. Botsivaly, K. Koutsourakis, “Ensuring the Continuity of Care of Cardio-respiratory Diseases at Home: Monitoring Equipment and Medical Data Exchange over Semantically annotated Web Services”, *Methods of Information in Medicine*, 2010; volume 49; issue 2, pp.156-160.
34. A. Tzavaras, B. Spyropoulos, “A wireless monitoring system supporting contemporary Home-care”, *Proc. 35th IEEE-EMBS Conf.* 3-7 July 2013, Osaka, Japan.
35. B. Spyropoulos, A. Tzavaras, P. Afentoulidis, M. Botsivaly, “Supporting Medical House-Call by expanding bedside in vitro Point of Care Test Range and attaining Respiratory Sounds’ Visualization”, *Proc. IEEE-EMBS POC T*, 16-18 Jan. 2013, Bangalore, India.
36. A. Tzavaras, B. Spyropoulos, P.R. Weller, “Fuzzy Reasoning Clinical Decision Support for Manual Titration of Positive Airway Pressure Support and Oxygen supply in Patients with Obstructive Sleep Apnea”, *Proc. IEEE-BHI* 2014, Valencia.
37. . Tzavaras, P.R. Weller, B. Spyropoulos, “Developing and Evaluating Intelligent Decision Support Systems in Ventilation Management”, *Proc. EFMI*, 17-19 Apr. 2013, Prague, CS.
38. B. Spyropoulos, M. Botsivaly, A. Tzavaras, et. al. “Enriching in vitro Diagnostics Point-of-Care Testing by developing appropriate software on a Charge-Coupled Device based Digital Microscope”, *Proc. 20th IFCC-EFCC Congr.* 2013 Milano, & B. Spyropoulos, “A low-cost and risk-free Optical System for Female Breast Inspection and Documentation at Home completing current early-detection plans”, *AMIA Ann. Symp.* 16-20 Nov. 2013, Washington DC, USA.
39. G. Angelopoulos, C. Tsigkas, A. Tzavaras, B. Spyropoulos, “Digital Multiplexer supported scanning Data Collection Method to be employed in Electrical Impedance Tomography simulation measurements”, *ESCR 2010 Meeting*, Prague, Czech Republic, October 28-30, 2010.
40. B. Spyropoulos, A. Tzavaras, M. Botsivaly, M. Moschidis, K. Koutsourakis, “An integrated System supporting Training in medical and administrative Decision Making in the Emergency Department”,

28th IEEE EMBS Annual International Conference, August 30 - September 3, 2006, New York, NY, USA.

41. M. Botsivaly, V. Pierros, V. Mamakou, A. Tzavaras, B.Spyropoulos, "A Web-based system allowing for in- and off-Hospital Patient Treatment Management and Supervision", *Proceedings of the 36th IEEE-EMBS Conference*, August 26-30, 2014, Chicago, Illinois, USA.
42. M. Botsivaly, B. Spyropoulos, V. Pierros, . Kallergi, A. Tzavaras, "Supporting in- and off-Hospital Patient Management Using a Web-based Integrated Software Platform", *26th Medical Informatics Europe Conference (MIE2015)*, 27-29 May 2015, Madrid, Spain.
43. V. Mamakou, B. Spyropoulos, "A patient medical imaging referral support system based on medical-managerial and patient-safety criteria", *e-JST*, pp. 47-57 Vol. 9-4/2014 http://e-jst.teiath.gr/triantaepta_teuxos.htm
44. M. Botsivaly, C. Koutsourakis, B. Spyropoulos, "Evaluation of a new technique for the detection of Ventricular Fibrillation and Ventricular Tachycardia", *CD-ROM Proceedings of the World Congress on Medical Physics and Biomedical Engineering*, TU-CXH-62, July 23-28, 2000, Chicago IL - USA.





11.3 μ μ μ μ [7].

(on-line)


The screenshot displays a medical software interface with the following components:

- Header:** "Handy patients enterprise edition" with standard window controls.
- Left Sidebar:**
 - Forms:** Meeting (Doctor), Full status (Doctor), Assistant, Billing, Reports, Statistics.
 - Sheets:** Neurologic, Vascular, Cardiac, Respiratory, Abdomen, Exams, Radiology, Summary, Patient documents, Letter.
 - Meetings:** 2 month checkup (5 Mar 09, 2m, 0d), 1 month checkup (5 Feb 09, 1m, 0d), Respiratory problem (22 Jan 09, 17d), 10 days checkup (13 Jan 09, 8d), Control for return at home (9 Jan 09, -4d), Birth (5 Jan 09, 0d).
 - Diagnosis:** General, My Diagnosis, Social.
 - Notes:** "Father ask many questions, add 10 minutes to consultation".
 - Current doctor:** Dr Herman.
- Main Content Area:**
 - Section:** "Digestive" with date "Thursday, 22 Jan 2009".
 - Digestive inspection:** Normal.
 - Digestive auscultation:** Normal abdomen noises.
 - Digestive palpation:** Little pain on the right lower area.
 - Liver:** No hepatomegaly.
 - Rectal:** (Empty field).
- Bottom Section:**
 - Images:** Two anatomical diagrams. The left one shows a human torso with red lightning bolts on the right side of the abdomen. The right one shows a detailed diagram of the digestive system with a red arrow pointing to the right lower quadrant (RLQ) and a question mark.
 - Tools:** "Documents manager" icon, "Page 1/1", "Draw", "Mark", "Color", "Pen", "8", "Previous page", "Next page".

11.4

[13].

[7]-[10].




11.5

[7]-[10].

11.3.

(Clinical Guidelines & Pathways), (Evidence based Medicine).

« »



11.7

[7].


(Dicom, 7, HL7, CDA .)

de facto

HL7,

systems) (EHRs), (order-entry systems) (evidence-based guidelines)

-
-
-
-
-



11.8

[7]-[8].

...

1. B. Spyropoulos, G. Papagounos, "A theoretical approach to Artificial Intelligence Systems in Medicine", *Artificial Intelligence in Medicine*, 7, (1995), 455-465.
2. B. Spyropoulos, "Artificial Intelligence Systems in Medicine: Limits and Perspectives", *Evening Workshop*, October 26th 1996 AMIA Annual Fall Symposium, Washington DC, p.27, W1.
3. B. Spyropoulos, P. Parvantonis, "A Hyper - and Hypolipoproteinemias Diagnosis Supporting System based on two-dimensional Electrophoresis Image Interpretation", *Proceedings of the 3rd European Conference on Engineering and Medicine*, Florence, April 30th-May 3rd, 1995, p. 393.
4. . Spyropoulos, P. Parvantonis, "A Universal System for the Diagnostic Evaluation of Biomedical Signals", *1996 AMIA Annual Fall Symposium*, October 26-30, 1996, Washington DC, p. 824.
5. B. Spyropoulos, P. Parvantonis, A. Mikronis, M. Maragkos, G. Argyrakis, "A Universal Bio-Signal and Pattern Acquisition", *Processing and Decision Supporting System, IEEE, Engineering in Medicine and Biology Society*, 18th Ann. Intern. Conference, October 31-November 3, 1996, Amsterdam, p 132, 7.1.2.-1.
6. B. Spyropoulos, J. Anagnostopoulos, P. Parvantonis, A. Micronis, D. Papanagiotou, M. Maragkos, "Present status on developing and interrelating Decision Support and Health-Care Information Systems", *14th International Congress of the European Federation for Medical Informatics (MIE 97)*, Thessaloniki, Greece, May 24-29 1997.
7. Edward H. Shortliffe (Editor), James J. Cimino (Editor), *Biomedical Informatics: Computer Applications in Health Care and Biomedicine* (Health Informatics) 4th ed. Springer 2014.
8. Robert A. Greenes (Editor), *Clinical Decision Support: The Road Ahead*, Academic Press, 2007.
9. B. Spyropoulos, G. Papagounos, "A theoretical approach to Artificial Intelligence Systems in Medicine", *Artificial Intelligence in Medicine*, 7, (1995), 455-465.
10. G. Papagounos, B. Spyropoulos, "The Multifarious Function of Medical Records: Ethical Issues", *Methods of Information in Medicine* 1999; 38: 317–20.98.
11. https://commons.wikimedia.org/wiki/File:Interior,_south_wing,_medical_records_storage._-_Fitzsimons_General_Hospital,_Nurses'_Mess_and_Kitchen,_Nurses'_Recreation,_West_McAfee_Avenue,_North_of_Building_507,_Aurora,_HABS_COLO,1-AUR,2BO-7.tif Interior, south wing, medical records storage. - Fitzsimons General Hospital.
12. https://commons.wikimedia.org/wiki/File:Electronic_medical_record.jpg An electronic medical record example.
13. https://www.google.gr/search?q=Medical+Record&source=lnms&tbn=isch&sa=X&ved=0ahUKEwiK843G6q3JAhVL2xoKHfFEBbAQ_AUIBygB&biw=1540&bih=796#tbn=isch&q=electronic+medical+records&imgc=CzmGoeOo6FSHZM%3A Digital Polyclinic: distributed electronic medical record system.

1

3

/

•
•
•

2
 ; μ
 /
 μ μ μ μ μ μ μ
 μ μ μ μ μ μ μ
 3 μ 3 μ .
 /
 • μ μ μ μ μ μ μ
 • μ μ μ μ μ μ μ
 • μ μ μ μ μ μ μ

12: μ

μ :
 μ .
 μ .
 μ .
 μ .
 μ .
« μ ».
 μ .
 μ .
 μ .
 μ .
 μ .
 μ .
 μ .

12.1.

О μ , 4 . . . , «
 μ », μ 23 .
19 George Boole (1840), Bertrand Russel, Wittgenstein 20 , μ μ μ
 μ , μ , μ .
- μ - μ μ μ μ .
 μ μ Alan Turing [1] μ μ μ ,
 μ « μ » μ .
« μ » « μ » « μ Turing»,
 μ (),
 μ « μ Turing»
 μ 1950, «Computing Machinery and Intelligence?»
 μ 1950 μ μ 1970
 μ , μ μ ,
 μ μ .
 μ o “Logistic Theorist” $\mu\mu$ μ ,
Allan Newell Herbert Simon 1957 [2] μ μ ,
“General Problem Solver” μ $\mu\mu$,
« μ » μ μ ,
 μ μ , μ μ « μ »
 μ 1970 μ μ 1980,
 μ μ μ μ , 1980 μ
 μ , μ , μ ,
 μ μ .
 μ , μ , μ ,
 μ , μ , μ .
 μ , μ , μ , μ ,
 μ , μ , μ .



12.1

12.2.

Η τεχνητή νοημοσύνη (ΤΝ) είναι ένα πεδίο της πληροφορικής που ασχολείται με την ανάπτυξη συστημάτων που μπορούν να μιμηθούν τη νοητική λειτουργία των ανθρώπων. Η ΤΝ έχει εφαρμογές σε διάφορα πεδία, όπως η ιατρική, η νομική, η γλωσσολογία και η βιολογία.

Η ΤΝ βασίζεται στην εφαρμογή τεχνικών που βασίζονται σε μαθηματικά μοντέλα. Τα βασικά στοιχεία της ΤΝ είναι η μάθηση, η αναζήτηση και η λογική. Η μάθηση είναι η διαδικασία με την οποία ένα σύστημα ΤΝ αποκτά γνώση από την εμπειρία. Η αναζήτηση είναι η διαδικασία με την οποία ένα σύστημα ΤΝ αναζητά λύσεις για ένα πρόβλημα. Η λογική είναι η διαδικασία με την οποία ένα σύστημα ΤΝ λαμβάνει αποφασιστικές ενέργειες.

Η ΤΝ έχει εφαρμογές σε διάφορα πεδία, όπως η ιατρική, η νομική, η γλωσσολογία και η βιολογία. Η ΤΝ χρησιμοποιείται στην ιατρική για την ανάλυση και την επεξεργασία δεδομένων, στην νομική για την ανάλυση και την επεξεργασία νομικών κειμένων, στη γλωσσολογία για την ανάλυση και την επεξεργασία γλωσσικών δεδομένων και στη βιολογία για την ανάλυση και την επεξεργασία βιολογικών δεδομένων.

Η ΤΝ έχει επίσης εφαρμογές στην εκπαίδευση, στην οικονομία, στην πολιτική και στην κοινωνία. Η ΤΝ χρησιμοποιείται στην εκπαίδευση για την ανάπτυξη εκπαιδευτικών προγραμμάτων, στην οικονομία για την ανάλυση και την επεξεργασία οικονομικών δεδομένων, στην πολιτική για την ανάλυση και την επεξεργασία πολιτικών δεδομένων και στην κοινωνία για την ανάλυση και την επεξεργασία κοινωνικών δεδομένων.

Η ΤΝ είναι ένα πεδίο που αναπτύσσεται γρήγορα και έχει μεγάλο ενδιαφέρον για την επιστήμη και την κοινωνία. Η ΤΝ έχει εφαρμογές σε διάφορα πεδία και έχει μεγάλο ενδιαφέρον για την επιστήμη και την κοινωνία. Η ΤΝ είναι ένα πεδίο που αναπτύσσεται γρήγορα και έχει μεγάλο ενδιαφέρον για την επιστήμη και την κοινωνία.

Toulmin,
:

-
-

Toulmin [8]

«

μ
μ

» [8].

μ

. Montgomery

μ

, K

. Montgomery

. Montgomery,

μ .

. Montgomery

[9], [10].

Montgomery

)

» [9].

μ

μ

μ », [9].

12.3.

μ
μ
μ

μ ,

μ ,


μ ,

μ

1988, Hackling Lawrence [11]


«...»,

«...»,



12.2


12.4.




12.4

“ (medical expertise) [11].

-
-
-
-




a) Normal QRS
b) Atrial Fibrillation
c) Ventricular Fibrillation



12.5

“



12.6 μ μ gel /

“ μ ”: $d_j = d_j(a_{1j}, a_{2j}, \dots, a_{kj})$. “ μ ”:

$$D_i = D_i(a_{1i}, a_{2i}, \dots, a_{ki}), i = 1, 2, \dots, m$$

(Reference Knowledge Base),

μ , μ :

$$M(d_j - D_i) = m, i = 1, 2, \dots, m$$

Based Reasoning) “ μ ” μ , (Case μ)

μ μ , μ :


[12] – [13],

μ , μ . μ μ , μ .


/

1. Turing A., “Computing Machinery and Intelligence”, *Mind* 59.236 (1950), pp. 433-460.

2. Newell . and Simon . . (1972). *Human problem solving*. Englewood Cliffs, N.J., Prentice-Hall.
3. Boorse C., "Health as a theoretical concept", *Philosophy of Science* 44 (1977) pp. 542- 573.
4. Ledley R. S., Lusted L. B., "Reasoning foundation of Medical Diagnosis", *Science* 130 (1959) pp. 9-21.
5. Schaffner K.F. "Exemplar reasoning about Biological Models and Diseases: A relation between the Philosophy of Medicine and the Philosophy of Science", *Journal of Medicine and Philosophy* 11(1986) p.p. 63- 80.
6. Feinstein A. "Taxonomy and logic in clinical data", *Annals of the New York Academy of Science* 161(1969) p.p. 50- 459.
7. Feinstein A. "An analysis of diagnostic reasoning", *Yale Journal of Biology and Medicine* 46(1973) p.p. 212- 232, 47(1974) p.p. 5-32.
8. Toulmin S. "On the Nature of the Physician's Understanding", *Journal of Medicine and Philosophy*, 1, (1976,), pp.32- 50.
9. , μ μ μ μ μ μ , , .
1999-2000.
10. Montgomery K. "A science of individuals: Medicine and casuistry", *Journal of Medicine and Philosophy* 14(1989) p.p. 193 - 212.
11. Hackling M.W. and Lawrence J.A. (1988). "Expert and novice solutions of genetic pedigree problems", *Journal of research in science teaching*, Vol. 25, No. 7, pp.531-546.
12. B. Spyropoulos, G. Papagounos, "A theoretical approach to Artificial Intelligence Systems in Medicine", *Artificial Intelligence in Medicine*, 7, (1995), 455-465.
13. B. Spyropoulos, G. Papagounos, "Ethical aspects of the employment of Expert Systems in Medicine", *Proceedings of the 4th International Conference on Ethical Issues of Information Technology*, p. 701-711, Rotterdam, 25-27 March 1998.




LIS
 LIS
 LIS
 ()
 (bar-code)
 LIS.



13.2 [2].

RFID, LIS
 LIS
 LIS


-
-
-
-
-
-
-



13.4 μ μ LIMS [4].

μ
 :
 • μ
 • μ
 • μ (e-mail).
 • μ μ μ (fax), μ
 • (interfaces) HL7 μ μ
 (EMRs).
 • μ μ
 • μ
 • μ μ
 • (rule engines).
 • μ μ (Laboratory information
 management Systems, LIMS), μ μ

μ μ (CT), μ μ (MRI), μ (CR-DR), terabytes (10^{12})
 μ (online), μ on-line (near-line), near-line
 , «off-line», μ .




μ . PACS μ (server) μ μ μ .
 μ μ μ μ , μ , laser
 μ . μ (e-mail), μ
 μ μ PACS μ .
 μ (μ) μ μ
 μ , μ (Hospital Information System-HIS)
 μ , μ (Radiology Information System-RIS).
 μ RIS μ μ μ , μ
 μ , μ . RIS μ IS μ μ PACS
 μ , μ μ (DICOM, Digital Imaging and

Communications in Medicine)


. DICOM Header (μ μ (bitmap) μ μ (jpeg, gif .).
 DICOM μ μ 3 μ μ (, ,)
 (standard) : μ μ
 • STORE: μ PACS
 • QUERY/RETRIEVE: PACS
 • PRINT: DICOM
 • MODALITY WORKLIST: μ
 () .

CIIM surgical or interventional computer-aided design / computer-aided manufacturing (CAD/CAM).



13.10

[9].



13.11

[9].

(imagers),

(registration).

$$d_{AB} = d_{AB} [F_B, T_{AB}(F_A)].$$

(, ,)

CIIM,


« »



13.12 :



μ Medtronic. : μ
 LASER (Osaka/Tokyo) [9].



13.16

Robin Heart. [10].

1. https://en.wikipedia.org/wiki/Laboratory_information_management_system#/media/File:Icos_Laboratories.JPG Laboratories around the world depend on a LIMS to manage data, assign rights, manage inventory, and more.
2. The Bika LIMS open source workflow fits all lab disciplines conforming to the ISO 17025 standard. <https://health.bikalabs.com/>
3. <http://www.noegen.com/en/fw.php?id=68> Laboratory information management system (LIMS).
4. <https://milenabonfim.wordpress.com/2014/03/24/unit-4-p4-laboratory-information-management-system-lims/> A Laboratory Information Management System (LIMS) is a software used in almost all laboratories to manage its activities and operations.
5. <http://www.elogic.gr/software/lims.html>
6. « (PACS)», 13
7. 6–9 2003.
8. « 2013.
9. http://wiki.ihe.net/index.php?title=Access_to_Radiology_Information Access to Radiology Information.
10. Edward H. Shortliffe, James J. Cimino (Eds), *Biomedical Informatics: Computer Applications in Health Care and Biomedicine (Health Informatics)*, 4th ed. Springer 2014.
11. <http://surgrab.blogspot.gr/2013/11/robin-heart-from-poland.html> Robin Heart from Poland, Europe's first cardiac surgery robot with semi-automatic movements, an advanced human-machine interface, and a 3D virtual training system.

11. Robert A. Greenes (Editor), *Clinical Decision Support: The Road Ahead*, Academic Press, 2007.
12. B. Spyropoulos, G. Papagounos, "A theoretical approach to Artificial Intelligence Systems in Medicine", *Artificial Intelligence in Medicine*, 7, (1995), 455-465.
13. G. Papagounos, B. Spyropoulos, "The Multifarious Function of Medical Records: Ethical Issues", *Methods of Information in Medicine* 1999; 38: 317-20.98.

3 **1** μ **LIS.**

- /
- μ .
 - μ .
 - .

4 **2** **PACs.**

- /
- STORE: μ PACS.
 - QUERY/RETRIEVE: PACS.
 - PRINT: DICOM.
 - MODALITY WORKLIST: μ
() .

K **3** μ :

- /
- μ μ .
 - μ μ .
 - μ , μ .

14:

μ

, μ

μ

μ

14.1.

μ

μ

μ

μ

μ (μ)

μ

μ ,

μ ,

μ , μ , μ ,

μ

μ

, μ μ

μ μ

μ μ μ μ

μ μ μ

μ

μ μ

, μ

μ

μ μ μ

μ

μ

μ

μ μ

μ

μ μ μ μ μ

μ

μ

μ

μ μ μ μ μ

μ μ

μ

μ

μ μ μ

, μ μ μ

μ μ

μ μ

μ

μ μ μ

μ

μ

μ μ μ

μ

μ

μ

μ μ μ μ μ

μ

μ

μ

μ μ μ μ μ

« μ μ ».

μ

μ

μ

μ μ μ

μ

μ

μ μ μ μ μ

μ

μ

μ

μ

μ μ μ μ μ

μ μ μ

μ

μ

μ

μ μ μ μ μ

μ

μ

μ

μ μ μ μ μ

μ μ μ μ μ

μ

μ

μ

14.2.

[1].

[2]: (Foundational), (Structural) (Semantic).

-
-
-

[3],

[4].

14.3.

•

•

()

14.4.

•

14.4.1. (ISO)

(International Standards Organisation - ISO) [5]

157 ISO / TC215 ISO [6], (health informatics)

- ISO / TC215 (CEN) HL7 20
- ISO / TC215 ISO,

14.4.2. (CEN)

(European Committee for Standardisation Comité Européen de Normalisation - CEN) [7]

TC 251 [8] CEN

403 [9].

14.5. Health Level Seven (HL7)

ANSI (. . .) DIN (μ)


14.5.1. Health Level Seven (HL7)

HL7 (www.hl7.org) [10]

ANSI (. . .) DIN (μ)


HL7

- Functional Group (μ)
- Message Type (μ μ)
- Message Definition (μ μ μ)
- Segment Definition (μ μ μ)
- Field ()
- HL7 : (Admission, Discharge and Transfer)



14.1

CCR (Copyright 2005 AAFP, ASTM International)




14.2

μ


CCR (Copyright 2005 AAFP, ASTM International)

μ μ μ μ CCR μ μ
 μ μ μ CCR μ μ
 (patient focus) μ μ

XML, CCR (browser), HL7 - CDA (Health Level 7 – Clinical Document Architecture) XML



14.3 CCR (Copyright 2005 AAFP, ASTM International)



14.4 XML CCR (Copyright 2005 AAFP, ASTM International)

14.6.

14.6.1. ICD

- International Classification of Diseases

(WHO) [14]. ()
 (complaints), (procedures)
 (Procedure Coding System ICD-10-PCS) [15].
 ICD 10.

(Chapter)	(Title)	(Blocks)
I	Certain infectious and parasitic diseases	A00–B99
II	Neoplasms	C00–D48
III	Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	D50–D89
IV	Endocrine, nutritional and metabolic diseases	E00–E90
V	Mental and behavioural disorders	F00–F99
VI	Diseases of the nervous system	G00–G99
VII	Diseases of the eye and adnexa	H00–H59
VIII	Diseases of the ear and mastoid process	H60–H95
IX	Diseases of the circulatory system	I00–I99
X	Diseases of the respiratory system	J00–J99
XI	Diseases of the digestive system	K00–K93
XII	Diseases of the skin and subcutaneous tissue	L00–L99
XIII	Diseases of the musculoskeletal system and connective tissue	M00–M99
XIV	Diseases of the genitourinary system	N00–N99
XV	Pregnancy, childbirth and the puerperium	O00–O99
XVI	Certain conditions originating in the perinatal period	P00–P96
XVII	Congenital malformations, deformations and chromosomal abnormalities	Q00–Q99
XVIII	Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	R00–R99
XIX	Injury, poisoning and certain other consequences of external causes	S00–T98
XX	External causes of morbidity and mortality	V01–Y98
XXI	Factors influencing health status and contact with health services	Z00–Z99
XXII	Codes for special purposes	U00–U99

14.1 ICD 10.

14.6.2. Current Procedural Terminology (CPT)

(American Medical Association –). CPT ,
 [16].

14.6.3. Systematized Nomenclature of Human & Veterinary Medicine SNOMED

College of American Pathologists (CAP)
 [17].
 65000 .

14.6.4. International Classification in Primary Care - ICPC-2

ICPC-2 is a classification system for primary care, developed by the World Health Organization (WHO) in 1987. It is based on the International Classification of Diseases (ICD) but is specifically designed for use in primary care settings. ICPC-2 is divided into 17 chapters, each representing a different body system or organ. The chapters are: A (General and unspecified), B (Blood, blood forming organs, lymphatics, spleen), D (Digestive), F (Eye), H (Ear), K (Circulatory), L (Musculoskeletal), N (Neurological), P (Psychological), R (Respiratory), S (Skin), T (Endocrine, metabolic and nutritional), U (Urology), W (Pregnancy, childbirth, family planning), X (Female genital system and breast), Y (Male genital system), and Z (Social problems). ICPC-2 codes are alphanumeric, with the first letter representing the chapter and the following three digits representing the specific condition. ICPC-2 is used for diagnosis, coding, and billing in primary care settings.

A	General and unspecified
B	Blood, blood forming organs, lymphatics, spleen
D	Digestive
F	Eye
H	Ear
K	Circulatory
L	Musculoskeletal
N	Neurological
P	Psychological
R	Respiratory
S	Skin
T	Endocrine, metabolic and nutritional
U	Urology
W	Pregnancy, childbirth, family planning
X	Female genital system and breast
Y	Male genital system
Z	Social problems

14.2 17 ICPC-2.

14.6.5. Read Codes

Read Codes are a classification system for primary care, developed by the Royal Free Hospital in London. They are used for diagnosis, coding, and billing in primary care settings. Read Codes are alphanumeric, with the first letter representing the organ system and the following three digits representing the specific condition. Read Codes are used in the United Kingdom and other countries. Read Codes are used for diagnosis, coding, and billing in primary care settings.

14.6.6. Diagnosis Related Group (DRG)


DRGs (Diagnosis Related Groups) are a classification system for hospital inpatient care, developed by the Social Security Administration in the United States. They are used for diagnosis, coding, and billing in hospital inpatient settings. DRGs are alphanumeric, with the first letter representing the organ system and the following three digits representing the specific condition. DRGs are used for diagnosis, coding, and billing in hospital inpatient settings.

14.3 14.5

25 DRGs.

μ
μ

14.3



14.5 μ μ μ DRGs

/	
1	Diseases and Disorders of the Nervous System
2	Diseases and Disorders of the Eye
3	Ear, Nose, Mouth, Throat, and Craniofacial Diseases and Disorders
4	Diseases and Disorders of the Respiratory System
5	Diseases and Disorders of the Circulatory System
6	Diseases and Disorders of the Digestive System
7	Diseases and Disorders of the Hepatobiliary System and Pancreas
8	Diseases and Disorders of the Musculoskeletal System and Connective Tissue
9	Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast
10	Endocrine, Nutritional and Metabolic Diseases and Disorders
11	Diseases and Disorders of the Kidney and Urinary Tract
12	Diseases and Disorders of the Male Reproductive System
13	Diseases and Disorders of the Female Reproductive System
14	Pregnancy, Childbirth and the Puerperium
15	Newborns and Other Neonates with Conditions Originating in the Perinatal Period
16	Diseases and Disorders of Blood, Blood Forming Organs and Immunological Disorders
17	Lymphatic, Hematopoietic, Other Malignancies, Chemotherapy and Radiotherapy
18	Infectious and Parasitic Diseases, Systemic or Unspecified Sites
19	Mental Diseases and Disorders
20	Alcohol/Drug Use and Alcohol/Drug Induced Organic Mental Disorders
21	Poisonings, Toxic Effects, Other Injuries and Other Complications of Treatment

22	Burns
23	Rehabilitation, Aftercare, Other Factors Influencing Health Status and Other Health Service Contacts
24	Human Immunodeficiency Virus (HIV) Infections
25	Multiple Significant Trauma

14.3 O 25 DRGs

E01A	Major Chest Procedures W Catastrophic CC
E01B	Major Chest Procedures W/O Catastrophic CC
E02A	Other Respiratory System O.R. Procedures W Catastrophic CC
E02B	Other Respiratory System O.R. Procedures W Severe CC
E02C	Other Respiratory System O.R. Procedures W/O Catastrophic or Severe CC
E66A	Major Chest Trauma Age>69 W CC
E66B	Major Chest Trauma (Age<70 W CC) or (Age>69 W/O CC)
E66C	Major Chest Trauma Age<70 W/O CC

14.4 DRGs.

14.6.7. LOINC

LOINC [21].
 μ μ μ
 14.5, 14.6 14.7 μ
 μ LOINC.

A/A	
1	Component (analyte): e.g., potassium, hemoglobin, hepatitis B antigen
2	Property measured: e.g., a mass concentration, enzyme activity (catalytic rate)
3	Timing: i.e., whether the observation applies to a moment in time or is an average or amount taken over a period of time, as is the case for a 24-h urine sodium concentration
4	System: i.e., type of sample or organ examined: e.g., urine, blood, chest
5	Scale: e.g., whether the measurement is quantitative (a true measurement), ordinal (a ranked set of options), nominal, or narrative (e.g., dictation results from x-rays)
6	Method used to produce the observation, but only when different methods give clinically significant different results

14.5 μ LOINC [22]

LOINC	μ LOINC
2951-2	SODIUM:SCNC:PT:SER/PLAS:QN
2955-3	SODIUM:SCNC:PT:UR:QN
2956-1	SODIUM:SRAT:24H:UR:QN
2164-2	CREATININE RENAL CLEARANCE:VRAT:24H:UR:QN
1514-9	GLUCOSE^2H POST 100 G GLUCOSE PO:MCNC:PT:SER/PLAS:QN
3665-7	GENTAMICIN^TROUGH:MCNC:PT:SER/PLAS:QN
17863-2	CALCIUM.IONIZED:MCNC:PT:SER/PLAS:QN
2863-9	ALBUMIN:MCNC:PT:SNV:QN:ELECTROPHORESIS

14.6 μ LOINC μ μ [22]

Code	Component	Property	Time	System	Scale	Method
8302-2	BODY HEIGHT:	LEN	PT	^PATIENT	QN	
3140-1	BODY SURFACE:	AREA	PT	^PATIENT	QN	DERIVED
8331-1	BODY TEMPERATURE:	TEMP	PT	MOUTH	QN	


14.6.9. Clinical Care Classification (CCC) System

The Clinical Care Classification (CCC) System is a classification system for nursing care. It was developed by the American Nurses Association (ANA) in 1988-1991. The system is based on the concept of nursing diagnoses and outcomes. It consists of four main components: Health Behavioral Components (I), Functional Components (II), Physiological Components (III), and Psychological Components (IV). These components are further divided into 21 specific components (A-U). The system is used to classify nursing care into 4 main categories (Patterns of Care), 21 specific components, and 4 care components. The system is based on the concept of nursing diagnoses and outcomes. It consists of four main components: Health Behavioral Components (I), Functional Components (II), Physiological Components (III), and Psychological Components (IV). These components are further divided into 21 specific components (A-U). The system is used to classify nursing care into 4 main categories (Patterns of Care), 21 specific components, and 4 care components.

4		21	
I	Health Behavioral Components	A	ACTIVITY COMPONENT
II	Functional Components	B	BOWEL/GASTRIC COMPONENT
III	Physiological Components	C	CARDIAC COMPONENT
IV	Psychological Components	D	COGNITIVE COMPONENT
		E	COPING COMPONENT
		F	FLUID VOLUME COMPONENT
		G	HEALTH BEHAVIOR COMPONENT
		H	MEDICATION COMPONENT
		I	METABOLIC COMPONENT
		J	NUTRITIONAL COMPONENT
		K	PHYSICAL REGULATION COMPONENT
		L	RESPIRATORY COMPONENT
		M	ROLE RELATIONSHIP COMPONENT
		N	SAFETY COMPONENT
		O	SELF-CARE COMPONENT
		P	SELF-CONCEPT COMPONENT
		Q	SENSORY COMPONENT
		R	SKIN INTEGRITY COMPONENT
		S	TISSUE PERFUSION COMPONENT
		T	URINARY ELIMINATION COMPONENT
		U	LIFE CYCLE COMPONENT

14.9

μ




14.7 μ CCC (Copyright © Virginia K Saba 1994, 2004, 2012)

μ

μ

μ



14.8 T μ μ (Copyright © Virginia K Saba 1994, 2004, 2012)

/

1. HIMSS *Dictionary of Healthcare Information Technology Terms, Acronyms and Organizations*, 2nd Edition, 2010, Appendix B, p.190.
2. National Committee on Vital and Health Statistics (NCVHS) *Report on Uniform Data Standards for Patient Medical Record Information*, July 6, 2000, pp. 21-22.

3. Institute of Electrical and Electronics Engineers, *IEEE Standard Computer Dictionary: A Compilation of IEEE Standard Computer Glossaries*, New York, NY: 1990.
4. *HIMSS Dictionary of Healthcare Information Technology Terms, Acronyms and Organizations*, 2nd Edition, 2010, Appendix B, p190, original source: HIMSS Electronic Health Record Association.
5. <http://www.iso.org/iso/home.html>
6. http://www.iso.org/iso/iso_technical_committee?commid=54960
7. <https://www.cen.eu/Pages/default.aspx>
8. http://standards.cen.eu/dyn/www/f?p=204:7:0:::::FSP_ORG_ID:6232&cs=18CA078392807EDD402B798AAEF1644E1
9. <http://www.ihe-europe.net/eu-affairs/ehealth-m403>
10. <http://www.hl7.org>
11. <http://www.hl7.org.gr/>
12. <http://www.nema.org>
13. ASTM E2369-05 Standard Specification for Continuity of Care Record, www.astm.org
14. <http://www.who.int/classifications/icd/en/>
15. <http://www.cms.gov/Medicare/Coding/ICD10/2014-ICD-10-PCS.html>
16. <http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt/about-cpt.page?>
17. <http://www.snomed.org>
18. <http://www.ulb.ac.be/esp/wicc/>
19. <http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes>
20. <http://www.dhcs.ca.gov/provgovpart/pages/DRG.aspx>
21. <http://www.loinc.org/>
22. Clement J. McDonald et.al., “LOINC a Universal Standard for Identifying Laboratory Observations: A 5-year Update”, *Clinical Chemistry*, April 2003 vol. 49, no 4, 624-633
23. http://www.whooc.no/atc/structure_and_principles/
24. http://www.ifet.gr/e_list/atc.htm
25. <http://www.sabacare.com>

1

μ μ μ

/

μ μ μ μ μ μ :

• μ μ μ μ μ ()

2

μ μ ;

/

- Health Level Seven (HL7)
- DICOM (Digital Imaging and Communications in Medicine)
- ASTM E2369 Standard Specification for Continuity of Care Record

3

μ ;

/

- μ : - International Classification of Diseases ICD
- Current Procedural Terminology (CPT)
- Systematized Nomenclature of Human & Veterinary Medicine SNOMED
- International Classification in Primary Care - ICPC-2
- Read Codes
- Diagnosis Related Group (DRG)
- LOINC
- ATC (Anatomical Therapeutic Chemical)
- Clinical Care Classification (CCC) System

15:

-
-
-

15.1.

[1]-[8]. (knowledge management), [9]-[13]. 80, (data base): (Knowledge base): ICD-10)

1853	W. Farr (1807-1883)
1893	J. Bertillon (1851-1922)
1946	WHO ()
1975	(ICD-9)
1979	(ICD-9-CM, HCIMO)
1992	(ICD-10)
2015	ICD-11

15.1 (WHO ICD-n)

		XII	
		XIII	
		XIV	
V		XV	
V		XVI	
VI		XVII	
VII		XVIII	
VIII		XIX	
IX		XX	
X		XXI	
XI			

15.2 WHO ICD-10.

35-39	
35	bypass (39.61).
	(35.96)
35.1	
35.2	


15.3 ICD-10.

15.2.

SNOMED (Systemized Nomenclature of Human and Veterinary MEDicine International).

- T (12.385)
- (4.991)
- L (25.265)

- C μ , μ : μ (14.075) .
- , μ : μ (1353) .
- J μ : μ μ μ (ILO) (1.886) .
- S : (433) .
- D : μ μ ICD-9-CM (28.622) .
- μ : , (25.000) .
- G : μ μ .



15.1 μ μ μ μ SNOMED.

μ : μ

$$T + M + F + E = D$$

μ , μ
: μ μ μ μ () μ μ () ,
μ μ μ μ (F), μ μ D.
() , μ μ μ μ μ μ μ μ

• (normal) μ μ μ μ
 • , μ , μ
 SNOMED 65000 μ
 LOINC (Laboratory Observation Identifier
 Names and Codes). LOINC μ μ μ 6.000
 μ μ ,

Class	LOINC #	Short Name	Related Names
ALLERGY	15570-5	Honey Bee IgE RAST QI	i1; immune globulin e; immunoglobulin e; honey bee; honeybee; honey bee;arbitrary concentration; point in time; random; serum; sr; ql; ordinal; ql;qualitative; qual; screen; antibodies; autoantibody; antibody; autoantibodies; antby; aby; anti; allergy testing
CHAL	40069-7	Calcium 1.5H p chal SerPl-mCnc	cal; ca; 1.5h p chal; mass concentration; level; point in time; random; serpl;serplas; serp; serum; sr; plasma; pl; plsm; quantitative; qnt; quant; quan; pst;90 minutes; 1 1/2 hours; 90m; 1.5hr; 1 1/2 hr; chemistry.challenge testing; chemistry.challenge testing

15.4 μ μ LOINC.

ICPC (International Classification in Primary Care).
 (μ μ μ)
 (), 90%
 (ICPC-2),
 μ μ μ

ICPC	μ
03	
R05	
R21	μ μ / μ
R07	μ / μ

15.5 μ ICPC-2.

ATC (Anatomic Therapeutical Classification System) μ
 (W) μ
 :
 • μ
 • μ DDD (Defined Daily Doses)
 • : μ
 • μ : μ μ μ μ
 μ μ . μ μ ,
 μ
 • μ : μ μ .


			(DDD)	(U)
A04	A04	ANTIEMETICS AND ANTINAUSEANTS		
A04A	A04A	ANTIEMETICS AND ANTINAUSEANTS		
A04AA	A04AA	<i>Serotonin (5HT₃) antagonists</i>		
	A04AA01	01	Ondansetron	16 mg
	A04AA01			16 mg
	A04AA01			16 mg
	A04AA02	02	Granisetron	2 mg
	A04AA02			3 mg
	A04AA03	03	Tropisetron	5 mg
	A04AA03			5 mg
	A04AA04	04	Dolasetron	0.2 g
	A04AA04			0.1 g
	A04AA05	05	Palonosetron	0.25 mg
A04AD	A04AD	<i>Other antiemetics</i>		
	A04AD01	01	Scopolamine	
	A04AD02	02	Cerium oxalate	
	A04AD04	04	Chlorobutanol	
	A04AD05	05	Metopimazine	15 mg
	A04AD05			15 mg
	A04AD10	10	Dronabinol	
	A04AD11	11	Nabilone	
	A04AD12	12	Aprepitant	95 mg
	A04AD51	51	Scopolamine, combinations	
	A04AD54	54	Chlorobutanol, combinations	

15.6 μ μ ATC.

Standard Organizations	Common Standards Clinical Terminologies & Vocabularies
WHO	ICD-9/10 (other: SNOMED, LOINC, ABC, CCC etc.)
ANSI	ASTM E2369-05 Continuity of Care Record
ISO	ISO 13606-1:2008 (EHR communication) ISO-22870 (Point-of-Care Testing)
CEN	prEN-13940 European Standard for Continuity of Care
HL7 (Health-Level 7)	CDA (Clinical Document Architecture)
ACR/NEMA300 1985	DICOM (NEMA Standard PS3 & ISO 12052:2006)
IEEE	Numerous mainly hardware-related Standards
ITU	Numerous Telecommunication-related Standards

15.7 μ μ (Standards) μ
[14]-[19].

15.3. μ



15.2

KMeX: A Knowledge-Based Approach for Scenario-Specific Medical Free Text Retrieval, Project funded in part by NIC/NIH Grant # 4442511-33780 [19].

Standard Web Ontology Language (SWOL),

Α. Κεφάλι (και Προβλήματα ΩΡΛ)				
P: εξέταση εκλογής		W: εξέταση 2 ^{ης} γραμμής	S: ειδική εξέταση	N: δεν ενδείκνυται
Κλινικό Ερώτημα	Απεικονιστική Εξέταση	Βαθμός Σύστασης	Σχόλιο	
A1 Εκ γενετής νοσήματα (για παιδιά βλ. M1)	MRI CT	P W	Καλύτερη απεικόνιση των δυσπλασιών. Εκτίμηση για βλάβες των οστών.	
A4 Εγκεφαλικό	CT	P	Επιβεβαίωση ή αποκλεισμός αιμορραγίας (ενδεχομένως CT-αγγειογραφία)	
	FKDS της αορτής, TCD	P W	Για ασθενείς που θα υποβληθούν σε χειρουργείο αποκατάστασης στένωσης καρωτίδων, για εγκεφαλικό επεισόδιο με υπόνοια διαχωρισμού ή εμφόλου	

(Codes 6609-7468)		
Γ.	ΑΠΕΙΚΟΝΙΣΗ – ΕΠΕΜΒΑΤΙΚΕΣ ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΕΣ ΑΚΤΙΝΙΚΕΣ ΠΡΑΞΕΙΣ	
Γ.1	ΑΚΤΙΝΟΔΙΑΓΝΟΣΗ ΚΑΤΑ ΠΕΡΙΟΧΕΣ. ΔΙΑΦΟΡΕΣ ΜΕΘΟΔΟΙ	6.609 – 6.848
Γ.2	ΕΠΕΜΒΑΤΙΚΗ ΑΚΤΙΝΟΛΟΓΙΑ ΓΑΣΤΡΕΝΤΕΡΙΚΟΥ	6.849 – 6.860
Γ.3	ΔΙΑΦΟΡΕΣ ΔΙΑΔΙΚΑΣΙΕΣ. ΑΓΓΕΙΟΓΡΑΦΙΕΣ ΚΑΙ ΑΚΤΙΝΟΛΟΓΙΚΕΣ ΕΠΕΜΒΑΣΕΙΣ ΑΓΓΕΙΩΝ	6.861 – 6.973
Γ.4	ΑΚΤΙΝΟΣΚΟΠΗΣΕΙΣ	6.974 – 6.986
Γ.5	ΠΡΟΣΘΕΤΕΣ ΜΕΛΕΤΕΣ ΑΞΟΝΙΚΗΣ / ΜΑΓΝΗΤΙΚΗΣ ΤΟΜΟΓΡΑΦΙΑΣ Κ.Λ.Π.	6.987 – 7.090
Γ.6	ΥΠΕΡΗΧΟΓΡΑΦΗΜΑΤΑ	7.091 – 7.161
Γ.7	ΑΚΤΙΝΟΛΟΓΙΚΕΣ ΚΑΘΟΔΗΓΗΣΕΙΣ	7.162 – 7.174
Γ.8	ΜΑΣΤΟΓΡΑΦΙΕΣ ΚΑΙ ΟΣΤΕΟΠΥΚΝΟΜΕΤΡΙΕΣ	7.175 – 7.194
Γ.9	ΠΑΙΔΙΑΤΡΙΚΗ ΑΚΤΙΝΟΛΟΓΙΑ	7.195 – 7.216
Γ.10	ΑΚΤΙΝΟΘΕΡΑΠΕΙΑ	7.217 – 7.295
Γ.11	ΠΥΡΗΝΙΚΗ ΙΑΤΡΙΚΗ	7.296 – 7.468

15.4 μ μ μ μ [15].

N28M	Σκλήρυνση κατά πλάκας και παρεγκεφαλιδική αταξία με συνυπάρχουσες παθήσεις - επιπλοκές	1.907 €	9
N68X	Σκλήρυνση κατά πλάκας και παρεγκεφαλιδική αταξία χωρίς συνυπάρχουσες παθήσεις - επιπλοκές	565 €	2
N29M	Παροδικό εγκεφαλικό ισχαιμικό επεισόδιο και προεγκεφαλική απόφραξη με καταστροφικές ή σοβαρές συνυπάρχουσες παθήσεις – επιπλοκές	1.230 €	6
N29X	Παροδικό ισχαιμικό επεισόδιο και προεγκεφαλική απόφραξη χωρίς καταστροφικές ή σοβαρές συνυπάρχουσες παθήσεις – επιπλοκές	545 €	3
N30A	Αγγειακό εγκεφαλικό επεισόδιο και άλλες αγγειακές εγκεφαλικές δυσλειτουργίες, ασθενούς που κατέληξε ή διακοσμήθηκε σε <5ημέρες	420 €	2
N30Ma	Αγγειακό εγκεφαλικό επεισόδιο και άλλες αγγειακές εγκεφαλικές δυσλειτουργίες με καταστροφικές συνυπάρχουσες παθήσεις - επιπλοκές	3.408 €	17
N30Mβ	Αγγειακό εγκεφαλικό επεισόδιο και άλλες αγγειακές εγκεφαλικές δυσλειτουργίες με σοβαρές συνυπάρχουσες παθήσεις - επιπλοκές	1.860 €	9

15.5 μ μ μ () [16].

DRGs

1. - , 2008.
2. B. Spyropoulos, M. Botsivaly, E. Oikonomi, and P. Diakoumi-Spyropoulou, "Software supporting the accreditation of Point-of-Care Testing (PoCT) services according to ISO-15189 and ISO-22870 and the supervision of its Quality Indicators", *Proc. of IFCC-WorldLab Berlin 2011, 21st International Congress of Clinical Chemistry and Laboratory Medicine & 19th IFCC-EFCC European Congress of Clinical Chemistry*, Berlin, Germany, 15-19 May 2011, p.
3. B. Spyropoulos, K. Lefteriotis, E. Nassioka, A. Tsouni, E. Papalexis, A. Tzavaras, "A web-based System supporting the Certification of a Surgical Department in a general Hospital", *IFMB Proceedings* (EMBECE September 14-18 2011, Budapest, Hungary), Springer 2011.
4. B. Spyropoulos, E. Oikonomi, A. Danelakis, K. Karaboulas, E. Kotsiliti, E. Maridaki, L. Papageorgiou, E. Papalexis, C. Sakellarios, D. Zogogianni and M. Botsivaly, "A web-based System supporting the Certification of the Outpatient and Emergency Departments and providing for post-discharge Continuity of medical Care Software", *IFMB Proceedings* (EMBECE September 14-18 2011, Budapest, Hungary), Springer 2011.
5. B. Spyropoulos, E. Oikonomi, M. Botsivaly, "Software supporting the Certification of an IVD-Point-of-Care Testing service according to ISO-15189 and ISO-22870 and its linkage to an ASTM-E2369-05 Continuity of Care Record", *Proceedings of the AMIA Annual Symposium 2011*, Washington, DC, October 22-26, 2011.
6. B. Spyropoulos. P. Diakoumi-Spyropoulou, "Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine", *Proceedings of the 20th IFCC-EFCC European Congress of Clinical Chemistry*, Milano 19-23 May 2013.
7. B. Spyropoulos, "Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine". *Innovation in Medical Biology (JIB) Conference*, CNIT 6-8 November 2013, Paris, France.
8. B. Spyropoulos, M. Botsivaly, "Discharging the patient from Hospital to Home-Care: An application attempting to combine E 2369 (CCR), ISO 13606-1, and prEN 13940 Standards, MEDINFO 2010", *13th International Congress on Medical Informatics*, 12 - 15 of September 2010, Cape Town, South Africa.
9. B. Spyropoulos, M. Marinis, V. Mamakou, M. Botsivaly, A. Tzavaras, "Software supporting Physicians Training in Patients DRG-Assignment Rules and ISO 13606-1 compliant Discharge Reporting", *AMIA Annual Symposium 2010*, Washington, DC, Nov. 13-17, 2010.
10. B. Spyropoulos, "25 years Education and Training in occupational Radiation Protection and Hospital Safety in the Biomedical Engineering Department of TEI of Athens: Experiences and Perspectives: Departmental Standards, Quality, Experimentation and Patent-searching", *International Conference on Occupational Radiation Protection*, IAEA Headquarters, 1-5 December 2014, Vienna, Austria.
11. "Evidence based practice for PoCT", NACB, AACC Press, USA.
12. "PoCT Implementation Guide", Australian Assoc. of Clinical Biochemistry.
13. "Management and Use of IVD-PoCT Devices", *Medical Devices Agency*, DB (N1) 2002/03.
14. B. Spyropoulos, "Combining Medical-Managerial Information and Communications Technology Standards to promote Interoperability in Health-Care: A Status Report", *Joint ITU-WHO Workshop on e-Health Standards and Interoperability*, Geneva, Switzerland, 26-27 April 2012.
15. B. Spyropoulos, "Combining ICT-Standards Essential-Patents and Medical-Managerial Guidelines towards sustainable Assisted Living and Home-care (3rd Best Paper Award)", *Proc. ITU Kaleidoscope Conference*, 3-5 June 2014, Saint Petersburg, Russian Federation.


16. V. Mamakou, B. Spyropoulos, “A patient medical imaging referral support system based on medical-managerial & patient-safety criteria”, pp. 47-57 Vol. 9-4/2014 http://ejst.teiath.gr/triantaepa_teuxos.htm
17. B. Spyropoulos, “An Introduction to Industrial Property Rights”, *4-hours Tutorial in the 35th IEEE-EMBS Conference*, 3-7 July 2013, Osaka, Japan.
18. B. Spyropoulos, “An Introduction to some important Industrial Property Rights aspects related to ICT (invited 3-hours Tutorial)”, *International Telecommunications Symposium (ITS 2014)*, 17-20 August 2014, São Paulo, Brazil.
19. <http://www.cobase.cs.ucla.edu/projects/kmex/> KMeX: A Knowledge-Based Approach for Scenario-Specific Medical Free Text Retrieval, Project funded in part by NIC/NIH Grant # 4442511-33780

- 1**
- 3 .
- /
- ICD-10.
 - SNOMED.
 - LOINC.
- 2**
- 3 μ .
- /
- HL7/HL7-CDA.
 - DICOM.
 - openEHR.
- 3**
- 3 μ (Standards) μ .
- /
- WHO ICD-10.
 - HL7 CDA (Clinical Document Architecture).
 - ANSI ASTM E2369-05 Continuity of Care Record.

01	DISEASES & DISORDERS OF THE NERVOUS SYSTEM
02	DISEASES & DISORDERS OF THE EYE
03	DISEASES & DISORDERS OF THE EAR, NOSE, MOUTH & THROAT
04	DISEASES & DISORDERS OF THE RESPIRATORY SYSTEM
05	DISEASES & DISORDERS OF THE CIRCULATORY SYSTEM
06	DISEASES & DISORDERS OF THE DIGESTIVE SYSTEM
07	DISEASES & DISORDERS OF THE HEPATOBILIARY SYSTEM & PANCREAS
08	DISEASES & DISORDERS OF THE MUSCULOSKELETAL SYSTEM & CONN TISSUE
09	DISEASES & DISORDERS OF THE SKIN, SUBCUTANEOUS TISSUE & BREAST
.....
.....

16.1


μ



16.2

DRGs.

μ μ μ μ DRGs, μ μ DRGs μ μ [4]. μ μ DRGs μ μ μ μ DRGs μ μ μ μ [5]. μ DRGs μ μ μ μ μ μ [6]. μ μ μ μ μ μ [7].



E01A	Major Chest Procedures W Catastrophic CC
E01B	Major Chest Procedures W/O Catastrophic CC
E02A	Other Respiratory System O.R. Procedures W Catastrophic CC
E02B	Other Respiratory System O.R. Procedures W Severe CC
E02C	Other Respiratory System O.R. Procedures W/O Catastrophic or Severe CC
E66A	Major Chest Trauma Age>69 W CC
E66B	Major Chest Trauma (Age<70 W CC) or (Age>69 W/O CC)
E66C	Major Chest Trauma Age<70 W/O CC


- ✓ A : υψηλότερο ποσοστό κατανάλωσης πόρων
- ✓ B : δεύτερο υψηλότερο ποσοστό
- ✓ C : τρίτο υψηλότερο ποσοστό
- ✓ D : τέταρτο υψηλότερο ποσοστό

16.3

DRGs μ


16.2. μ

μ DRGs



16.8 μ $\mu\mu$ μ μ μ μ μ μ μ μ (μ μ) [11].

« μ » , $\mu\mu$ μ μ μ , μ μ , μ μ , μ μ μ μ , μ μ μ μ . μ μ μ : μ μ μ ,



16.9



Δημόσια Υγεία

Πρωτοβάθμια Φροντίδα Υγείας

Αγωγή Υγείας

Δομές και Δράσεις για την Υγεία

Εθνικό Σχέδιο Δράσης

Κωδικοποιήσεις-Διαδικασίες

Ψυχική Υγεία

Εμπνευσμένα Φάρμακα

Χρήσιμα Σύνδεσμοι

Αρχική > Υγεία > Δομές και Δράσεις για την Υγεία > Κωδικοποιήσεις-Διαδικασίες

Κλειστά Ενοποιημένα Νοσήλια



Εφαρμογή Αντιστοίχισης ΚΕΝ – ICD 10 – Ιατρικών Προβλημάτων (1/2/2012)



ΦΕΚ-Λίστα ΚΕΝ από 1/3/2012 (κόστος, ΜΔΝ)



ΦΕΚ-Λίστα ΚΕΝ από 1/2/2012 (κόστος, ΜΔΝ)



Δελτία Έμφυτου-Ενημερωτικό Σημειώματα



1. Υπουργικές Αποφάσεις - Εγκύκλιοι Ι.Ι., ΥΥΚΑ



2α. Επιτροπές Ιατρών και Αντιστοίχιση ΚεΝ ICD-10



2β. Επιτροπές Ιατρών και Αντιστοίχιση ΚεΝ Ιατρικής Πράξης



3. Οδηγίες



4. Κωδικοποιήσεις



5. Πρότυπα Έντυπα



6. Δεδομένα Εταιρειών



7. Αγγλικές Έκδόσεις Κωδικοποιήσεων



8. Ενημερωτικό Σημειώματα - Φορείς Κοινωνικής Ασφάλισης



9. Εκπαίδευση

Σχόλια χρηστών:

Οι απαντήσεις για όλα τα ερωτήματα που υποβλήθηκαν, έχουν ενσωματωθεί σε αρχείο (συχνών ερωτήσεων) που έχει αποσταλεί σε ΔΥΠε και Νοσοκομεία

< επιστροφή

16.10


<http://www.moh.gov.gr/articles/health/domes-kai-drasesis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1>

1. **In Vitro Diagnostic Reagents**
 2. **Medical Equipment**
 3. **In Vitro Diagnostic Reagents**
 4. **Medical Equipment**
 5. **In Vitro Diagnostic Reagents**
 6. **Medical Equipment**
 7. **In Vitro Diagnostic Reagents**
 8. **Medical Equipment**
 9. **In Vitro Diagnostic Reagents**
 10. **Medical Equipment**
 11. **In Vitro Diagnostic Reagents**
 12. **Medical Equipment**
 13. **In Vitro Diagnostic Reagents**
 14. **Medical Equipment**
 15. **In Vitro Diagnostic Reagents**
 16. **Medical Equipment**
 17. **In Vitro Diagnostic Reagents**
 18. **Medical Equipment**
 19. **In Vitro Diagnostic Reagents**
 20. **Medical Equipment**
 21. **In Vitro Diagnostic Reagents**
 22. **Medical Equipment**
 23. **In Vitro Diagnostic Reagents**
 24. **Medical Equipment**
 25. **In Vitro Diagnostic Reagents**
 26. **Medical Equipment**
 27. **In Vitro Diagnostic Reagents**
 28. **Medical Equipment**
 29. **In Vitro Diagnostic Reagents**
 30. **Medical Equipment**
 31. **In Vitro Diagnostic Reagents**
 32. **Medical Equipment**
 33. **In Vitro Diagnostic Reagents**
 34. **Medical Equipment**
 35. **In Vitro Diagnostic Reagents**
 36. **Medical Equipment**
 37. **In Vitro Diagnostic Reagents**
 38. **Medical Equipment**
 39. **In Vitro Diagnostic Reagents**
 40. **Medical Equipment**
 41. **In Vitro Diagnostic Reagents**
 42. **Medical Equipment**
 43. **In Vitro Diagnostic Reagents**
 44. **Medical Equipment**
 45. **In Vitro Diagnostic Reagents**
 46. **Medical Equipment**
 47. **In Vitro Diagnostic Reagents**
 48. **Medical Equipment**
 49. **In Vitro Diagnostic Reagents**
 50. **Medical Equipment**
 51. **In Vitro Diagnostic Reagents**
 52. **Medical Equipment**
 53. **In Vitro Diagnostic Reagents**
 54. **Medical Equipment**
 55. **In Vitro Diagnostic Reagents**
 56. **Medical Equipment**
 57. **In Vitro Diagnostic Reagents**
 58. **Medical Equipment**
 59. **In Vitro Diagnostic Reagents**
 60. **Medical Equipment**
 61. **In Vitro Diagnostic Reagents**
 62. **Medical Equipment**
 63. **In Vitro Diagnostic Reagents**
 64. **Medical Equipment**
 65. **In Vitro Diagnostic Reagents**
 66. **Medical Equipment**
 67. **In Vitro Diagnostic Reagents**
 68. **Medical Equipment**
 69. **In Vitro Diagnostic Reagents**
 70. **Medical Equipment**
 71. **In Vitro Diagnostic Reagents**
 72. **Medical Equipment**
 73. **In Vitro Diagnostic Reagents**
 74. **Medical Equipment**
 75. **In Vitro Diagnostic Reagents**
 76. **Medical Equipment**
 77. **In Vitro Diagnostic Reagents**
 78. **Medical Equipment**
 79. **In Vitro Diagnostic Reagents**
 80. **Medical Equipment**
 81. **In Vitro Diagnostic Reagents**
 82. **Medical Equipment**
 83. **In Vitro Diagnostic Reagents**
 84. **Medical Equipment**
 85. **In Vitro Diagnostic Reagents**
 86. **Medical Equipment**
 87. **In Vitro Diagnostic Reagents**
 88. **Medical Equipment**
 89. **In Vitro Diagnostic Reagents**
 90. **Medical Equipment**
 91. **In Vitro Diagnostic Reagents**
 92. **Medical Equipment**
 93. **In Vitro Diagnostic Reagents**
 94. **Medical Equipment**
 95. **In Vitro Diagnostic Reagents**
 96. **Medical Equipment**
 97. **In Vitro Diagnostic Reagents**
 98. **Medical Equipment**
 99. **In Vitro Diagnostic Reagents**
 100. **Medical Equipment**

- (Medical Equipment)
- In Vitro (In Vitro Diagnostic Reagents)

- ECRI (Emergency Care Research Institute) (FDA, In Vitro)
- EDMA (European Diagnostic Manufacturers Association)
- ATC (Anatomical Therapeutic Classification System)

Microsoft Visual Basic, Microsoft Access.



16.14 [7].

DRGs.

- General_Administrator,

Value".

“Overheads

Παρουσίαση ήδη καταχωρημένων Τμημάτων

Στοιχεία προς εισαγωγή Τμήματος

Department Description	Department Category	Square meters	Overheads/month	Time Variant	Extra Month
Department-1	ΑΙΜΟΔΟΣΙΑ	1000	100.00	1	0
Department-2	ΜΟΝΑΔΑ ΕΝΤΑΤΙΚΗΣ ΒΕΡΑΠΕΙΑΣ	222	22.20	0	0.00
Department-3	ΒΙΟ-ΦΗΜΚΟ ΕΡΓΑΣΤΗΡΙΟ	1000	100.00	0	0.00
Department-4	ΑΚΤΙΝΟΛΟΓΙΚΟ	1000	100.00	0	2300.00

Department's Description: Department-5

Type: ΑΚΤΙΝΟΛΟΓΙΚΟ

Square meters: 800

Overheads Value: 80.00

Time Dependent: No Yes

Running Hours: 0

Extra Expenses / month: 200

Details:

Save Save and Exit Exit

16.16 μ μ μ [7].

μ μ μ μ

μ

/

EDMA

μ , μ

EDMA, μ

μ

“Custom Data Base”

μ μ μ
“All”.

μ μ μ
_____ μ :

μ

μ

μ

μ

μ

μ

μ ECRI (

μ)


μ

μ

μ μ

/μ

μ



16.20

μ [7].

Materials_Economical_Details

Records Found: 3

Total Per Month: 1558.33

Total Per Year: 18700.00

Name	Internal_Code	Quantity/Order	Frequency/Year	Value/Piece	Total/month	Total/year
ΦΙΛΤΡΟΚΑΤΩ ΚΟΙΛΗΣ ΦΛΕΒΑΣ, 31MM-50MM	0	200	20	1.50	500.00	6000.00
ΕΙΔΙΚΟΙΤ ΒΡΟΜΒΟΛΥΣΗΣ ΓΙΑ ΦΙΛΤΡΑ ΑΝΤΗΘΟΡ	0	50	10	23.00	958.33	11500.00
ΣΥΣΤΗΜΑ ΦΙΛΤΡΩΝ ΚΑΤΩ ΚΟΙΛΗΣ ΑΝΤΗΘΟΡ ΤΕΜΠ	0	15	8	10.00	100.00	1200.00

Exit

Αριθμός εγγραφών

Συνολικό μηνιαίο λειτουργικό κόστος

Συνολικό ετήσιο λειτουργικό κόστος

Βασικοί οικονομικοί παράμετροι

Μηνιαίο και ετήσιο λειτουργικό κόστος κάθε αναλωσίμου

16.21

μ

μ

μ

μ μ [7].

μ

μ

μ

μ

ECRI

ECRI, μ

μ μ

μ

μ

μ μ μ

μ

μ

μ μ μ

μ μ

μ

μ :

μ

μ μ

μ

μ

μ μ μ μ

μ μ ,

μ

μ

μ

μ μ μ μ

μ μ

μ μ

ATC (μ μ)

μ μ

/μ

μ

μ

μ μ

μ

μ

μ

μ


μ

μ

μ

μ

μ



16.22



ICD-9 (ICD-10)

dependent”, “time

16.5.

/	€	/	€
	21.90		8.39
B	16.40		8.39
μ	10.80	Management Nurse	8.39
	18.33	Trainee Nurse	6.91
	13.50	Total	113.01

16.2 μ μ .

/	€	/	€
μ	2.41	(4)	8.96
μ	2.41	(1)	9.21
(2)	4.48	(2)	12.28
Total			39.75

16.3


DATEX COMPACT S5 Monitor (Registration Sheet)	
μ/	μ/
μ μ	μ μ

μ	μ
μ	μ
μ	μ
μ	μ
μ	μ


16.4 μ μ Monitor .

			μ (€)
NIMBEXAMP 10ML X 2 MG / ML	1 BT : 5 AMP	10	299.66
NITROLINGUAL	1 INJ.SO.INF: 1	4	21.58
NORCURON	1 BT: 10,00 AMP	16	245.41
NORCURON	1 BT: 10 VIALS	8	292.56
NOVAQUASOL A	1 CR.EXT.US : 1 TUB	2	2.16
OXYTOCIN/GAP	1 BT : 2 AMP	94	95.65
PENTOTHAL/ABBOTT	1 VIALS	77	137.94
PRIMPERAN	1 BT : 6 AMP	12	8.90
PROPOFOL / ABBOTT 20 ML	1 BT : 5 VIALS	14	204.05
PROPOFOL-LIPURO 100ML	1BT: 1 FLACON	30	437.25
PROPOFOL-LIPURO AMP	1 BT : 5 AMP	40	583.00

16.5 μ μ μ .




16.25 μ μ μ [16].



16.26 μ μ μ (: μ , :) [16].

	E (€)
μ (/)	228.10
	487.87
μ	79.71
	37.01
	12.36
	min
-	35
μ	65
	15

16.6 μ μ .



16.27 μ 52 μ [16].

3. Ellis R.P. (2001). "Hospital Payment in the United States: An overview and discussion of current policy issues". *Colloque International, International Conference on "Setting prices for disease: lessons from foreign experience"*, 2001, Paris, France.
4. European Observatory on Health Care Systems: Countries summaries, Available at: <http://www.euro.who.int/observatory>
5. Spyropoulos B. (2002). "Supporting the Acquaintance of Health-Care Personnel to Operational-Cost Monitoring". *CD-ROM Proceedings of TEHRE 2002*, 8-11 December, London, United Kingdom.
6. Spyropoulos B. (2004). "Ethical implication of the combined employment of electronic health records (EHR) and the DRG codification in contemporary Hospital Care". *Proceeding 20th Anniversary TEPR 2004*, Fort Lauderdale, FL, USA, May 2004.
7. Spyropoulos B., Botsivaly M. (2005). "Relating Home Care to the DRGs based reimbursement by introducing an adapted Continuity of Care Record. 21st TEPR 2004 (Towards an Electronic Patient Record)", May 16-18, 2005, Salt Lake City, USA.
8. A. Tzavaras, B. Spyropoulos, R. Gruen, "Diagnosis Related Groups: Approval and suitability for the Greek National Health System", *Proceedings of ITAB 2006*, 26-28 October 2006, Ioannina, Greece.
9. <http://www.moh.gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1>
10. μ , μ , « μ , 23-25 μ 2005, .255-263.
11. μ , « μ » , 2006, .321-328.
12. , R. Gruen, «Ομ μ (DRGs): μ » , 2006, . 303-311.
13. μ μ (DRGs) μ , 2006, .313-320.
- 14.B. Spyropoulos, M. Marinis, "Supporting the acquisition of Hospital-Care Cost Data to feed a refined DRG system for the Greek National Health System: Status report", *Proceedings of the 29th Annual IEEE Northeast Bioengineering Conference*, Nr. 144, NEBE 2003, March 22 -23, 2003, NJIT, Newark, NJ.
- 15.B. Spyropoulos, M. Botsivaly, A. Tzavaras, G. Nikoloudakis, I. Balabanis, N. Karagiannis, I. Limnou, "Acquisition of Cost Data for Surgery and Intensive Medicine to be employed for drafting a DRGs Hospital Reimbursement System in Greece, Paper Nr. 2067", *Proceedings of the EMBEC' 05 Conference*, 20-25 November 2005, Prague, Czech Republic.
- 16.M. Botsivaly, B. Spyropoulos, M. Marinis, P. Sarantakis, G. Nikoloudakis, I. Balabanis, N. Karagiannis, I. Limnou, M. Moschidis, A.Tzavaras, K. Koutsourakis, "Software Development for the Estimation of the Mean DRGs related Treatment Cost", *Proceedings of MIE 2006*, 27-30 August 2006, Maastricht, The Netherlands (also appears in *Stud Health Technol Inform* 124 (2006) 307-312).
- 17.B. Spyropoulos, M. Botsivaly, A.Tzavaras, K. Koutsourakis, "Extending the use of DRGs to estimate mean Home-Care cost by employing an adapted ASTM E2369-05 Continuity of Care Record", *28th IEEE EMBS Annual International Conference*, August 30 - September 3, 2006, New York, NY, USA.

- 18.Spyropoulos, B. Marinis, M. Diakoumi-Spyropoulou, P., “Development of a tool facilitating the allocation of the in vitro Diagnostics operational cost component to the data-set necessary for the development of a refined Greek DRG system”, *Proceedings of Euromedlab 2003*, M-449, Barcelona 1 - 5 June 2003.
- 19.Spyropoulos, B. Marinis, M. Diakoumi-Spyropoulou, P., “Development of a tool facilitating the allocation of the in vitro Diagnostics operational cost component to the data-set necessary for the development of a refined Greek DRG system”, *Proceedings of Euromedlab 2003*, M-449, Barcelona 1 - 5 June 2003.
- 20.B. Spyropoulos, M. Botsivaly M. Marinis, A. Tzavaras, K. Koutsourakis, “Estimation of the DRGs related Mean Surgical Treatment Cost for 535 Patients in Greece by employing custom-made Software”, *AMIA 2006*, November 10-15, 2006, Washington DC, USA.
- 21.B. Spyropoulos, M. Marinis, V. Mamakou, M. Botsivaly, A. Tzavaras, “Software supporting Physicians Training in Patients DRG-Assignment Rules and ISO 13606-1 compliant Discharge Reporting”, *AMIA Annual Symposium 2010*, Washington, DC, Nov. 13-17, 2010.

1
 5 μ DRGs.
 /
 μ DRGs μ :
 •
 •
 •
 •
 •
 •
 •
 •
 2
 3 « » μ μ μ .
 /
 •
 • In Vitro
 • μ
 • μ
 •
 •
 • μ .

- ... μ , μ , μ
- IEC 601.1.
- [9]-[11].
- μ (. . . μ ,) .
- μ μ μ (. . . μ in vivo μ) .

17.2.2. in vitro

- μ : μ μ , μ , μ , μ
- A μ : RIA (-Counter, liquid scintillation counter .), ELISA (μ μ), μ μ , LIA, μ , IFA .
- μ : μ , μ , coagulometers, μ
- : , , μ μ ,
- : , μ μ .
- : , μ , , μ , .
- in vitro μ μ [5].
- μ μ , μ μ , μ μ , μ μ μ μ .
- μ , μ .
- μ (μ , , μ μ) , RIA, μ .
- μ μ , μ .
- μ , μ
- μ μ (quality assurance) , μ - μ , .

17.2.3.

- X .
- [3].
- .
- .

- : μ (, μ , day light),
 , multi-format camera,
 - μ μ . μ (),
 - format, μ (μ , ,
 , μ .)
 - μ μ , , ,
 μ μ , / ()
 - μ μ μ . μ (. .
 - , μ , μ).
 - , μ μ (. . μ ;
).
 - μ .
 - , μ μ , μ μ , μ μ .
 - , μ μ μ , μ μ .
(. .
 -), μ , μ .
 - μ , μ , μ .
 - MRI, μ , μ /
 .
-
- $\mu\mu$, μ after - loading (. . , Co 60 , Cs 137 , Betatrons,
 μ .

- μ (films, μ μ),
- , μ .
- , μ μ , μ 7-11%
 μ μ , μ .

17.3. μ μ

« μ » μ , μ μ . μ μ . μ μ , μ μ , μ . μ μ .

- - μ (. . . rendelemburg, Fowler). μ , μ
 - μ (. . . ,
 - μ μ (. . . μ ,
 - μ (. . . μ ,
 - μ (lift) μ .
- - μ , μ , μ , (. . . , telefax, PCs, ,
- - μ & μ (. . . , μ , μ [mixer]).
 - $\mu\mu$, μ .
 - μ μ μ .
 - μ μ .
- - μ μ (. . . tunnel .
 - (. . . μ μ).
 - ().
 - μ μ μ & μ .
 - containers μ μ μ μ .
- - μ / .
 - μ .
 - μ / μ μ μ μ .
 - .
 - .
 - .
 - μ .

17.4. μ μ

μ μ μ μ μ μ , .
 μ μ μ μ (. . . μ) μ ,

817).

/

1. Spyropoulos : "The perspective of a Common European Framework for the future of Biomedical Technology in Greece", *Erasmus Meeting of the European Institutions offering Training in Biomedical Engineering*, Aarhus (Denmark), September 1991.
2. Spyropoulos : "Experience on Classification of Medical Equipment in major Hospitals and a proposal for the coding system to be used in the BEAM project", "*BEAM*" *Workshop on Classification, Codification and Nomenclature of Medical Devices*, Athens 10-11 February 1992.
3. Spyropoulos B, Dervos C, Siafaka I. et al, "Methods and measurements for the quantitative determination of the extend of chemical, electrical and electromagnetic radiation hazard sources in the operating room", *Proceedings of the International Conference on Clinical Engineering*, Merano October 1995, pp. 149-154.
4. Spyropoulos B., Yannakoudakis E., Anagnostopoulos J. et al, "A low-cost modular information system enabling management of Biomedical Technology, Hospital Departments, Clinical Information and Medical Decision Support", *Proceedings of the International Conference on Clinical Engineering*, Merano October 1995, pp. 241-246.
5. « », 2 . 19-22.12.1985.
6. „, 2 . 08.11.1986.
7. „, 2 . 18-22.12.86
8. „, 2 . 16-20.12.89.
9. „, 2 . 19
10. „, 2 . 19
11. „, 2 . 11
12. „, 2 . 1997.

- in vitro μ , μ
- μ μ , μ , μ , $\mu\mu$,
 μ μ .
- μ , (. . . ,
 ,) .
- μ μ μ (μ μ μ μ / ,
 .) .
- , μ , μ .
- , μ , μ , μ .
- , μ μ μ . μ () ,
 μ μ .
- format, μ (μ , ,
 , μ) .
- μ μ , ,
 μ μ / ()
- μ μ μ μ . (. . .)
- , μ , μ .
- , μ (. . . μ ;
 .) .

18:

- ISO 9001:2008.
- IVD-POCT (ISO-15189 & ISO-22870).
- ISO 9001:20xx



18.1. , ISO 9001:2008

ISO 9001
ISO 9001
1979
BS 5750, Quality systems,
1979
TC 176 ISO
ISO/TC 176
1987
ISO 9000:1987.
BS 5750:1979.
CEN
ISO 9000:1987
EN 29000:1987
ASQE
ANSI/ASQC Q90
CSA
ISO 9000:1994
2000
CSA:9000. 1994
ISO 9000:2000.
Deming (18.1).

18.2.

« »
• Grosby. (1)
•
• (2)

μ μ μ , μ μ « μ μ , μ μ μ » . (3)



18.1 : μ μ μ μ μ μ ISO 9001:2000, : Deming [1].

ISO 1946

«...»

ISO 9001

ISO 9000

ISO 9000:2001

18.2.




1, 2 3

1


ISO 9001

ISO 9001

ISO 9001:2008.



18.4 μ μ μ [5], [8]. POCT μ



18.5 μ μ POCT μ [8].

μ , μ POCT, μ μ μ POCT (. .)
 μ μ Levey-Jennings). , μ μ μ
 (μ μ) μ μ μ μ μ μ
 μ μ μ μ μ μ μ μ μ μ

APPENDIX 3 ADVERSE INCIDENT REPORT FORM

FORM A3 ISSUE 1 OCTOBER 2001 ADVERSE INCIDENT REPORT FORM – *IN VITRO* DIAGNOSTIC MEDICAL DEVICES

Please tick the appropriate boxes

Origin of report

Hospital / Institution _____
 Address _____
 Laboratory _____
 Reporter _____
 Position _____
 Telephone number _____
 Consultant-in-charge (if known) _____
 Local reference number (if available) _____

This report confirms a telephone report a fax report neither

Device description (tick one box only)

Clinical Chemistry Microbiology Self/Home Testing
 Haematology Cytopathology/Histopathology Genetic Testing
 Immunology Extra-Lab Testing Specimen Receipts

Product

Test kit - Colorimetric Instrumentation/ Calibrators
 Test kit - Immunossay Software Reagent
 Test kit - Other QC Materials Reagent strip

Details of device - Instrumentation

Product Name _____
 Model _____
 Manufacturer _____
 Telephone no: _____
 Supplier _____
 Telephone no: _____
 Serial No _____ Approximate age _____

Is there a CE mark? Yes No

28

Details of device - Kits, reagents and specimen receptacles

Brand Name _____
 Analyte / Marker _____
 Manufacturer _____
 Supplier _____
 Batch No _____ Expiry date _____

Is there a CE mark? Yes No

Nature of defect / details of incident

Contact name for further details _____
 Telephone number _____

Action taken by staff / manufacturer / supplier

Further details can be given on additional sheets if necessary

FORM A3 OCTOBER 2001

Please send completed form to: NIAC, Health Estates, Estate Policy Directorate, Storey Road, Dundonald, Belfast, BT16 1US Tel: 02890523734, Fax: 02890 523900, E-Mail: NIAC@idhspsni.gov.uk

29

18.6 μ μ μ C(UK) μ μ μ μ μ (adverse incidents, adverse events).

Διαγνωστικό μέρος

Αρχική
 Νομοθετικό πλαίσιο
 Διαδικασίες μιας υπηρεσίας POCT
 • Οδηγίες
 • Καταχώρηση ασθενή
 • Διαγνωστικό μέρος
 • Εξεταστικό μέρος

Στοιχεία Ασθενή

Επώνυμο _____
 Όνομα _____
 Πατρώνυμο _____
 Φύλο _____
 Ημ.Γέννησης _____
 ΑΜΚΑ _____


Προσθήκη διάγνωσης

Περιγραφή διάγνωσης: _____
 Παρόμοιος κωδικός: _____

← →

18.7 ICD-10) μ μ μ μ [8]. (W

μ , μ (R), μ μ , μ (LIS). μ



18.8


μ μ μ

	μ
2002 / 98 / μ 27 2003	μ , μ , μ , μ , μ
2004 / 33 / 2004 22	μ μ 2002/98 μ μ
2005 / 61 / μ 2005 30	μ 2002/98 μ μ , μ μ .
2005 / 62 / μ 2005 30	μ 2002/98 μ μ μ
μ R (95)15	μ , μ

18.1

μ .

- μ μ μ μ μ μ μ , μ μ μ
- μ μ μ
- μ μ (barcode) μ unique classifiers μ μ ISBT 128.
- μ (traceability) μ μ Webservices:



18.9

[17].

ISO 9001:2000

	2005/61/	

- discharge Continuity of medical Care Software”, *IFMB Proceedings* (EMBECC September 14-18 2011, Budapest, Hungary), Springer 2011.
5. B. Spyropoulos, E. Oikonomi, M. Botsivaly, “Software supporting the Certification of an IVD-Point-of-Care Testing service according to ISO-15189 and ISO-22870 and its linkage to an ASTM-E2369-05 Continuity of Care Record”, *Proceedings of the AMIA Annual Symposium 2011*, Washington, DC, October 22-26, 2011.
 6. B. Spyropoulos. P. Diakoumi-Spyropoulou, “Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine”, *Proceedings of the 20th IFCC-EFCC European Congress of Clinical Chemistry*, Milano 19-23 May 2013.
 7. B. Spyropoulos, “Software-tools facilitating a quantitative comparison among Blood-Services based upon Quality Indicators in Transfusion Medicine”. *Innovation in Medical Biology (JIB) Conference*, CNIT 6-8 November 2013, Paris, France.
 8. B. Spyropoulos, M. Botsivaly, “Discharging the patient from Hospital to Home-Care: An application attempting to combine E 2369 (CCR), ISO 13606-1, and prEN 13940 Standards, MEDINFO 2010”, *13th International Congress on Medical Informatics*, 12 - 15 of September 2010, Cape Town, South Africa.
 9. B. Spyropoulos, M. Marinis, V. Mamakou, M. Botsivaly, A. Tzavaras, “Software supporting Physicians Training in Patients DRG-Assignment Rules and ISO 13606-1 compliant Discharge Reporting”, *AMIA Annual Symposium 2010*, Washington, DC, Nov. 13-17, 2010.
 10. B. Spyropoulos, “25 years Education and Training in occupational Radiation Protection and Hospital Safety in the Biomedical Engineering Department of TEI of Athens: Experiences and Perspectives: Departmental Standards, Quality, Experimentation and Patent-searching”, *International Conference on Occupational Radiation Protection*, IAEA Headquarters, 1–5 December 2014, Vienna, Austria.
 11. “Evidence based practice for PoCT”, NACB, AACC Press, USA.
 12. “PoCT Implementation Guide”, Australian Assoc. of Clinical Biochemistry.
 13. “Management and Use of IVD-PoCT Devices”, Medical Devices Agency, DB (N1) 2002/03.
 14. B. Spyropoulos, “Combining Medical-Managerial Information and Communications Technology Standards to promote Interoperability in Health-Care: A Status Report”, *Joint ITU-WHO Workshop on e-Health Standards and Interoperability*, Geneva, Switzerland, 26-27 April 2012.
 15. B. Spyropoulos, “Combining ICT-Standards Essential-Patents and Medical-Managerial Guidelines towards sustainable Assisted Living and Home-care (3rd Best Paper Award)”, *Proc. ITU Kaleidoscope Conference*, 3-5 June 2014, Saint Petersburg, Russian Federation.
 16. V. Mamakou, B. Spyropoulos, “A patient medical imaging referral support system based on medical-managerial & patient-safety criteria”, pp. 47-57 Vol. 9-4/2014 http://e-jst.teiath.gr/triantaapta_teuxos.htm
 17. B. Spyropoulos, D. Dimitriadis, M. Botsivaly, “Developing a Web-Service based Senario for ISBT 128 compliant Blood Product Management in Greece”, *Transfusion*, Vol. 46, 2006, No 2S, 180.

1

3

μ

/

•

•

•

μ

μ

3 2 μ .

/
• μ
• ,
• .

3 3 μ in vitro .

- /
- ISO 9001:2008.
 - ISO-15189.
 - ISO-22870.

19:

- μ μ μ :
- μ μ μ :
- , μ μ :
- μ μ μ :
- μ μ μ :
- μ μ μ :
- μ μ μ :
- *In vivo* μ *in vitro* μ :
- μ μ μ :
- μ μ μ :
- μ μ μ :

19.1.

μ

- T μ μ μ , μ μ μ μ μ :
- T μ μ μ μ μ , μ μ μ μ :
- T μ μ μ μ , μ μ μ μ μ :

μ μ	mSv
μ μ	30
μ μ	50
μ μ	30


19.1

- E μ μ μ :
- A μ μ μ :
- A μ μ μ (Roentgen) , μ μ :

(μ)	mSv
μ μ	1
μ μ	2
μ	1
μ	50
μ	1


19.2

μ μ μ ,



19.1

μ μ μ ,




μ

μ . [1]

μ
•
•
•
μ μ μ ,
μ μ


μ

μ
μ
μ



19.2

μ μ 450, μ




μ μ μ μ μ μ [1].

19.5.


μ
μ
μ μ μ μ μ μ

DIN 6811




19.3

() . [2].



19.4



19.4

19.6.

- (UV-)
- ()
- ()

(J/kg)	
0.1	
0.2 - 0.5	
1	
2	
3	
5	


19.3

19.4.:

(J/kg)	
10-2 - 1	
1-2	
2-5	
5-30	
>30	

19.4

UV (170 - 370nm)




19.8 () μ , , G-M, () , $n i$ μ μ , U μ , J μ , () μ G-M μ [7].

19.9.

μ

μ , μ , μ pn. - μ , μ μ μ μ pin- μ 5-10 mm. () μ , μ μ .




19.9 μ () pn- () pin- μ [7].

μ Geiger-Mueller. μ , μ μ pn, μ μ μ μ μ μ μ μ μ .

19.10.

μ μ

μ (. . CdS) μ , μ μ μ , μ μ μ μ μ μ μ μ μ μ .




19.10 A $\mu \mu$ CdS [7].

30eV).

19.11.

$\mu \mu$

$\mu \mu \mu$ (... μ , μ J CsJ).
 μ (... μ -Tl NaJ),
 $\mu \mu$
 $\mu \mu \mu$
 $\mu \mu \mu$ Roentgen -
 $\mu \mu$



19.11 $\mu \mu$, μ : F , D , SZ , G , S [7].

19.12.

^{131}I

μ

μ


μ

μ : μ ^{131}I , μ . μ

μ :	1 / 8 μ
μ :	100mCi ^{131}I /
μ :	100% μ (μ)

19.5 $\mu \mu \mu$ ^{131}I .

$\mu \mu$
 10 m^3 , μ μ
 μ .
 $\mu \mu$ μ 50 l μ
 $(100/8) = 25$ μ . μ μ 2 x
 μ μ 10 000 : (2 x 50) = 100 μ . μ
 μ μ μ ^{131}I $^{131}\text{I}^{1/2} = 8 \mu$, μ
 μ μ ^{131}I μ



19.13 μ

[10].

19.13.5. μ μ μ

μ , μ μ μ μ , μ

19.13.5.1. μ μ

μ

A1 - A2.

μ : μ μ , μ μ . μ μ .

μ , μ : μ .

$R = 15 \text{ mSv.m}^2/\text{mA.min}$	$k = 0.002 \text{ m}^2$
$W = 3000 \text{ mA.min/w}$	$H_w = 0.1 \text{ mSv}$
$U = 1$	$a_2 = 0.9 \text{ m}$
$T = 0.3$	$d = 1.5 \text{ m}$
$t_B = 1 \text{ w}$	

19.7 μ μ 19.13.5.1

($l - 2$).


μ : $F_S = 148$, 0.9 mm Pb.

μ μ : μ , 1 - 2 20 cm μ μ ,

μ 3 mm Pb,

μ , 1 mm Pb μ , μ (μ) μ

μ 1 mm.



19.14 $\mu \mu \mu$ (1:50) μ

A2 - A3.

_____ : μ μ : μ .

$R = 15 \text{ mSv.m}^2/\text{mA.min}$	$k = 0.002 \text{ m}^2$
$W = 3000 \text{ mA.min/w}$	$H_w = 0.1 \text{ mSv}$
$U = 1$	$a_2 = 0.9 \text{ m}$
$T = 1$	$d = 2.9 \text{ m}$
$t_B = 1 \text{ w}$	

19.8 μ μ *19.13.5.1*
 (2 - 3).

μ : $F_S = 132$, 0.8 mm Pb.
 _____ μ : _____ , 2 - 3 20 cm μ μ ,
 μ μ , 3 mm Pb,
 μ , μ , μ , μ ,
 μ .

A3 - A4.

_____ : μ . μ μ
 :

$R = 15 \text{ mSv.m}^2/\text{mA.min}$	$k = 0.002 \text{ m}^2$
$W = 3000 \text{ mA.min/w}$	$H_w = 0.1 \text{ mSv}$
$U = 1$	$a_2 = 0.90 \text{ m}$
$T = 1$	$d = 2.85 \text{ m}$
$t_B = 1 \text{ w}$	

19.9 μ μ *19.13.5.1*
 (3 - 4).

μ : $F_S = 14$, 0.3 mm Pb.
 _____ μ : 3 - 4 , μ μ 1 mm.
 μ μ ,
 , μ , relais μ , μ μ μ ,
 μ , μ ,
 (. . 75 x 100 cm), μ μ 1.0 mm Pb.
 ,

4 - 1.

_____ : μ () μ ,
 : μ .

$R = 15 \text{ mSv.m}^2/\text{mA.min}$	$t_B = 1 \text{ w}$
$W = 3000 \text{ mA.min/w}$	$H_w = 0.1 \text{ mSv}$
$U = 1$	$a_1 = 1.0 \text{ m}$
$T = 1$	

19.10 μ μ *19.13.5.1*
 (4 - 1).

μ : $F = 2500$, 1.8 mm Pb.

$\frac{\mu}{\mu} \frac{\mu}{\mu} :$, 4 - 1 , $\frac{2 \text{ mm}}{20 \text{ cm}}$, μ

μ , 20 cm, . μ relais μ μ , .

$\frac{\mu}{\mu} :$ μ μ . μ : μ

$R = 15 \text{ mSv.m}^2/\text{mA.min}$	$k = 0.002 \text{ m}^2$
$W = 3000 \text{ mA.min/w}$	$H_w = 0.1 \text{ mSv}$
$U = 1$	$a_2 = 0.90 \text{ m}$
$T = 1$	$d = 1.8 \text{ m}$
$t_B = 1 \text{ w}$	

19.11

() . μ μ *19.13.5.1*

μ : $F_S = 62$, 0.7 mm Pb.

$\frac{\mu}{\mu} \frac{\mu}{\mu} :$ μ μ μ 20 cm, μ

3 mm Pb

19.13.5.2.


μ μ μ

1 - 2.

$\frac{\mu}{\mu} :$, μ μ μ μ μ μ .

μ μ μ , μ , 0.25
 μ μ μ μ 0.01 mSv/scan, μ , 0.25
 mSv/h 25 scans/h, μ , (1000 scans/w μ μ DIN 6812 4.1),
 $F_S = 100$, 0.8 mm Pb.

$\frac{\mu}{\mu} \frac{\mu}{\mu} :$ μ μ 1 mm, , ,
 μ 1 mm Pb, μ () , μ μ μ μ
 1 mm. , (20 cm μ μ ,
 3 mm Pb), μ , μ , μ
 , μ μ , μ (, =1) . μ



19.16 μ μ , μ [8].

4- 1.

_____ : (). μ
 μ μ , μ μ μ 0.01 mSv/scan, μ , 0.25
 mSv/h 25 scans/h, μ μ , (1000 scans/w μ μ DIN 6812 4.1),
 $F_S = 100$, 0.8 mm Pb.

μ μ : μ μ 1 mm, , μ
 μ , 20 cm, . μ
 μ relais μ μ , μ μ μ μ μ

_____ : 245 cm μ . μ .
 μ μ , μ μ μ 0.02 mSv/scan, μ , 0.5
 mSv/h 25 scans/h, μ μ , (1000 scans/w μ μ DIN 6812 4.1),
 $F_S = 200$, 1.1 mm Pb.

2 mm, 100 mm, 0.5 mm Pb.

1.75 mSv/h, 25 scans/h, 0.07 mSv/scan, (1000 scans/w, $F_S = 700$, DIN 6812 4.1), 1.6 mm Pb.

20 cm, 3 mm Pb,

19.13.5.3.

DIN 6812 5.3.2 ICRP Publication 21.

$$F_L = \frac{C_L W U T t_B f}{H_w a_1^2 \Delta Q / \Delta t}$$

F_L : (mSv·m²/min).
 C_L : (mA·min / w).
 W : (μA·min / w).
 U : (mSv).
 t_B : (m).
 H : (m).
 a_{min} : (m).
 f : (mA·min/h) DIN 6811 3.1.5.1

ICRP Publication 21, DIN 6812 5.3.3.

DIN 6811 (Medizinische Roentgeneinrichtungen bis 300 kV; Strahlenschutzregeln fuer die Herstellung) (DIN 6812 5.3.3.1)

DIN 6811 3.1.5.1 DIN 6812 4:

$C_L = 1 \text{ mSv}\cdot\text{m}^2/\text{h}$	$H_w = 0.1 \text{ mSv}$
$W = 3000 \text{ mA}\cdot\text{min}/\text{w}$	$a_{min} = 0.9 \text{ m}$
$U = 1$	$f = 1$

T = 1	Q/ t = 20 000 mAs/h
t _B = 1 w	

19.12

μ μ μ

μ

19.13.5.3.

μ : F_L = 40, 0.5 mm Pb
μ , (DIN 6812 3).

μ μ .

μ μ DIN 6811 3.1.5.1 DIN 6812 4:

C _L = 1 mSv.m ² /h	H _w = 0.1 mSv
W = 5000 mA.min/w	a _{min} = 2.0 m
U = 1	f = 1
T = 1	Q/ t = 20 000 mAs/h
t _B = 1 w	

19.13

μ μ μ

19.13.5.3.

μ : F_L = 38, 0.5 mm Pb
μ , (DIN 6812 3).

μ

	μ (mm Pb)	(m ²)
3 - 4	1	6.5 2.5
4 - 1	2	4.0 2.5
μ		
	(mm Pb)	(m ²)
1 - 2	1	5.2 2.5
2 - 3	2	4.2 2.5
3 - 4	2	5.2 2.5
4 - 1	1	4.1 2.5
	2	4.1 5.2

19.14

μ

19.13.5.3.

19.13.6.

- o , 250 cm.
- , μ μ (μ μ)
- μ 1.0 x 2.5 m², μ
- (sandwiches) μ « μ »
- μ « » μ « » 20 cm,
- μ μ , μ
- μ μ , 3 cm, μ μ .

- $1 \text{ m}^3 / \text{min. O}_2$ / μ (12 mm Pb), μ 10 cm, μ 5 m, μ .
- μ μ μ μ (1.2 cm Pb) «
», μ (. . μ μ
- μ μ μ μ (μ »), 6 Atm, μ 10 cm), μ .
- μ μ , μ , μ μ « μ », μ μ , μ μ .
- μ μ μ μ , μ μ μ , μ μ μ , μ μ μ .
- μ μ μ μ , μ μ μ PVC. μ μ « μ μ μ », μ , μ .
- « μ » μ μ , μ μ μ « μ » μ (. .)).
- μ μ , μ μ μ « μ ».
- μ : μ , μ μ (survey meter).
- μ μ μ μ μ μ μ .
- μ μ .

19.14.2.2.

- μ μ μ , μ μ μ . μ μ μ 1.5 x 1.5 m² μ μ .
- μ μ , μ μ μ PVC. μ μ « μ μ μ », μ , μ μ μ .
- « μ » μ , μ « μ » μ μ (. .)).
- μ μ , μ μ μ « μ ».
- μ , μ μ μ .

19.14.2.3.

- μ « μ » , μ μ (2.5 x 1.0 m²), μ μ 2.5 x 4.0 m² μ (-Camera)

• μ 0.01 mR/h (in vitro μ (- Counter) μ J^{131}), μ (μ /) μ , μ , μ , μ , μ (μ μ , μ), μ 15 mCi (555 MBq), , .

19.14.3.1.

μ d (cm) (R/h) μ (μ) , (mCi),

$$E = \frac{\Gamma A U T}{d^2}$$

:
 : (R.cm²/h.mCi).
 U: (U=1).
 : (0 ≤ ≤ 1).
 μ μ / μ_{max} μ (NCRP Report 49).

19.14.3.2. μ

μ (in vivo & in vitro). μ , μ , μ μ μ

μ μ , μ μ , μ μ ,
 (d = 25 cm) μ .

= 15 mCi (555 MBq) J^{131}	T = 0.25
= 2.23 R.cm ² /h.mCi	d = 25 cm
U = 1	E _{max} = 2.5 mR/h.

19.15 μ μ () μ 19.14.3.2.

(HVL), μ , μ J^{131} 10.5 mm Pb. : = 13.38 mR/h 3 μ

μ μ , μ μ μ

= 15 mCi (555 MBq) J^{131}	T = 1
= 2.23 R.cm ² /h.mCi	d = 100 cm
U = 1	E _{max} = 2.5 mR/h.

19.16 μ μ () μ 19.14.3.2.

(HVL), μ , μ J^{131} 3.5 mm Pb. : = 3.35 mR/h 1 μ

μ - Camera

$A = 15 \text{ mCi (555 MBq) J}^{131}$	$T = 1$
$R = 2.23 \text{ R.cm}^2/\text{h.mCi}$	$d = 600 \text{ cm}$
$U = 1$	$E_{\text{max}} = 0.01 \text{ mR/h.}$

19.17 μ μ () μ 19.14.3.2.

(HVL), μ, μ : = 0.09 mR/h 3 μ
 J^{131} 10.5 mm Pb.

μ - Counter

$A = 15 \text{ mCi (555 MBq) J}^{131}$	$T = 1$
$R = 2.23 \text{ R.cm}^2/\text{h.mCi}$	$d = 900 \text{ cm}$
$U = 1$	$E_{\text{max}} = 0.01 \text{ mR/h.}$

19.18 μ μ () μ 19.14.3.2.

(HVL), μ, μ : = 0.04 mR/h o 2 μ
 J^{131} 7 mm Pb.

μ μ 10.5 mm Pb, μ
 μ μ

19.14.3.3. μ μ
 , μ μ μ , μ μ
 μ μ μ μ μ (artifacts), μ μ .

19.14.3.4. μ μ
 $A = 10 \text{ mCi (370 MBq) Tc}^{99m}$, μ μ μ μ μ μ μ μ μ μ μ
 (d = 20 cm). μ μ μ μ μ μ μ μ μ μ μ
 , μ l = 175 cm. H μ μ μ μ μ μ μ μ μ μ μ
 :

$$E = \frac{\pi \Gamma A U T}{l d} 5$$

:
 : (R.cm²/h.mCi).
 U: (U=1).
 : (0 ≤ ≤ 1).

μ μ :
 $A = 10 \text{ mCi (370 MBq) Tc}^{99m}$ μ μ :
 T = 1
 $R = 0.61 \text{ R.cm}^2/\text{h.mCi}$
 d = 20 cm
 U = 1
 $E_{\text{max}} = 0.01 \text{ mR/h}$

μ (HVL), μ , μ Tc^{99m}, 2 mm Pb. : = 41.05 mR/h o 8
 μ μ , 20 cm, 9 μ (VL).

19.14.4.5.

μ - Camera

μ μ A = 10 mCi (370 MBq) Tc^{99m}, μ , μ , μ , μ , μ -
 Camera μ , μ μ , μ μ : H
 μ μ μ - Camera :

$$E = \frac{\Gamma A U T}{d^2} 5$$

μ μ :
 = 10 mCi (370 MBq) Tc^{99m}
 T = 1
 = 0.61 R.cm²/h.mCi
 d = 250 cm
 U = 1
 E_{max} = 0.01 mR/h

μ μ , μ Tc^{99m}, 1.75 mm Pb. : = 0.72 mR/h o 7
 μ (HVL), μ ,

μ - Counter

μ μ :
 = 10 mCi (370 MBq) Tc^{99m}
 T = 1
 = 0.61 R.cm²/h.mCi
 d = 450 cm
 U = 1
 E_{max} = 0.01 mR/h

μ μ , μ : = 0.10 mR/h o 4
 μ (HVL), μ , Tc^{99m} 1 mm Pb. H μ μ
 20 cm 9 μ (VL)

μ μ , μ μ ,
 μ μ .

	(mm Pb)	(m ²)
1 - 2	2	4.2 2.5
2 - 3	2	4.2 2.5
3 - 4	1	4.2 2.5
4 - 1	2	4.2 2.5

19.19

19.14.4.5.

μ μ : 42 m² , 2 mm, μ
 10% , μ μ , μ

(μ μ) . 45 m² (1000 kg). I

(), μ μ .

19.14.5

19.14.5.1

μ μ μ

- μ / (), μ
- μ μ , μ . μ ,
- μ μ () , μ
- μ μ μ μ . (RIA), μ .
- μ μ . (,
- μ) , μ .
- μ μ , μ .
- μ μ μ .
- μ μ μ .

19.14.5.2

, μ , μ . μ

19.14.5.3

in vitro

μ μ J¹²⁵ 1500 μCi (55.5 MBq), 50% μCi (111 KBq), μ μ , μ 2, 16.2 μCi (600 KBq).

H μ (. . μ μ),
15 m³/100 m² . μ

μ , 500 m², 3 m³ . μ
() : = 3 μCi/3000 l = 10⁻⁶ μCi/ml, μ μ
10⁻⁵ μCi/ml.

μ μ ()
μ : μ :
= 3000 l/[12 h x 60 min/h] = 4.16 l/min.
μ J¹²⁵ 1 min, μ : = 3
μCi/4160 ml = 0.0007 μCi/ml, μ 0.1 μCi/ml.

19.14.5.4

in vivo

μ , μ μ μ μ μ

	(mCi)	(MBq)
--	-------	-------

- μ μ μ .), μ μ , μ
- μ μ 6.6.
- /
1. Becker J., Kuhn H.M., Wenz W., Willich E., *Radiologie und Strahlenschutz*, Springer Verlag, Berlin, Heidelber, New York 1976.
 2. CGR Bureau d' Etudes Hospitalieres, *Etude des conditions d' organisation et d' implantation des services de Radiologie Medicale*, Paris 1980.
 3. DIN 6811: *Medizinische Roentgeneinrichtungen bis 300 kV*; Strahlenschutzregeln fuer die Herstellung.
 4. DIN 6812: *Medizinische Roentgeneinrichtungen bis 300 kV*; Strahlenschutzregeln fuer die Errichtung.
 5. DIN 6813: *Strahlenschutzzubehoer bei medizinischer Anwendung von Roentgenstrahlern bis 300 kV*; Regeln fuer die Herstellung und Benutzung.
 6. Dirichlet G., Labryga F., Poelzig P., Schlenzig G., Krankenhausbau, *Institut fuer Krankenhausbau der TU Berlin*, Verlagsanstalt Alexander Koch GmbH, Stuttgart 1980.
 7. Eichmeyer J., *Medizinische Elektronik*, Springer Verlag, Heidelberg, 1983.
 8. Johns H.E., Cunningham J.R., *The Physics of Radiology*, C. C. Thomas, Springfield IL, 1978.
 9. μ , 539, , 19 1991.
 10. ICRP Publication 21: *Data for Protection against Ionizing Radiation from External ources*.
 11. ICRP Publication 34: *Protection of the Patient in Diagnostic Radiology*.
 12. NCRP Report 33: *Medical X-Ray and Gamma-Ray Protection for Energies up to 10 MeV: Equipment, Design and Use*.
 13. NCRP Report 35: *Dental X-Ray Protection*.
 14. ICRP Publication 17: *Protection of the Patient in Radionuclide Investigations*.
 15. ICRP Publication 25: *The Handling, Storage, Use and Disposal of Unsealed Radionuclides in Hospitals and Medical Research Establishments*.
 16. NCRP Report 8: *Control and Removal of radioactive Contaminations in Laboratories*.
 17. NCRP Report 30: *Safe Handling of Radioactive Materials*.
 18. NCRP Report 70: *Nuclear Medicine: Factors Influencing the Choise and Use of Radionuclides in Diagnosis and Therapy*.
 19. DIN 6843: *Strahlenschutz beim Arbeiten mit Radioaktivem Material in offener Form in medizinischen Betrieben, Regeln*.
 20. DIN 6844: *Nuklearmedizinische Betriebe, (Regeln fuer die Errichtung und Ausstattung)*.

1

Geiger-Mueller;

/

μ

μ

μ


μ

,

μ


.

/
 • μ μ μ μ :
 • μ μ μ (μ μ , μ 1.2).
 • μ 0.01 mR/h. in vivo μ (- Camera) μ
 μ 0.01 mR/h (in vitro μ (- Counter) μ
 μ μ , μ J^{131} ,
 μ , μ , , , (μ μ , , (μ
) μ / μ , μ , , , (μ μ , , μ 15 mCi
 (555 MBq), , , , .




20.5 μSO_2 μ , L , P , F , V , G , $1, 2, 3$, V [1].

(3), μ Br_2 ($2\text{Br}^- \rightarrow \text{Br}_2 + 2e^-$).



K_2SO_4 μ Br_2 , μ SO_2 , μ 3 ppb, H_2 , μ μ μ 0.394 μm , μ SO_2 , μ , μ μ μ SO_2 , μ ppb, 30 sec.




20.6 μSO_2 μ , L , F , Fi , PM , E , V [1].

μ UV (μ), SO_2 μ 0.24 μm , μ 5pp, 1min.

20.6. O_x

(3) μ 0.6 μm , μ μ μ 1.5 μm , μ μ 0.2 μm , μ μ , μ μ μ Peltier.




20.9 μ μ μ μ μ μ μ UV: L, F, g μ μ μ , D [1].

20.8.

Cl

μ μ μ Cl μ μ μ μ .
 μ . H μ μ μ μ μ .
 μ μ μ μ μ , . . SO₂, CO₂ NO₂.




20.10 μ μ μ μ : 1 μ μ μ , 2 [1].
 μ , 3 μ μ μ , 4 , 5 , 6 μ μ , 7

20.9.

μ μ :
 μ μ - , μ Geiger-Mueller
 μ μ μ μ . . . ⁶³ Ni.
 μ μ m_s :

$$m_s = K \ln(N_r/N_s)$$

μ :
K: μ μ μ μ μ μ .
N_r, N_s: μ μ μ G-M, μ μ μ μ . μ μ μ μ μ μ μ μ μ .
 μ μ μ μ , background μ μ μ μ μ μ μ μ .
 μ μ μ μ μ μ μ μ μ ,
 μ μ μ μ Geiger-Mueller. μ μ μ μ μ μ μ μ μ μ .




20.11

Geiger-Mueller, [2].

(Sensor),

f

LASER



20.12

LASER, L [2].


20.10.

- Roentgen,
- LASER:

- $\frac{\mu \mu \mu}{\mu} : 2$, $\mu \mu$,
- $\frac{\mu}{\mu} : \mu \mu$ $\mu \mu$
- $\mu \mu \mu \mu \mu + n \rightarrow A+1 M + \mu \mu$
- $\frac{\mu \mu \mu}{2 - 4 \text{ MeV}} : \mu \mu$ $\mu \mu$.

20.11. μ

- $\mu \ll \mu$, $\mu \ll \mu$ »
- $\mu \mu \mu : \mu \mu$ ()
- $\mu \mu \mu , \mu$



20.13 2 , 3 $\mu \mu : L$, 1 $\mu \mu$,

95% 99% $\mu \mu$, μ

$\mu \mu \mu \mu \mu$.


/

1. Eichmeyer J., *Medizinische Elektronik*, Springer Verlag, Heidelberg, 1983.
2. Hicks, R.M., Schenken, J.R., Steinrauf M.A., *Laboratory Instrumentation*, Harper & Row, Hagerstown, 1980.
3. Khandpur R.S., *Handbook of Analytical Instruments*, Tata Mc Graw - Hill, New Delhi, 1989.
4. Kuwana T., *Physical Methods in Modern Chemical Analysis*, Vol. 1, Academic Press, New York 1978.
5. Toribara T Y, Coleman J R, Dahneke B E, Feldman I (Eds.), *Environmental Pollutants*, Plenum Press, New York, London, 1980.
6. Willard H.H. et al., *Instrumental Methods of Analysis*, CBS, New Delhi 1986.


9 mA . H 6
 [Lee, 1966].
 $20 - 100 \text{ mA}$,
 100 mA ,
 ()
 3 min , $2 -$
 (International Electrotechnical Commission, IEC), 500
 $0 - 1 \text{ kHz}$
 100μ
 μ

21.3.

17μ
 [Roy, 1980]. IEC 601.1,
 $0 - 1 \text{ kHz}$, 50μ , 10μ ,
 1 kHz .



21.1





[7].

[Hill & Dolan, 1976]:
 •
 • ECG - monitor
 •

21.4

This diagram illustrates the electrical safety of a medical instrument. It shows a circuit with a 'Line' and 'Neutral' input. A '1 ohm ground resistance' is connected to the neutral line. The instrument contains a 'Mains transformer' and an 'Electronic circuit'. 'Leakage capacitance' is shown between the line and neutral. A 'Catheter' is connected to the instrument, and a human figure is shown with a '1000 ohms' resistance. The current flowing through the patient is labeled as '0.1 microamp. current'.




21.2

This diagram illustrates the electrical safety of a medical instrument. It shows a circuit with a 'Line' and 'Neutral' input. A 'Broken ground connection' is indicated by an 'X' on the ground line. The instrument contains a 'Mains transformer' and an 'Electronic circuit'. 'Leakage capacitance' is shown between the line and neutral. A 'Catheter' is connected to the instrument, and a human figure is shown. The text indicates 'All leakage current flowing through the patient'.

10 - 50 Volts [Darby & Hammond, 1979].

(baseline).

-
-
-



21.6 [3].

[C 601.1], single fault condition),


21.6.

-
-
-


15 - 20

0.15 μ F, 1 k [AAMI].

- μ
- $(FDA):$
- F: $\mu \mu \mu \mu \mu \mu \mu \mu \mu \mu \mu$ F, $\mu \mu$
- CF: $\mu \mu \mu \mu \mu \mu \mu \mu \mu \mu$ F, $\mu \mu \mu \mu \mu \mu$ F μ



21.9 μ [1].




21.10 μ [1].

21.8. μ


, μ [, 1993]. μ , μ

601.1, μ μ , μ μ IEC,


• (, ENDER).
 • (R).
 • 250 (& μ).
 • ().
 • μ (&).
 • μ μ (. &).
 • μ (&).
 • μ (&).
 • & μ μ .
 • (μ μ).
 • (IEC 601.1), ,
 • μ :
 • μ μ : 1.5%.
 • μ μ : 15%.
 • μ μ / (IEC 601.2.4.) 5%
 • :
 • 90% , μ (5 Joules).
 • 5% , μ (100 Joules).
 • 10% , (360 Joules).
 • μ μ μ R μ μ PQRST
 • μ μ μ μ ,
 • μ μ 21.10, μ μ



21.11 , μ μ IEC 601.1, μ μ 2500 [, 1993].



21.12 $\mu \mu \mu \mu \mu \mu \mu \mu$ IEC 601.1, [$\mu \mu \mu$, 1993].



21.13 $\mu \mu \mu \mu \mu \mu \mu \mu$ 2500 [$\mu \mu \mu$, 1993].

/

1. " (: . ") , $\mu \mu$, 1990.
2. Bruner, J.M., "Hazards of electrical apparatus", *Anesthesiology*, 28, (1967), 396.
3. Carr J.J., *Biomedical Equipment: Use, Maintenance & Management*, Prentice Hall, New Jersey, 1992.
4. Darby C.F., Hammond P., "A patient virtual earth and electrical interference monitor", *Med. & Biol. Eng. & Comput.* 17, (1979), 107.
5. Hill D. W., Dolan, A.M., *Intensive Care Instrumentation*, Grune & Stratton, New York, 1976.

3

μ

FDA;

/

(FDA):

- _____: μ + μ μ μ
 - _____: μ + μ μ .
- μ
- (FDA):
- _____: μ
 - F: μ μ μ μ μ μ F, μ μ
 - CF: μ μ μ μ μ μ F. μ μ μ μ F μ

-
-
-

EEG, , μ

μ

20.1.

	μ	dBA (μ)	μ	dBA ()
		45		35
		50		35
μ		70		70
	μ	50		-
		70		-
		85		-

22.1

μ

[1].

μ

μ 90 dBA,
μ

μ

μ μ


μ

22.2.

μ

(μ μ), μ μ μ (DIN 45633). M

$$J(d) = 2 l \mu (P/P_0)$$



22.4 Block

μμ () μ

μ () μ

μ

μ :

μ (), μ

μ

P_0 , μ : $P_0 = 20 \mu\text{N/m}^2 = 2 \times 10^{-5} \text{ Pa}$.

(F),

(HV),

(VV),

μ μ

μ μ

μ

1-200 ms

μ

μ μ

μ

22.3.

μ

μ

(μ

μ

22.5

22.6)


μ

μ


μ

Υλικό	Πυκνότης ρ (GR/CM ³)	Μέτρο Ελαστικότητας E (dyn/cm ²)	cL_(cm/sec)
Αλουμίνιο	2,7	$72 \cdot 10^{10}$	$5,2 \cdot 10^5$
Μολύβι	11,3	$17 \cdot 10^{10}$	$1,25 \cdot 10^5$
Σίδηρος	7,8	$200 \cdot 10^{10}$	$5,05 \cdot 10^5$
Ατσάλι	7,8	$210 \cdot 10^{10}$	$5,1 \cdot 10^5$
Χρυσός	19,3	$80 \cdot 10^{10}$	$2,0 \cdot 10^5$
Χαλκός	8,9	$125 \cdot 10^{10}$	$3,7 \cdot 10^5$
Μπρούντζος	8,5	$95 \cdot 10^{10}$	$3,2 \cdot 10^5$
Ψευδάργυρος	7,13	$13 \cdot 10^{10}$	$1,35 \cdot 10^5$
Άσβεστοκονίαμα	2,0	$28 \cdot 10^{10}$	$3,7 \cdot 10^5$
Άσφαλτος	1,8-2,3	$7,7 \cdot 10^{10}$	$1,9 \cdot 10^5$
Δρυς	0,7-1,0	$2 \cdot 10^{10}$	$1,5-3,5 \cdot 10^5$
Πεύκο	0,4-0,7	$1-5 \cdot 10^{10}$	$2,5 \cdot 10^5$
Φελλός	0,12-0,25	$0,03 \cdot 10^{10}$	$0,43 \cdot 10^5$
Γυψοσανίδες	1,2	$7 \cdot 10^{10}$	$2,4 \cdot 10^5$
Γυαλί	2,5	$60 \cdot 10^{10}$	$4,9 \cdot 10^5$
Νοβοραν	0,6-0,7	$4,6 \cdot 10^{10}$	$2,7 \cdot 10^5$
Σοβάς	1,7	$4,4 \cdot 10^{10}$	$1,6 \cdot 10^5$
Μπετόν	2,3	$26 \cdot 10^{10}$	$3,4 \cdot 10^5$
Άμμος	1,5	$0,03 \cdot 10^{10}$	$0,1-0,17 \cdot 10^5$
Plexiglas	1,15	$5,6 \cdot 10^{10}$	$2,2 \cdot 10^5$
Τούβλο	1,9-2,2	$16 \cdot 10^{10}$	$2,5-3 \cdot 10^5$
Κοντραπλακέ	0,6	$5,4 \cdot 10^{10}$	$3 \cdot 10^5$

22.5 μ μ μ [5].



22.6 $\mu\mu$ μ μ [5].




22.8 μ 4.0 surround (Quadro). μ μ [4].

1/f (Hz), μ μ μ , μ μ «), μ μ μ μ μ μ μ μ [4]. 3




22.9 $\mu\mu$ μ



μ REM2 () [4].

22.5.

Organization, WHO), 30 dB, US EPA (Environmental Policy Act) 40 dB, (World Health Organization) 45 dB.



22.10

WHO [7].



22.11

[7].


Johns Hopkins University, Engineering Department, Baltimore, MD, Johns Hopkins (JHH):

-
-
-
-
-


•
•
μ
•
•
μ μ

Division	No. of Surgeries	Ave. Level dB(A)	Range dB(A)
Pediatric Orthopedic	2	57.9	56.8 – 58.7
Gynecological	2	60.2	54.4 – 63.4
Thoracic	4	62.9	61.6 – 63.6
Gastrointestinal	9	62.9	54.9 - 68.8
Cardiology	10	63.4	57.1 – 67.8
Urology	11	63.6	55.6 – 67.0
Pediatric Urology	2	64.1	64.0 – 64.1
Neurosurgery	8	64.5	60.2 – 67.3
Otolaryngology	4	64.8	53.0 – 66.4
Pediatric Plastic	4	65.2	62.2 – 68.4
Orthopedic	19	66.3	56.7 – 70.3
Plastic	3	66.9	58.8 – 68.9

22.12 μ μ [7].



22.13 WHO μ μ JHH, μ μ [7].




22.14

μ

[7].

Bassett Medical Center Quiet at Night Scores

Q1-2010 through Q1-2012



22.15

1 μ

2012

« μ »

10%

Bassett Medical Center

1 μ

2010 μ [8].

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

[8].

μ

μ

μ

μ

μ

μ

μ

μ

μ

...


22.6. ...

...

/

1. Bajog M, *Schach dem Laerm*, Droemer - Knauer, Muenchen - Zuerich, 1979.
2. Eichmeyer J., *Medizinische Elektronik*, Springer Verlag, Heidelberg, 1983.
3. Neumann J., *Laermmesspraxis*, Expert Verlag, Grafenau Wuerttembrg, 1980.
4. Solet, J. M., Buxton. O.M., Ellenbogen, J.M., Wang, W., and Carballiera, A. (2010), *Evidence-based design meets evidence-based medicine: The sound sleep study, Concord, CA Center for Health Design*

5. <http://195.251.240.254:8080/handle/10184/285>
6. Interim Sound and Vibration Design Guidelines for Hospital and Healthcare Facilities, AIA Healthcare Guideline Revision Committee, Public Draft 1, Last Revision Date: November 1, 2006
7. West J. E. "Noise in Hospitals: Effects and Cures", *Johns Hopkins University Baltimore MD*, 2008 Gegenheimer Lecture Series in Innovation.
8. Madaras G. S., Apps N., "The Hospital Noise Project: Lessons on Addressing Noise from 241 U.S. Hospitals", *The Beryl Institute*, 2012 Webinar Series



23:

- μ (M) μ :
- .
- μ / μ / μ .
- μ μ .
- μ - μ .
- μ μ .
- .
- μ .

23.1. μ (M)

- μ - μ / μ :
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- μ
- UPS μ
- μ
- μ
- μ
- μ
- μ

23.2.

μ , μ : 12V μ , data, data (internet)

μ μ (μ), μ (internet -).

μ TV. μ (μ), μ data RJ45 μ (μ), μ data RJ45 μ

μ

μμ

_____ :

μ

μ μ μ μ

GPS.

25 cm 1 m.

, μ

,

, μ

μ

μ

μ

, μ

μ

, μ

μ

μ

μ

μ

μ

μ

_____ :

μ

μ

μ

"Springler",

:

•

μ

•

μ

μ

•

μ

μ

, μ

•

μ

"SPRINGERL".

μ

μ

.

•

μ

/

μ

μ

IP 65

μ

μ

μ

•

81813/5428/1993 (μ μ 647 . ') . . 54229/2498/1994 (μ μ 312 . ')]]

•

•

μ

•

μ

•

μ

μ

•

μμ

•

•

μ

•

μ

μ

•

μ

•

-

_____ :

μ

μ

μ

μ

,

μ

μ

μ

μ

μ

μ

μ


:

•

•

•

•



23.7.

() (Air Handling Unit=AHU)

- (SFAN)
- (Cooling Coil)
- μ
- (dampers)
- μ
- μ
- (return fan)
- / μ
- (precooling coil)
- (humidifier).

μ μ μ 2,000 63,000 cfm (1 cfm

= 1.7m³/h). μ μ , μ

(RA=ReturnAir) (OA=OutdoorAir) (SA=SupplyAir)
 (supply duct) (air diffuser).

Draw-Through Blow-Through.

- Draw-Through
- Blow-Through

(Fan Coil Unit- FCU): o Fan-coil unit
 02, 03, 04, 06, 08, 10 12.
 200 cfm, 04 400 cfm, . . .

Fan-coil unit

- 250 mm. 0.125 hp
- 2, 3 4
- mm.

:
 :
 :

$$\frac{\mu}{\mu} = \mu$$
 , μ , μ (μ , μ)
 μ . μ μ μ)
 , μ (μ , μ) , μ ,
 μ . μ μ , μ) , μ (μ , μ) .

23.9.

μ

:

- μ (μ μ μ μ μ)
- μ μ μ μ μ μ (μ μ μ μ) .
- μ μ μ μ (μ μ μ μ) .
- μ μ μ μ (μ μ μ μ) .
- μ - μ (μ μ μ)
- μ μ , μ μ (μ μ μ) .

23.10.


μ

μ

- BMS (Building Management System – μ)
- BAS (Building Automation System – μ μ μ)
- IBMS (Integrated Building Management System – μ μ)


μ , μ , μ , μ , μ , μ , μ , μ , μ , μ .
 BMS μ μ . CO2 μ μ .
 BMS μ μ μ μ , μ μ μ μ .
 CO2 μ μ μ , μ μ μ μ .
 μ μ O₂ μ μ - μ μ BMS
 μ μ μ μ . μ μ μ BMS
 μ CO2 μ , μ μ , μ , μ μ .
 μ μ μ BMS μ , μ μ μ μ .

(ACCESS CONTROL), (),
 (MEP – Mechanical, Electrical, Plumbing).
 (HVAC – Heating, Ventilation, Air-Conditioning)



23.1 BMS [10].

HVAC. 60,
 70, 80.
 (DDC) 90
 « »



23.2

BMS [10].

- RS232
- RS485
- modem
- ISDN,
- (AI) : 0-20mA, 4-20mA, 0-10VDC
- (AO) : 0-10VDC
- (DI) :
- (DO) : 24VAC


23.11.

BMS

« » BMS

BACnet

Ethernet 10/100 Mbps.
 ARCNET 2.5 Mbps.
 BACnet MS/TP (Master-Slave/Token-Passing)
 LonTalk (LANs).
 Echelon
 PTP
 EIA-232.
 Ethernet, ARCNET
 - RG-58 Ethernet RG-62
 EIA/TIA 568,
 CAT-5



23.3

BACnet.

μ

(server PC) μ

« μ [8]. ».

« : μ μ μ » μ

1. μ , μ , / , / , ,
2. http://ydraylikoservice.blogspot.gr/2011/10/blog-post_21.html
3. https://www.central-uni.co.jp/e/ew_gas.html
4. <http://elleipsis.gr/el/content/40>
5. http://www.medimax.co.kr/en/product/medical_gas_distribution_system.html
6. <http://www.soldatos.gr/html/automatismoi.html>
7. <http://www.firesecurity.gr/pyran.htm>

8. <http://www.bacnet.org/Bibliography/EC-9-97/EC-9-97.html>
9. http://www.kmcccontrols.com/products/Understanding_Building_Automation_and_Control_Systems.aspx
10. 3, BMS μ .
- 11.
12. μ μ μ
13. <http://artemis.cslab.ntua.gr/Dienst/UI/1.0/Display/artemis.ntua.ece/DT2010-0149>

3 1 .
/
• μ .
•
•

3 2 .
/
• .
•
•

3 3 μ .
/
• .
• μ .
• μ .



24.1 μ (~1942) Amache, Colorado [16].

24.2.

μ

μ /

- μ .1568/1985 μ , μ .186/95
- μ 90/679/ , 93/88/ μ .174/97 μ .15/99.
- μ (WHO). μ 1982 μ 1 -5433/19.5.82
- 1 4234 (μ 733 /13-06-2001) μ μ .

μ , μ μ .

μ , μ , μ μ μ μ μ μ .

- μ :
- μ μ μ μ , μ μ μ μ μ .
- μ μ (μ , μ , μ , (
- μ μ)), / , (, , , (
- μ , μ , μ μ .
- μ , μ μ & μ .
- μ .
- μ .
- μ .

Techniques –

2 (BSL-2):
 (. . . M. Tuberculosis, SARS).
 3 (BSL-3):
 (. . . M. Tuberculosis, SARS).
 4 (BSL-4):
 (. . . Ebola).

1	1		()	
2	2	μ	+ μ, μ	μ aerosols ()
3	3	μ	2+ μ, μ μ	/
4	4	μ	3+ μ	, μ 2


24.2 μ 4 .

4
 HBV, HCV, HIV),
 (guidelines)
 (ISO 9001, ISO 15189),
 « μ » μ
 – μ 2 .
 μ μ μ ,


24.4.

[1], [2].
 •
 •
 •
 •
 latex,
 •
 10 sec,
 •
 •
 •

BIOHAZARD
 ADMITTANCE TO AUTHORIZED PERSONNEL ONLY
 Biosafety Level: _____
 Responsible Investigator: _____
 In case of emergency call: _____
 Daytime phone: _____ Home phone: _____
 Authorization for entrance must be obtained from the Responsible Investigator named above.



24.2 : μ (μ :) μ



24.6 (K) [19].

/

1. *Laboratory Biosafety Manual*, 3rd Edition, World Health Organization (WHO), Geneva 2004.
2. *Biosafety guidelines for diagnostic and research laboratories working with HIV* World Health Organization, Geneva 1991.
3. . . . , « » , 2007, 32, . 16-27.
4. Center for Disease Control and Prevention (CDC), “Laboratory security and emergency response guidance for laboratories working with select agents”, 2002, 51 (RR-19) :1-6.
5. JC Trim, TS Elliott, “A review of sharps injuries and preventative strategies, *J. Hosp.Infect.* 2003 ; 53 (4) : 237-242.
6. *Recommendations on the transport of dangerous goods*, 13th revised edition, New York and Geneva, United Nations, 2003.
7. http://www.unece.org/trans/danger/publi/unrec/rev13/13files_e.html
8. Economic Commission for Europe Inland Transport Committee, *Restructured ADR applicable as from 1 January 2003*. New York and Geneva, United Nations, 2002. <http://www.unece.org/trans/danger/publi/adr/adr2003/ContentsE.html>
9. *Guidance on regulations for the transport of Infectious substances 2009 – 2010*, World Health organization, WHO/HSE/EPR/2008.10.
10. 52167/4683/2012 (37 /2012).

11. . , « » , 22-11-2013 .
12. μ μ 2007.
13. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, Recommendations and Reports. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6210a1.htm>
14. Surveillance of Occupationally Acquired HIV/AIDS in Healthcare Personnel, as of December 2010 Updated: May, 2011 <http://www.cdc.gov/HAI/organisms/hiv/Surveillance-Occupationally-Acquired-HIV-AIDS.html>
15. Hepatitis C and Health Care Personnel <http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm>
16. https://commons.wikimedia.org/wiki/File:Granada_Relocation_Center,_Amache,_Colorado._Autoclave_equipment_for_sterilizing_surgical_bandages,_..._-_NARA_-_539923.jpg
17. 2015», 1-3 , « » , μ μ : « μ 2015 () .
18. Sterilization area of Cambridge location Coronation Dental Specialty Group, <https://commons.wikimedia.org/wiki/File:Sterilization.jpg>
19. https://commons.wikimedia.org/wiki/File:Sterilization_by_Freezing_and_Drying_Unit_-_3_door_freezer.JPG Sterilization by Freezing and Drying Unit - 3 door freezer.

- 1
- 3
- /
- NaClO (5%).
- Ca(ClO)₂
- (70%). (60%)
- (μ 1.5 g Cl)
- 2
- 3 μ μ .
- /
- (70 %).
-
- μ .
- 3
- 3
- /
- μ .
- μ .
-

25: μ
 μμ

μ μ . μ : μ μ μμ
• μ μ μ . . μ .
• μ μ μμ . μ μ .
• μ μ μ μ . μ μ .
• μ μ μ μ μ μ . μ μ .
• μ μ μ μ μ μ μ . &
 μμ .

25.1. μ μ μ

μ μ μ μ μ μ μ μ μ μ
μ : μ μ μ . 4 / .123783 μ μ μ
• μ , μ μ μ .
• μ . μ μ μ μ ,
• , μ μ μ .
• , μ μ μ .
 μ μ μ μ μ μ .
μ μ μ μ μ μ ,
μ μ μ μ μ μ μ μ ,
 μ μ μ μ μ μ μ .
μ , μ , μ μ , μ

25.2.

μ μ μ μ μ μ μ μ μ μ
 μ μ μ μ μ μ μ μ μ μ μ μ μ
 μ . [1]-[3]. μ
_____ :
 μ , ,
μ , μ μ μ μ μ μ



25.6 « » μ .

α/α	ΠΑΡΕΧΟΜΕΝΗ ΥΠΗΡΕΣΙΑ	ΣΥΧΝΟΤΗΤΑ
1	Σκούπισμα - σφουγγάρισμα δαπέδων, θαλάμων ασθενών και W/C, υγρό ξεσκόνισμα	Καθημερινά τουλάχιστον μία φορά σε κάθε βάρδια
2	Βεράντες-ξηρό σκούπισμα-σφουγγάρισμα δαπέδων	Κάθε εβδομάδα
3	Κοινόχρηστα WC	Τουλάχιστον 2 φορές ανά βάρδια (πιο συχνά στα Τ.Ε.Ι. και στα Τ.Ε.Π.)
4	Πλαστικά δάπεδα-γυάλισμα	Μηνιαία
5	Πλαστικά δάπεδα-αντικατάσταση παρκετίνη	Κάθε 3μηνο & όταν κριθεί απαραίτητο
6	Αποκομιδή Απορριμμάτων	Καθημερινά, τουλάχιστον δύο φορές στην πρωινή βάρδια και δύο φορές το απόγευμα, συχνότερα σε Μονάδες, Χειρουργεία, Εργαστήρια & ΤΕΠ
7	Καθαριότητα-απολύμανση θαλάμων ασθενών (box), Μονάδων (ΜΕΘ-ΜΕΘ-ΚΔΧ), σκούπισμα, σφουγγάρισμα, αποκομιδή, απορριμμάτων	Καθημερινά δύο φορές το πρωί και δύο φορές το απόγευμα καθώς και σε κάθε νέο ασθενή
8	Η/Μ χώροι-τούνελ (συνοδεία τεχνικού)	Κάθε τετράμηνο
9	Κοινόχρηστοι χώροι, κλιμακοστάσια, ασανσέρ	Καθημερινά
10	Εξωτερικοί χώροι εισόδων	Καθημερινά
11	Κλινικές που λειτουργούν	Καθημερινά
12	Χώροι που δεν λειτουργούν	Σύμφωνα με τις υποδείξεις του Νοσοκομείου


25.7 μ μ μ .

25.5. μ & μμ μ μ


.4042 (μ 1537 2012), μ & μμ : μ μ & 14
μ (),

[21]-[24]. μ () μ

- () μ μ .
- μ ():
- μ μ () .
- () .
- () ,
- μ .



25.10 μμ (Use Case)[9].



25.11 μμ μ [9].

The screenshot shows the CLEANDESK website interface. At the top, there is a navigation menu with links for Αρχική, Εισαός, Υλικό-Εξοπλισμός, Προσφύ, Βοήθεια, and Επικοινωνία. Below this is a secondary menu with Αρχική/ Προσφύ, Διοικητικά/ Προσωπικά/ Χρονοδιάγραμμα, and Αναζήτηση... The main content area is titled "Χρονοδιάγραμμα εργασιών καθαριότητας" and includes a sub-header "Ημερήσιο Πρόγραμμα Εξαγωγή σε PDF". A table lists cleaning activities with columns for ΤΜΗΜΑ, ΗΜΕΡΑ, ΩΡΑ, ΠΛΗΘΟΣ ΑΤΟΜΩΝ, and ΠΑΡΑΤΗΡΗΣΕΙΣ. The table contains five rows of data for different departments and dates. At the bottom of the table area, there are buttons for "ΠΡΟΣΘΗΚΗ ΝΕΑΣ ΕΡΓΑΣΙΑΣ" and "ΕΝΗΜΕΡΩΣΗ". A footer menu includes Όροι χρήσης, Site Map, and Επικοινωνία.

ΤΜΗΜΑ	ΗΜΕΡΑ	ΩΡΑ	ΠΛΗΘΟΣ ΑΤΟΜΩΝ	ΠΑΡΑΤΗΡΗΣΕΙΣ
ΧΕΙΡΟΥΡΓΕΙΟ	29/9/2014	6:00-10:00	2	-
ΕΡΓΑΣΤΗΡΙΑ	30/9/2014	8:00-12:00	2	-
ΜΑΓΕΙΡΕΙΟ	1/10/2014	18:00-20:00	2	-
ΜΟΝΑΔΑ ΕΝΤΑΤΙΚΗΣ ΘΕΡΑΠΕΙΑΣ	1/10/2014	20:00-22:00, 01:00-04:00	2	-
ΦΑΡΜΑΚΕΙΟ	3/10/2014	22:00-24:00	1	-

25.12

μ [9].

The screenshot shows the CLEANDESK website interface with a complaint form. The navigation menu is identical to the previous screenshot. The secondary menu has Αρχική/ Προσφύ, Υπεύληλο/ Καθαριότητα/ Φάρμα/ Ατυχήματα, and Αναζήτηση... The main content area is titled "ΦΟΡΜΑ ΑΝΑΦΟΡΑΣ ΑΤΥΧΗΜΑΤΟΣ ΠΡΟΣ ΤΟΝ ΥΔΑΥΜ". The form includes fields for Φύση του Συμβάντος, Τόπος Συμβάντος, Χρόνος Συμβάντος, Άμεσα Εμπλεκόμενο Πρόσωπο, Ενέργειες για την αντιμετώπιση του συμβάντος, and Άλλες σχετικές πληροφορίες. A "ΑΠΟΣΤΟΛΗ" button is located at the bottom of the form area. The footer menu includes Όροι χρήσης, Site Map, and Επικοινωνία.

25.13

μ

μ

μ

[9].

- /
1. Castle M, *Hospital infection control*, Awiley Medical Publication, New York 1980.
 2. Daschner F, *Hygiene auf Intensivstationen*, Springer Verlag, Berlin 1981.
 3. Steuer W, *Krankenhaushygiene*, Gustav Fischer, Stuttgart - New York 1988.
 4. <http://www.sentrex.co.uk/Hospital-Cleaning-Service.aspx>
 5. <http://infectioncontrol.equipment/en/multimedia>
 6. <http://openbuildings.com/buildings/st-vincent-private-hospital-profile-40802>
 7. https://commons.wikimedia.org/wiki/Category:Floor_cleaning_machines#/media/File:Hako_Jonas_1500.jpg, Hako Jonas 1500
 8. https://commons.wikimedia.org/wiki/Category:Floor_cleaning_machines#/media/File:Salon_du_Livre_2015_-_Les_coulisses_-_4.jpg, Behind the scenes at the Book Fair 2015 in Paris
 9. « μ μ », μ & μ : « μ μ », « μ μ & (. : .) .
 10. : 443469077- 3, μ
 11. 2 μ μ μ μ « μ » (CPV 90911200-8) μ μ μ 4 μ 2012.
 12. http://www.rethymnohospital.gr/index.php?option=com_content&view=article&id=283%3A2011-05-30-17-27-48&Itemid=68 .
 13. *National Cleaning Manual Appendices*, Hospital Office–National Cleaning Manual, September 2006.
 14. *The NHS Healthcare Cleaning Manual*, Department of Health Publications, 3/2004 www.dh.gov.uk/
 15. Pollak N. et al. “Falling Standards, Rising Risks: Issues in hospital cleanliness with contracting out”, Vancouver, B.C. October 2004.
 16. *The national specifications for cleanliness in the NHS: A framework for setting and measuring performance outcomes*, National Patient Safety Agency, April 2007.
 17. Infection Control Policy, Document Number PD2007_036, Ministry of Health, NSW, Australia, 23-May-2007. <http://www.health.nsw.gov.au/policies/>
 18. Provincial Infectious Diseases Advisory Committee (PIDAC), *Best Practices for Cleaning, Disinfection and Sterilization of Medical Equipment/Devices in all Health Care Settings*, 3rd edition, Ontario Agency for Health Protection and Promotion, Canada, Third Revision: May 2013 www.oahpp.ca
 19. BSI: *A comparison between ISO 14001 Environmental Management and ISO 9001 Quality Management*, BSI Milton Keynes MK14 6WT, United Kingdom www.bsigroup.co.uk/improve
 20. μ – , « μ ISO 9001/2000 μ μ μ », I μ μ « μ μ μ μ μ μ : - μ 21-22/10/2005.

21. μ. .146163: μ ,
1537, 1537, 8 2012.
22. μ. 1. . .114971, , μ
μ , . μ
2014. 388, 18
23. Ν μ 1568/85, μ , 177/ /18-10-85.
24. Ν μ 4144/85, μ
μ , , . μ
88, 18 2013.

1

« μ μ » μ ;
/
μ μ μ , μ μ μ ,
μ μ μ .

2

μ μ ;
/
, μ μ μ , :
• μ μ μ .
• μ μ .
• μ μ .
• μ μ .

3

μ μ μ ;
/
:
• μ μ .
• μ μ .
• μ μ .
• μ μ .
• μ μ .
• μ μ .